A LOT CAN HAPPEN IN EXTRA TIME

- **PATIENTS WITH HIGH-RISK PROSTATE CANCER**
  - Fast and lasting testosterone and PSA control over time

- **PATIENTS WITH A HISTORY OF CVD**
  - 56% relative risk reduction in CVD events or death after the 1st year of treatment compared to LHRH agonists

FOR PATIENTS WITH ADVANCED HORMONE-DEPENDENT PROSTATE CANCER

Results from pooled analysis of multiple prospective, phase III, open-label randomized controlled trials comparing degarelix and LHRH agonists in prostate cancer patients requiring androgen deprivation therapy

CVD: cardiovascular disease; LHRH: luteinising hormone-releasing hormone; PSA: prostate-specific antigen

References:

For additional information, please consult the product package insert before prescribing.

Abbricated Prescribing Information of FIRMAGON

Indications: Treatment of advanced hormone-dependent prostate cancer in adult males. Dosage & Administration: Initially 240 mg administered as 2 120 mg of 133 mg subcutaneously at 1 36 mg weekly administration). Contraindications: Hypersensitivity to the active substance or to any of the excipients. Special Warnings: Seizures with any depression therapy may prolong QT interval. Therapy of concurrent QTS syndrome is contraindicated. Due to the prolonged QT interval, patients with a history of heart conditions, such as heart block, should be monitored closely for serious arrhythmias. Patients with a history of QT prolongation should also be monitored closely for any signs of the syndrome. The use of FIRMAGON is not recommended for patients with a history of QT prolongation.

FIRMAGON is an antiarrhythmic drug that decreases the risk of arrhythmias in patients with a history of QT prolongation. Start strong, stay in control.
## Table of contents

Congress Chairman’s welcome message ................................................................. 4
UAA Executive Committee members .................................................................... 5
Organising and Scientific Committee ................................................................. 6
    About the societies ......................................................................................... 8
General information ............................................................................................. 11
Programme overview ......................................................................................... 15
Detailed programme ........................................................................................... 20
    Tuesday 1st August ...................................................................................... 20
    Wednesday 2nd August ............................................................................... 22
    Thursday 3rd August .................................................................................. 24
    Friday 4th August ...................................................................................... 27
    Saturday 5th August ................................................................................... 42
    Sunday 6th August ..................................................................................... 55
Posters information ............................................................................................ 58
Faculty list .......................................................................................................... 72
Social events and description .............................................................................. 78
Sponsors & exhibition information ....................................................................... 79
Company profiles ............................................................................................... 82
Venue floor plan ................................................................................................. 94
CONGRESS CHAIRMAN’S WELCOME MESSAGE

Dear Colleagues,

2017 is the year the Hong Kong Urological Association has been awarded the hosting of the annual UAA Congress in our wonderful city, scheduled on 3 – 6 August 2017. It is therefore my pleasure to invite you be part of this endeavor and share with you the latest developments in our field with a faculty representing the key opinion leaders in the field. We welcome our UAA members and anticipate over 1,000 delegates to join the event.

Our objective is to create a state of the art scientific program to foster knowledge sharing and exchange experiences in a series of panel sessions, discussion forums and symposia, highlighting innovations and developments in various urological areas, including uro-oncology, voiding dysfunction, stone management etc. Also proposal on guidelines & consensus statements on some common urological problems in Asia will be presented, with aims to encourage close collaboration within Asian countries.

All this in a setting along Hong Kong’s skyline, as the event is hosted at the Hong Kong Convention Centers located in the center of the city, easily accessible from surrounding hotels and area. Hong Kong, as a world-renowned destination, will be a welcoming experience for everyone, whether regular visitor or first timer.

Please visit the website www.uaa-congress.org and leave us your email so we can update you on the progress of the developments and welcome you the Hong Kong UAA 2017 Congress.

Chi-Wai MAN
Congress Chairman
UAA EXECUTIVE COMMITTEE MEMBERS

President
Dr. Man-Kay Li, MD

Li Man Kay Urology
Gleneagles Medical Centre #02-18
6 Napier Road,
SINGAPORE

Immediate Past President
Dr. Ying-Hao SUN MD, PhD

President, Second Military Medical University (SMMU)
Honorary Director & Professor, Department of Urology Shanghai
Changhai Hospital, SMMU, China

President Elect
Dr. Chi-Wai MAN

Chief of Service (Surgery) & Head of Urology Division
New Territories West Cluster, Hong Kong

Secretary - General & Representative to ICUD Steering Committee (2014-18)
Allen Wen-Hsiang CHIU, MD

Professor, Department of Urology, School of Medicine, National Yang-Ming University
Professor, EMBA, National Cheng-Chi University
No 155 Sec 2, Linong St.
Taipei City 112,
Taiwan

Honorary Treasurer (2014-18)
Dr. Toh Khai LEE, MD

Toh Khai Lee Urology Clinic
3 Mount Elizabeth
#05-05 Singapore 228150
ORGANISING AND SCIENTIFIC COMMITTEE

Organising Committee
Dr. Chi Wai MAN – Congress Chairman
Dr. Peggy S K CHU – Deputy Congress Chairperson
Dr. Chi Wai FAN – Deputy Congress Chairperson
Dr. Lap Yin HO – President, HKUA
Dr. Fu Keung CHEUNG
Dr. Ringo W H CHU
Dr. Wai Kit MA
Prof. Chi Fai NG
Dr. James C M LI
Dr. Hing Shing SO
Dr. Bill T H WONG
Dr. Joseph H M WONG
Dr. Sidney K H YIP
Dr. Ming Kwong YIU
Ms. Crystal S Y LI

Scientific Committee
Prof. Chi Fai NG – Co-Chair
Dr. Ming Kwong YIU – Co-Chair
Dr. Chi Kwok CHAN
Dr. Eddie S Y CHAN
Dr. Wayne K W CHAN
Dr. Chak Lam CHO
Dr. Peter K F CHIU
Dr. Yi CHIU
Dr. Peggy S K CHU
Dr. Raymond W M KAN
Dr. Wai Kit MA
Dr. Chi Wai MAN
Dr. Ada T L NG
Dr. Hing Shing SO
Dr. Jeremy Y C TEOH
Dr. James H L TSU
Dr. Bill T H WONG
Dr. Chi Hang YEE

Honorary advisors
Prof. Allen W H CHIU
Prof. Shin EGAWA
Prof. Keong Tatt FOO
Dr. Man Kay Li
Prof. Ying Hao SUN
Dr. Khai Lee TOH
Prof. Jian HUANG
Prof. Chi CHUANG
Prof. Vu Le CHUYEN
Prof. Chuan Liang XU
Prof. David WINKLE
Prof. Nitin KEKRE
Prof. Mototsugu OYA
Prof. Michael WONG
Prof. Hann-Chorng KUO
ABOUT THE SOCIETIES

ABOUT UAA

The UAA was founded in August 1990 in Fukuoka, Japan. Its main objective is to promote Urology in Asia and to improve the care of Urology patients in the region, which has 60% of the world’s population. Originally an association of individual members, it was restructured to become an association of member regions so as to achieve its goals in more cost effective ways. However, a decision has recently been taken to again initiate individual membership along with association memberships in order to promote a sense of belonging among the members.

History of UAA

The UAA was established in 1990 in Fukuoka, Japan and the Founder President was Prof. Joichi Kumazawa. The international members who signed the original documents were:

• Dr. Chieh Ping Wu
• Dr. Stephen Lim
• Dr. Kwok-Kee Wong
• Dr. Djoko Rahardjo
• Dr. Young Kyoong Kim
• Dr. Teong-Chang Tsai
• Dr. Hussein Awang
• Dr. David A. Abraham
• Dr. Verasing Muangman

Our member associations include:

1. Bahrain Urological Association
2. Bangladesh Association of Urological Surgeons
3. Cambodian Association of Urology
4. Chinese Urological Association
5. Emirates Urological Society
6. Hong Kong Urological Association
7. Indonesian Urological Association
8. Iranian Urological Association
9. Japanese Urological Association
10. Korean Urological Association
11. Kuwait Urological Association
12. Macau Urological Society
13. Malaysian Urological Association
14. Myanmar Urological Association
15. Nepal Association of Urological Surgeons
16. Pakistan Association of Urological Surgeons
17. Philippine Urological Association
18. Singapore Urological Association
19. Sri Lanka Association of Urological Surgeons
20. Taiwan Urological Association
21. Thai Urological Association
22. Turkish Urological Association
23. Urological Society of India
24. Vietnam Urological Association
25. Urological Association of Australia and New Zealand (Affiliated)

Visit the UAA website to learn more about the Urological Association of Asia and its member societies.
ABOUT HKUA
The main objectives of the association are:

- To promote the interest in and a better understanding of Urology in Hong Kong;
- To provide a venue for discussion of problems related to Urology;
- To improve and set the standard of urological care in Hong Kong;
- To provide a means of liaison with workers in Urology in other parts of the world;
- To advise and provide information on postgraduate urological training;
- To collect and disseminate information regarding members of the Association and information of any event or happening.
- To achieve the objectives, monthly council meeting is held to plan, organise, implement and review the activities of the Association.

Regular academic meetings, which include case presentations, topic discussions and talks by invited speakers, are held monthly. Renowned overseas speakers have been invited to deliver lectures on subjects of special interest. Seminars, workshops, education programmes and talks to the public, general practitioners and other associations have been organised to enhance communication with the community and other medical specialties.

30th Birthday
HKUA will celebrate his 30th birthday during the 15th Urological Association of Asia Congress in Hong Kong and in this occasion they will organize the UAA Gala dinner to celebrate their Pearl Jubilee.

Local Sightseeing Tours

NO jewellery factories visits

City Tour
- Saturday 0915
- Sunday 1315
- 4½-5 hours duration

Each Tour HK$520 per person

Heritage Tour
- Saturday 1315
- Sunday 0915

Aqualuna Harbour Tour
- Monday afternoon
- HK$520

For booking, please contact the tour desk 9223 1865
Minimize stone migration
with the long pulse option of the
Rhapsody H-30® Holmium Laser System.*

Visit the laser skills lab (booth #A09) for a hands-on demonstration.

GENERAL INFORMATION

REGISTRATION DESK OPENING HOURS
The congress opens on Friday 4 August 2017 - 07:00 and closes on Sunday 6 August 2017 - 13:45.

Thursday 3 August: 08:00 – 17:30
Friday 4 August: 07:00 – 19:00
Saturday 5 August: 07:00 – 19:00
Sunday 6 August: 07:00 – 14:00

VENUE
The Hong Kong Convention and Exhibition Centre (HKCEC) is located in the heart of Hong Kong Victoria Harbour. The harbour provides a spectacular backdrop to this impressive exhibition and meeting venue. The facilities are located in the heart of the Hong Kong Island and just a few minutes’ walk from a wide range of hotels, and is readily accessible by various means of public transport.

Hong Kong Convention & Exhibition Centre (HKCEC)
Harbour Road, Wan Chai, Hong Kong

ORGANISING SECRETARIAT
In charge of registration, abstract handling, partnership & investment opportunities, hotel reservations.

MCI Suisse SA
9, Rue du Pré-Bouvier
1242 Satigny, Geneva
Switzerland

Phone: +61 2 8039 1920
Email: uaa2017reghot@mci-group.com

LOCAL ORGANISING SECRETARIAT
For social events, transfers, company events

MCI Hong Kong
Portion B1 G/F Tung Chong Factory Building
653-659 King’s Road
Quarry Bay, Hong Kong

Phone: +852 2911 7978
E-mail: uaa2017reghot@mci-group.com
Website: www.mci-group.com

BADGES
Access to all scientific events will only be possible with your personal badge which you will receive at the registration desk, located in the entrance hall level 0 on Harbour road entrance. All participants are requested to wear their name badge throughout the congress. For replacement of a lost badge a fee of USD 100.00 will be charged.

BADGES ARE COLOUR-CODED AS FOLLOW:
Transparent: Congress participants
Golden colour line: Invited speakers and committees
Green colour line: Exhibitors
Red colour line: Accompanying persons

COFFEE BREAKS
Coffee breaks are served in the exhibition area on level 1 from Friday to Sunday.

Friday 4 August: 10:15 – 10:45
Saturday 5 August: 10:15 – 10:45
Sunday 6 August: 10:15 – 10:45

CONGRESS EVALUATION
We would be grateful if you could take a few minutes to complete the evaluation form that will be sent to you by email after the congress. It will be used to get your opinion about the congress and the scientific programme. This will help us to continue improving the congress in future years.

CURRENCY
All official congress prices are indicated in US Dollars. The official currency in Hong Kong is the Hong Kong Dollar (HKD). All major credit cards are accepted in most hotels, restaurants and shops.

EXHIBITION
The UAA 2017 exhibition presenting the latest technical equipment and pharmaceutical products will take place in the convention hall foyer on level 1 and Mezzanine floor.

EXHIBITION OPENING HOURS
Friday 4 August: 09:00 – 17.30
Saturday 5 August: 09:00 – 17:30
Sunday 6 August: 09:00 – 14:00

INSURANCE
It is recommended that participants obtain adequate cover for travel, health and accident insurance before they depart from their countries. UAA and MCI as organisers cannot accept responsibility for personal injuries, or loss of, or damage to, private property belonging to the congress participants and accompanying persons.

LANGUAGE
The official language of the congress is English. There will be no simultaneous interpretation for the congress in the main sessions.
MOBILE APPLICATION
Get all the information you need at your fingertips with the UAA 2017 Mobile Application AVAILABLE FOR FREE ON APPLE AND GOOGLE PLAY STORES.

SCIENTIFIC INFORMATION ABSTRACTS
All accepted research abstracts are published in a Supplement of the International Journal of Urology available online.

CERTIFICATE OF ATTENDANCE
A certificate of attendance will be sent to all participants by email after the congress.

CONTINUED MEDICAL EDUCATION (CME) ACCREDITATION
The College of Surgeons of Hong Kong (CSHK) has accredited the UAA 2017 scientific programme. Please check website or Mobile App for exact number of hours. CME/CPD points.

CNE is accredited by Urology Nursing Chapter of Hong Kong Urological Association (Urology Nursing Chapter of Hong Kong Urological Association is accredited as a provider of continuing nursing education by the Nursing Council of Hong Kong for the period 21 Sept 2016 – 20 Sept 2019.)

ePOSTERS
ePosters will be available on touch screens for the whole duration of the congress in the ePoster area (level 2) during all breaks.

SPEAKER PREVIEW ROOM
The Speakers’ Preview Room is connected to all main lecture rooms. The Speaker Preview Room is located in the media room on, level 1.

INSTRUCTIONS FOR SPEAKERS & AUTHORS
Please locate your session room in due time and be there at least 15 minutes prior to the start of the session. Lecturers should deliver and view/check the presentation at the Preview Room at least 2 hours prior to the start of the respective session. For morning sessions, the PowerPoint presentation should be delivered on the previous day in order to avoid any delay. Please make sure you copy your presentation to the proper place. If you have a movie in the presentation or have difficulties with uploading, please ask help from the onsite technicians.

ACKNOWLEDGEMENTS
WITH SINCERE THANKS TO OUR SUPPORTING ORGANIZATIONS

Hong Kong Tourism Board European Association of Urology American Urological Association British Journal of Urology International (BJU) Société Internationale D’Urologie (SIU)
Urologia Internationalis offers many benefits to authors:

**Cost-effective publishing**
No submission fee, free online color figures, no page limit, no publication fee for papers of 3 printed pages or less.

**Rapid review**
A fast review process of less than 30 days after submission.

**Quality**
The journal stands out both for its efficient submission process and the excellent picture quality. Each article is fully copyedited by highly trained staff and monitored throughout every stage of its production.

**Impact**
Inclusion in all the major abstracting and indexing services including Journal Citation Reports, PubMed/MEDLINE, Biological Abstracts, Embase.

**Submission Guidelines for authors at**
www.karger.com/uin
INTRODUCING THE
da Vinci. Xi
SURGICAL SYSTEM

REVOLUTIONARY
ANATOMICAL ACCESS

CORE TECHNOLOGY

MAGNIFIED 3D HD VISION

ENDOWRIST® INSTRUMENTATION WITH INTUITIVE® MOTION

ENHANCED ERGONOMICS

Chindex Hong Kong Limited
Rm 903, 9/F, No.148 Electric Road, North Point, Hong Kong
Tel: (852) 2547-1536  Fax: (852) 2548-4664
### TUESDAY 1ST AUGUST 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>06:00</th>
<th>07:00</th>
<th>08:00</th>
<th>09:00</th>
<th>10:00</th>
<th>11:00</th>
<th>12:00</th>
<th>13:00</th>
<th>14:00</th>
<th>15:00</th>
<th>16:00</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Prince of Wales Hospital</td>
<td><strong>Asian Urology Residents’ Course I</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### WEDNESDAY 2ND AUGUST 2017

<table>
<thead>
<tr>
<th>Time</th>
<th>06:00</th>
<th>07:00</th>
<th>08:00</th>
<th>09:00</th>
<th>10:00</th>
<th>11:00</th>
<th>12:00</th>
<th>13:00</th>
<th>14:00</th>
<th>15:00</th>
<th>16:00</th>
<th>17:00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Place</td>
<td>Prince of Wales Hospital</td>
<td><strong>Asian Urology Residents’ Course II</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Convention Hall B + C</td>
<td>Theatre 1</td>
<td>Room 221</td>
<td>Room 224 + 225</td>
<td>Room 228</td>
<td>Theatre 2</td>
<td>Room 223</td>
<td>Room 227</td>
<td>Surgical Skills Center, Li Ka Shing Faculty of Medicine, The University of Hong Kong</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------------</td>
<td>-----------</td>
<td>----------</td>
<td>---------------</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>----------</td>
<td>---------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN LAPAROSCOPIC SURGERY (PORCINE DISSECTION)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN LAPAROSCOPIC SURGERY (PORCINE DISSECTION)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>MASTERCLASS IN KIDNEY CANCER</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event Description</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>OPENING CEREMONY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MORNING SYMPOSIUM: MEDIFOCUS ASIA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>OPENING CEREMONY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>PROSTATE CANCER GUIDELINES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>HEALTH ECONOMICS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>COFFEE &amp; TEA BREAK</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>OPENING CEREMONY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>ADVANCED ONCOLOGY I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>ANDROLOGY / MEN’S HEALTH</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>NURSING WORKSHOP 1: PRACTICAL ADVICE FOR BASIC UROLOGICAL CARE (PART I)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>ABSTRACTS PODIUM PRESENTATION 1 (VIDEO SESSION)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>ABSTRACTS PODIUM PRESENTATION 2 (URO-ONCOLOGY)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>TRANSPLANTATION</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>ABSTRACTS MODERATED POSTER 1 (VOIDING DISFUNCTION AND OTHER RENAL URINARY CONDITIONS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>ABSTRACT MODERATED POSTER 2 (BASIC AND TRANSLATIONAL RESEARCH)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>UAA BUSINESS MEETING OF THE GENERAL COUNCIL OF UAA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>MASTERCLASS IN ROBOTIC PROSTATECTOMY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>ASIAN SOCIETY OF UTI / STD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>ABSTRACT MODERATED POSTER 3 (NURSING SESSION)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>ABSTRACT MODERATED POSTER 4 (BLADDER CANCER AND TRANSITIONAL CELL CARCINOMA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>SEMI-LIVE SURGERY I</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>ASE / EASE / HKSE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>NURSING WORKSHOP 1: PRACTICAL ADVICE FOR BASIC UROLOGICAL CARE (PART II)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>ABSTRACT MODERATED POSTER 3 (NURSING SESSION)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>ABSTRACT MODERATED POSTER 4 (BLADDER CANCER AND TRANSITIONAL CELL CARCINOMA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>HKUA OPEN PUBLIC LECTURE</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Convention Hall B + C</td>
<td>Theatre 1</td>
<td>Room 221</td>
<td>Room 224 + 225</td>
<td>Room 228</td>
<td>Theatre 2</td>
<td>Room 223</td>
<td>Room 227</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------</td>
<td>-----------</td>
<td>----------</td>
<td>---------------</td>
<td>----------</td>
<td>-----------</td>
<td>----------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Venue/ Session</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>----------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:00</td>
<td>Convention Hall B + C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MORNING SYMPOSIUM - ERBE CHINA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>08:30</td>
<td>RECONSTRUCTIVE &amp; PAEDIATRIC UROLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:30</td>
<td>RECONSTRUCTIVE &amp; PAEDIATRIC UROLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>RECONSTRUCTIVE &amp; PAEDIATRIC UROLOGY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>MORNING PLENARY</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
DETAILED PROGRAMME
TUESDAY 1ST AUGUST

08:30 - 16:00  Asian Urology Residents’ Course I

08:30  WELCOME ADDRESS
Eddie CHAN (Hong Kong), Shin EGAWA (Japan)

08:45  MIS & UROLITHIASIS
08:45  My Journey of laparoscopic urology – what I have learned and what is next?
Allen CHIU (Taiwan)
09:00  How to treat lower pole stones?
Yuigi YUMINAGA (Japan)
09:10  Medical management of stone disease
Qasim Mohamed ALI LSA (Bahrain)
09:20  How to create an ideal PCN tract?
Ka Lun LO (Hong Kong)
09:35  How to prevent stone recurrence?
Reaksmey OUK (Cambodia)
09:45  Q&A

09:55  BENIGN PROSTATIC HYPERPLASIA
09:55  Pathophysiology of BPH
Keong-tatt FOO (Singapore)
10:10  Clinical assessment of male patients with lower urinary tract symptoms
Jerry Tsz LEUNG (Hong Kong)
10:20  Medical management of BPH
Riyank YADAV (India)
10:30  Surgical treatment of BPH
Shin EGAWA (Japan)
10:45  Q&A

10:55  TEA BREAK

11:10  FEMALE UROLOGY
11:10  How do you assess female patients with urinary incontinence?
Rais Syaeful HAQ (Indonesia)
11:20  Non-surgical treatment of stress urinary incontinence
Hamidreza SHEMSHAKI (Iran, Islamic Republic of)
11:30  Pharmacological treatment options of overactive bladder
Eni FUKAGAWA (Japan)
10:45  Surgical management of stress urinary incontinence
Peggy CHU (Hong Kong)
11:55  Q&A
12:05 **BLADDER CANCER**
12:05 Diagnostic challenges in non-muscle invasive bladder cancer
Syed Hasanul-Hadi SYED MOHSIN (Malaysia)
12:15 Treatment strategies for non-muscle invasive bladder cancer
Henry HO (Singapore)
12:30 Surgical management of muscle-invasive bladder cancer
Eddie CHAN (Hong Kong)
12:45 How to follow-up patients with bladder cancer?
Robin Bahadur BASNET (Nepal)
12:55 Q&A

13:05 **LUNCH BREAK**

14:05 **KIDNEY CANCER**
14:05 How to diagnose and stage RCC?
Paul Nimrod Borja FIRAZA (Philippines)
14:15 Surgical treatment of RCC
Ho-Yee TIONG (Singapore)
14:30 Immunotherapy for metastatic RCC
Darren POON (Hong Kong)
14:45 How to follow-up patients with RCC?
Yeow SIYING (Singapore)
14:55 Q&A

15:05 **TESTICULAR CANCER**
15:05 Diagnosis and staging of testicular tumours
Mariyanayagam AGNEL ANOMILAN (Sri Lanka)
15:15 What’s next if it is seminomatous germ cell tumour?
Chakorn TIOOKLURS (Thailand)
15:25 What’s next if it is non-seminomatous germ cell tumour?
Ming-Hsuan KU (Taiwan)
15:35 Role of retroperitoneal lymph node dissection for testicular cancer
Simon HOU (Hong Kong)
15:50 Q&A
DETAILED PROGRAMME

WEDNESDAY 2ND AUGUST

08:30 - 16:00  Asian Urology Residents’ Course II

PRINCE OF WALES HOSPITAL

08:30  OPENING ADDRESS
Michael WONG (Singapore)

08:35  PROSTATE CANCER 1
08:35  Controversies in PSA screening: Why all the commotion in the U.S.
   Sam CHANG (United States)
08:55  Localized prostate cancer: Evidence-based treatment options
   Sam CHANG (United States)
09:05  Chemotherapy and hormone therapy: the old has become new again
   Sam CHANG (United States)
09:25  New treatment agents for castration-resistant prostate cancer
   Sam CHANG (United States)
09:45  Q&A

10:05  TEA BREAK

10:25  RENAL TRANSPLANTATION
10:25  Immunosuppression in renal transplantation
   Dicken KO (United States)
10:45  Ischemia-reperfusion injury in renal transplantation
   Dicken KO (United States)
11:05  Living donor kidney transplantation with complex vasculature
   Dicken KO (United States)
11:25  Management of surgical complications of renal transplant
   Dicken KO (United States)
11:45  Q&A

12:00  LUNCH BREAK

13:00  ANDROLOGY AND INFERTILITY
13:00  Management of late-onset hypogonadism
   Cigdem TANRIKUT (United States)
13:20  The role of varicocelectomy in male fertility
   Cigdem TANRIKUT (United States)
13:40  Overview of sperm extraction techniques
   Cigdem TANRIKUT (United States)
14:00  Management of erectile dysfunction
   Cigdem TANRIKUT (United States)
14:20  Q&A
14:30  **TEA BREAK**

14:45  **UROLITHIASIS**

14:45  Optimization of extracorporeal shock wave lithotripsy  
       Manoj MONGA (United States)

15:05  The role of flexible ureteroscopy in treating renal stones  
       Manoj MONGA (United States)

15:25  Percutaneous nephrolithotomy: Surgical tips and instrumentation  
       Manoj MONGA (United States)

15:45  Q&A
DETAILED PROGRAMME
THURSDAY 3RD AUGUST

09:00 - 14:00  Asian Urology Residents’ Course III  
ROOM 224 - 225

08:00  OPENING ADDRESS
Ming-Kwong YIU (Hong Kong)

08:05  CASE PRESENTATION
  08:05  Urological trauma  
          Bill WONG (Hong Kong)
  08:25  Paediatric urology  
          Hau-Yee CHAN (Hong Kong)
  08:45  UAA guidelines 2015 for assessment of male LUTS/BPH with Case Examples  
          Keong Tat FOO (Singapore)
  09:05  Penile cancer  
          Lap-Yin HO (Hong Kong)

09:25  TEA BREAK

09:45  AURC / AUA INTERNATIONAL EXAMINATION
  09:45  MCQ
  12:45  Presenting certificate

13:00  COURSE END

09:00 - 17:00  Masterclass in kidney cancer  
ROOM 228

  09:00  Opening remarks  
          Ringo CHU (Hong Kong), Joseph WONG (Hong Kong)
  09:15  Advances in histopathology and molecular basis of RCC  
          KaFai TO (Hong Kong)
  09:45  Percutaneous biopsy of renal tumours: when, whom and how?  
          Alessandro VOLPE (Italy)
  10:15  Radiological Diagnosis & Ablative therapy in RCC  
          Carmen CHO (Hong Kong)

10:45  TEA BREAK

  11:00  Robotic & laparoscopic partial nephrectomy: Techniques  
          Joseph WONG (Hong Kong)
  11:30  Retroperitoneal robotic partial nephrectomy  
          Shuo WANG (China)
  12:00  Eliminating ischaemia: Non-clamping partial nephrectomy  
          Ringo CHU (Hong Kong)
# Detailed Programme

## Thursday 3rd August

### 13:00 **Lunch**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 13:30 | Surgical management of locally advanced RCC  
Daniel MOON (Australia)                     |
| 14:00 | Role of neoadjuvant & adjuvant systemic therapy in RCC  
Axel BEX (Netherlands)                     |
| 14:30 | RCC EAU guidelines 2017: What has changed?  
Alessandro VOLPE (Italy)                    |

### 15:00 **Tea Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 15:15 | Role of metastatectomy in mRCC  
Jian-Ri LI (Taiwan)                           |
| 15:45 | Managing complications associated with TKI in mRCC  
Darren POON (Hong Kong)                      |
| 16:15 | Emergence of Immunotherapy in mRCC  
Axel BEX (Netherlands)                        |
| 16:45 | Closing remarks                                                                           |

### 08:30 - 16:30 **Masterclass in 3-D Laparoscopic Urological Surgery and Flexible Ureteroscopy**

*Surgeon Skills Center, Li Ka Shing Faculty of Medicine, The University of Hong Kong*

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 08:30 | Welcome address  
Wai-Ki MA (Hong Kong)                                                                     |
| 08:40 | Laparoscopic upper tract surgery: different approaches  
Jens RASSWEILER (Germany)                                                                 |
| 08:55 | Minimizing renal ischaemia during laparoscopic nephron-sparing surgery  
Christian SCHWENTNER (Germany)                                                             |
| 09:05 | The role of simulation in nephron-sparing surgery  
Domenico VENEZIANO (Italy)                                                                 |
| 09:30 | Animal dissection with 3D laparoscopy - Lap. Partial nephrectomy / pyeloplasty - Wet model station - flexible Ureteroscopy |

### 12:00 **Lunch Break**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 12:45 | Flexible ureterorenoscopy: Tips and Tricks  
Janak DESAI (India)                                                                          |
| 13:00 | Development of laparoscopic urological surgery in China  
Zhu-Dong ZHANG (China)                                                                      |
| 13:15 | Nerve-sparing techniques in laparoscopie radical prostatectomy and cryoablation  
Lu-Tin MA (China)                                                                           |
| 13:30 | Animal dissection with 3D laparoscopy - Lap. ureteric reimplantation / cystectomy - Wet model station - flexible Ureteroscopy |

---

*15th Urological Association of Asia Congress*
DETAILED PROGRAMME
THURSDAY 3RD AUGUST

14:00 - 17:00  Young urologist section  
ROOM 224 - 225

14:00  WELCOME  
Man-Kay Li (Singapore)

14:05  INTRODUCTION TO THE UAA  
Allen CHIU (Taiwan)

14:15  PRESENTATION OF CERTIFICATES TO FELLOWS  
Shin EGAWA (Japan)

14:30  SESSION: RESEARCH AND WRITING AND PRESENTATIONS  
14:30  IMRAD: the basics of writing a paper  
Rajeev KUMAR (India)
15:00  Research methodologies: understanding study types  
Takeshi KAWAHARA (Japan)
15:20  Making effective presentations  
George LEE (Malaysia)

15:40  SESSION: TRAINING OPPORTUNITIES  
Moderator: Eddie CHAN (Hong Kong)
15:40  Experience with international training  
Wayne LAM (Hong Kong)
15:50  Training opportunities in the USA for Asian Urologists  
Manoj MONGA (United States)

16:00  SESSION: FELLOWS AND MEMBERS SESSION  
Moderator: Peggy CHU (Hong Kong)
16:00  How would I manage this case?  
Peggy CHU (Hong Kong)

16:40  UROLOGY IN MY COUNTRY  
Farzin SOLEIMANZADEH (Iran, Islamic Republic of)
DETAILED PROGRAMME
FRIDAY 4TH AUGUST

07:45 - 08:30 Medifocus Asia Limited Morning Symposium:
Changing the Natural History of BPH: A 10-Year Follow-Up Study of Prolieve Thermodilatation
Chairman: Raymond TONG (Hong Kong)
07:45 Welcome and Introduction
Raymond TONG (Hong Kong)
07:50 Changing the Natural History of BPH: A 10-Year Follow-up Study of Prolieve Thermodilatation
William JOW (USA)
08:20 Concluding Remarks and Q&A
Raymond TONG (Hong Kong), William JOW (USA)

08:30 - 08:50 Opening ceremony
CONVENTION HALL B-C

08:50 - 10:10 Morning plenary
CONVENTION HALL B-C
Moderators: Man-Kay LI (Singapore), Chi-Wai MAN (Hong Kong), Masato FUJISAWA (Japan), Allen CHIU (Taiwan)
08:50 AUA Lecture - AUA Localized Prostate Cancer Guidelines: What They Say and How We Decided
Sam CHANG (United States)
09:10 Epidemiology of Prostate Cancer in Asia
Zengnan MO (China)
09:30 UAA Lecture - Asian Guidelines: Too Good to be True?
Christophe CHAPPLE (United Kingdom)
09:50 Role of health economic analysis in guideline development
Eng-Kiong YEOH (Hong Kong)

10:10 - 10:45 COFFEE & TEA BREAK - OPENING CEREMONY OF THE EXHIBITION

10:45 - 12:30 Advanced oncology I
CONVENTION HALL B-C
Moderators: Chui Hee PARK (Korea), Osamu OGAWA (Japan), Chaiyong NUARYONG (Thailand), Alex LIN (Taiwan)
10:45 Robotic versus Open Cystectomy: Key Comparison Points
Sam CHENG (United States)
11:05 Radical cystectomy and urinary diversion: Laparoscopic or robotic?
Jian HUANG (China)
11:25 Bladder sparing treatment for muscle invasive bladder cancer
Byong Chang JEONG (Korea, Republic of)
11:45 Enhanced recovery after surgery in radical cystectomy
Lux-Shiong LEE (Singapore)
12:05 Debate: Adjuvant chemotherapy after radical cystectomy (support)
Keng-Siang PNG (Singapore), Cheng-Kuang YANG (Taiwan)
DETAILED PROGRAMME

FRIDAY 4TH AUGUST

10:45 - 12:30  Andrology / Men’s health  
THEATRE 1

Moderators: George LEE (Malaysia), Andrew YIP (Hong Kong), Peter CHIU (Hong Kong)

10:45  Late onset hypogonadism: Diagnosis and management  
Peter UM (Singapore)

11:05  Update in microsurgical technique for azoospermia  
Cigdem TANRIKUT (United States)

11:25  Penile prosthesis: an update  
Mike HSIEH (United States)

11:45  Update on Peyronie’s Disease in 2017  
Eric CHUNG (Australia)

12:05  Vasoepididymostomy in China  
Zheng LI (China)

10:45 - 12:30  Transplantation  
THEATRE 2

Moderators: Howard LAU (Australia), Lap Hong IAN (Macau), Tin-Yu CHU (Hong Kong)

10:45  Strategies to improve deceased organ donation  
WaiMing CHAN (Hong Kong)

11:05  Robotic kidney transplantation  
Rajesh AHLAWAT (India)

11:25  Combined kidney and pancreatic transplantation  
Ho-Yee TIONG (Singapore)

11:45  Vascular access for renal replacement therapy  
Alfred WONG (Hong Kong)

12:05  Penile transplantation  
Dicken KO (United States)

10:45 - 12:30  Abstracts Podium Presentation 1  
(Video Session)  
ROOM 224 - 225

Moderators: Shu-Keung LI (Hong Kong), Joseph HM WONG (Hong Kong), Kin-Man LAM (Hong Kong), Yee-Ping YUNG (Hong Kong)

10:45  OC1.04  NON-CLAMPING LAPAROSCOPIC PARTIAL NEPHRECTOMY USING CAVITRON ULTRASONIC SURGICAL ASPIRATOR (CUSA)  
Ringo Wing Hong CHU (Hong Kong)

10:54  OC1.10  “3R” TECHNIQUE FOR ROBOTIC PARTIAL NEPHRECTOMY  
Xiangjun LYU (China)

11:03  OC1.03  SURGICAL NAVIGATION USING INTUITIVE IMAGE-TO-PATIENT REGISTRATION FOR ROBOT-ASSISTED PARTIAL NEPHRECTOMY  
Satoshi KOBAYASHI (Japan)

11:12  OC1.02  INDOCYANINE GREEN: LIGHTHOUSE IN THE DARK OCEAN  
Ho Fai WONG (Hong Kong)

11:21  OC1.06  AN IMPROVED SCROTOSCOPIC TECHNOLOGY FOR HYDROCELECTOMY OF TESTIS  
Tiejun ZOU (China)

11:30  OC1.05  ZERO-ISCHEMIA, INDO-CYANIN GREEN ASSISTED ROBOTIC HEMINEPHRO-URETRECTOMY FOR A DUPLICATED RENAL COLLECTING SYSTEM: OUR NOVEL TECHNIQUE.  
Raj TIWARI (Singapore)
11:39 OC1.09  SUPINE NAVIGATION PERCUTANEOUS NEPHROLITHOTOMY WITH ENDOSCOPIC COMBINED INTRA-RENAL SURGERY (ECIRS) IN MODIFIED LITHOTOMY
Hin Lysander CHAU (Hong Kong)

11:48 OC1.07  COMBINED PERCUTANEOUS NEPHROLITHOTOMY (PCNL) AND RETROGRADE INTRARENAL SURGERY (RIRS) IN TREATMENT OF COMPLEX STONE DISEASE
Wayne Kwan Wai CHAN (Hong Kong)

11:57 OC1.08  SIMULTANEOUS ULTRA-MINI NAVIGATION PERCUTANEOUS NEPHROLITHOTOMY WITH UPPER POLE PUNCTURE
Hin Lysander CHAU (Hong Kong)

12:06 OC1.01  LONGITUDINAL INTUSSUSCEPTION VASEOEPIDIDYMOSTOMY: STEP BY STEP
Rajeev KUMAR (India)

12:06 OC1.07  COMBINED PERCUTANEOUS NEPHROLITHOTOMY (PCNL) AND RETROGRADE INTRARENAL SURGERY (RIRS) IN TREATMENT OF COMPLEX STONE DISEASE
Wayne Kwan Wai CHAN (Hong Kong)

12:15 OC1.11  RETAINED BROKEN PCN: AN INNOVATIVE BALLOON REMOVAL METHOD
Lee Fung LEE (China)

12:24 OC1.12  COMPLEX PFUDD WITH RECTO-URETHRAL FISTULA: A SURGICAL CHALLENGE
Vineet NARANG (India)

10:45 - 12:30 Abstracts Podium Presentation 2 (Uro-Oncology)

ROOM 228

Moderators: Edmund CHIONG (Singapore), Richard LO (Hong Kong)

10:45 OC2.11  HIGH LEVELS OF E2F1 PREDICT SHORTER DISEASE-FREE SURVIVALS OF PROSTATE CANCER PATIENTS
Hai HUANG (China)

10:52 OC2.12  THE APPLICATION OF PROSTATE HEALTH INDEX IN TAIWANESE PROSTATE CANCER DETECTION - A PROSPECTIVE VALIDATION
Yung-Ting CHEN (Taiwan)

11:00 OC2.06  EVALUATING THE CLINICAL UTILITY OF PROSTATE MRI: A FAUX MULTIDISCIPLINARY TEAM STUDY.
Samantha KOSCHEL (Australia)

11:16 OC2.08  PERMANENT IODINE-125 SEED BRACHYTHERAPY FOR LOW AND INTERMEDIATE RISK PROSTATE CANCER: 13 YEAR RESULTS AT A SINGLE AUSTRALIAN INSTITUTION
Andrej BECE (Australia)

11:24 OC2.09  IMPACT OF HIGH VOLUME DISEASE IN ASIAN POPULATION WITH NEWLY DIAGNOSED METASTATIC PROSTATE CANCER
Yung-Ting CHENG (Taiwan)

11:32 OC2.10  THE PRELIMINARY EFFICACY AND TOLERABILITY OF CHEMOTHERAPEUTIC THERAPY IN METASTATIC HORMONE-NAIVE PROSTATE CANCER – THE FIRST ASIA’S REAL LIFE EXPERIENCE
Darren MC POON (Hong Kong)

11:40 OC2.13  LOCO-REGIONAL CONTROL (LRC) IN PENILE CANCER (PECA)
Peter JOHNSTONE (United States)

11:48 OC2.03  NEUTROPHIL –LYMPHOCYTE RATIO (NLR) AS A BIOMARKER IN UROTHELIAL BLADDER CANCER
Girdhar Singh BORA (India)

11:56 OC2.02  IS PRIOR TB INFECTION CONTRAINDICATED FOR INTRAVESICAL BCG TREATMENT?
Che-Wei HSU (Taiwan)

12:04 OC2.01  THE INITIAL REPORT OF TRANSURETHRAL EN BLOC RESECTION OF BLADDER TUMOUR WITH A HYBRID KNIFE®.
Chun JIANG (China)
DetaileD pRogramme
FRIDAY 4TH AUGUST

12:12 OC2.05 REVIEW OF RADICAL AND PARTIAL NEPHRECTOMY FOR LOCALISED RENAL TUMOUR IN HONG KONG: A 5-YEAR MULTICENTRE STUDY
Chung Ting PUN (Hong Kong)

12:24 OC2.04 COMPARATIVE STUDY OF NEW RENAL TUMOR COMPLEXITY SCORING SYSTEM “3S+F” WITH R.E.N.A.L. SCORING SYSTEM
Shudong ZHANG (China)

10:45 - 12:30 Nursing workshop 1: Practical advice for basic urological care (part I) ROOM 221
Moderators: Shing-Hwa LU (Taiwan), Mei Sum YIM (Hong Kong)
With kind support from Tronda Electronics Ltd.
10:45 Welcome speech
Crystal LI (Hong Kong)
10:50 Anatomy & physiology of the urinary tract
Wai-Ki MA (Hong Kong)
11:10 Update on urological investigation
Khatijah BINTI ABDULLAH (Malaysia)
11:50 Tips on common urological nursing procedures
Karina SO (Australia)

10:45 - 12:30 Abstracts Moderated Poster 1 ROOM 223
(Voiding dysfunction and other benign urological conditions)
Moderators: Narmada GUPTA (India), Hing-Shing SO (Hong Kong)
10:50 PM01.12 SOLUBLE EPOXIDE HYDROLASE INHIBITION IMPROVES ERECTILE FUNCTION IN DIABETIC MICE THROUGH ATTENUATION OF FIBROSIS AND APOPTOSIS
Hao LI (China)
11:00 PM01.01 OUTCOME OF 980-NM DIODE LASER VAPORIZATION FOR BENIGN PROSTATIC HYPERPLASIA: A PROSPECTIVE STUDY
M Hammad Ali MITHANI (Pakistan)
11:05 PM01.04 HOLMIUM LASER ENucleATION OF THE PROSTATE PREVENTS POSTOPERATIVE STRESS INCONTINENCE IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA: RUNNING TITLE: TUEVP HOPEP OR POSTOPERATIVE STRESS INCONTINENCE
Wen-Hui SONG (China)
11:10 PM01.03 RENAL FUNCTION AFTER HOLMIUM LASER ENucleATION OF THE PROSTATE IN PATIENTS WITH BENIGN PROSTATE HYPERPLASIA
Taek Sang Kim (Korea, Republic of)
11:15 PM01.05 BLADDER WALL THICKNESS AND DETRUSOR WALL THICKNESS CAN HELP PREDICTING THE BLADDER OUTLET OBSTRUCTION IN MEN OVER THE AGE OF 70 YEARS WITH SYMPTOMATIC BENIGN PROSTATE HYPERPLASIA
Hwanchel SON (Korea, Republic of)
11:20 PM01.18 EFFICACY AND SAFETY OF MINIRIN MELT IN ELDERLY WITH NOCTURIA – A RANDOMIZED DOUBLE-BLINDED PLACEBO CONTROLLED TRIAL
Yiu Chung LAM (Hong Kong)
11:25 PM01.02 THE EFFICACY OF MIRABEGRON 50MG ADDITIONAL THERAPY ON TAMSULOSIN 0.2MG/0.4MG AND DUTASTERIDE 0.5MG COMBINATION THERAPY FOR LOWER URINARY TRACT SYMPTOMS OF ELDERLY TREATMENT-NAIVE BENIGN PROSTATIC HYPERPLASIA PATIENTS: PROSPECTIVE ANALYSIS
Han Soo CHUNG (Korea, Republic of)
11:30 PM01.15 THE TREATMENT OF BTX-A INJECTIONS FOR MALE PATIENTS WITH DO AND DESD SECONDARY TO SPINAL CORD INJURY IN CHINA
Hui CHEN (China)

11:40 PM01.09 LAPAROSCOPIC INSERTION OF PERITONEAL DIALYSIS CATHETER IN PEDIATRIC PATIENT AT CIPTO MANGUNKUSUMO HOSPITAL, JAKARTA-INDONESIA: OUR EARLY EXPERIENCE
Endrika NOVIANDRINI (Indonesia)

11:45 PM01.13 CHARACTERISTICS AND CLINICAL OUTCOMES OF LIVING RENAL DONOR IN HONG KONG: A RETROSPECTIVE REVIEW
Chi-Fai NG (Hong Kong)

11:50 PM01.14 TADALAFIL FOR MALE LOWER URINARY TRACT SYMPTOMS SUGGESTIVE OF BENIGN PROSTATIC HYPERPLASIA IMPROVES VASCULAR ENDOTHELIAL FUNCTION
Keiichiro HAYASHI (Japan)

12:05 PM01.06 ASSESSING PROSTATE VOLUME: SHOULD MRI BE THE NEW GOLD STANDARD?
Samantha KOSCHEL (Australia)

10:45 - 12:30 Abstract Moderated Poster 2
ROOM 227
Moderators: Eiji KIKUCHI (Japan), Hiroji UEMURA (Japan)

10:50 PM02.05 THE ROLE OF GENETIC POLYMORPHISMS IN IMMUNE RESPONSE GENES AND RESPONSE TO BACILLUS CALMETTE-GUERIN IMMUNOTHERAPY IN NMIBC PATIENTS IN ASIAN POPULATION
Yew Koon LIM (Hong Kong)

10:55 PM02.07 MIR-148A-3P REPRESSES PROLIFERATION AND EMT BY ESTABLISHING A TRI-CIRCUIT BETWEEN ERBB3/AKT/CAMYC/CCAT1 AND DNMT1 IN BLADDER CANCER
Xiao WANG (China)

11:00 PM02.08 HIGH-THROUGHPUT CHEMICAL SCREENING FOR SENSITIZATION OF BLADDER CANCER TO GEMCITABINE AND CISPLATIN CHEMOTHERAPY
Yuki KITA (Japan)

11:05 PM02.02 THERAPEUTIC EFFICACY OF AN ORIDONIN ANALOGUE FOR UROLOGIC MALIGNANCIES
Jiancheng ZHOU (United States)

11:15 PM02.09 LNCLBCS INHIBITS THE SELF-RENEWAL OF BLADDER CANCER STEM CELLS THROUGH HNRNPK-MEDIATED SOX2 REPRESSION
Xu CHEN (China)

11:20 PM02.10 PHARMACOCHEMICAL ASSOCIATION BETWEEN XRCC1 POLYMORPHISMS AND IMPROVED OUTCOMES IN BLADDER CANCER PATIENTS FOLLOWING INTRAVESICAL INSTILLATION OF EPIRUBICIN
Zengjun WANG (China)

11:25 PM02.11 H19-DERIVED MIR-675 CONTRIBUTES TO BLADDER CANCER CELL PROLIFERATION BY REGULATING P53 ACTIVATION
Zengjun WANG (China)

11:35 PM02.15 ADIPONECTIN DEFICIENCY RESULTS IN REACTIVATION OF MEK-ERK-P90RSK SIGNALING IN PROSTATE CANCER
Shi FU (China)

11:40 PM02.14 THE WATER CHANNEL AQUAPORIN 3 IS MAINLY INTRACELLULAR IN PROSTATE CANCER, AND ITS PLASMA MEMBRANE INSERTION IS REGULATED BY RALA
Jianbo WANG (China)
11:45  PM02.12  ASSOCIATION OF THE GLUTATHIONE S-TRANSFERASE M1, T1 POLYMORPHISMS WITH CANCER: EVIDENCE FROM A META-ANALYSIS
Zengjun WANG (China)

11:50  PM02.17  APPLICATION OF WNT PATHWAY INHIBITOR DELIVERING SCAFFOLD FOR INHIBITING FIBROSIS IN URETHRA STRICTURES: IN VITRO AND IN VIVO STUDY
Kaile ZHANG (China)

11:55  PM02.01  CONCURRENT EXPOSURE TO BISPHENOL A AND NONYLPHENOL ASSOCIATED WITH THE BALANCE OF ANDROGEN AND ESTROGEN IN THE PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA
Wei-Hsiang CHANG (Taiwan)

12:00  PM02.18  MECHANICALLY-INDUCED ATP RELEASE HAS OSCILLATIONS IN CORRELATION WITH THE CX43 EXPRESSION IN UROTHEelial CELLS.
Atsushi SENGIKU (Japan)

12:10  PM02.13  PROGNOSTIC ROLE OF SECRETORY CLUSTERIN IN MULTIPLE HUMAN MALIGNANT NEOPLASMS IN 26 IMMUNOHISTOCHEMISTRY ARTICLES: A META-ANALYSIS
Zengjun WANG (China)

12:30 - 14:00  Janssen Afternoon Symposium
CONVENTION HALL B-C
The Evolution in the treatment of metastatic hormone sensitive Prostate Cancer (mHSPC)
Chairman: Edmund CHIONG (Singapore)

12:30  Welcome and Introduction
Edmund CHIONG (Singapore)

12:50  Updates in STAMPEDE from ASCO
Gerhardt ATTARD (United Kingdom)

13:15  Updates in LATITUDE from ASCO
Dingwei YE (China)

13:40  Panel Discussion
Gerhardt ATTARD (United Kingdom), Dingwei YE (China), Wai-Kit MA (Hong Kong)

12:30 - 14:00  Olympus Hong Kong and China Limited Symposium:
CONVENTION HALL B-C
Advanced Imaging Technology in Laparoscopic Urology
Chairman: Ringo CHU (Hong Kong)

12:30  Welcome and Introduction
Ringo CHU (Hong Kong)

12:45  3D Laparoscopy: To infinity and Beyond
Tiong Ho YEE (Singapore)

13:25  Segmental artery clamping partial nephrectomy: Tips and tricks
Joseph WONG (Hong Kong)

14:00 - 17:00  Semi-live surgery I
CONVENTION HALL B-C
Moderators: Soo Dong KIM (Korea), Chi-Wai FAN (Hong Kong), Chi-Kwok CHAN (Hong Kong)

14:00  RIRS with Avicenna Roboflex
Yasser FARAHAT (United Arab Emirates)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:20</td>
<td>ICG assisted varicocelectomy</td>
</tr>
<tr>
<td></td>
<td>Chak-Lam CHO (Hong Kong)</td>
</tr>
<tr>
<td>14:40</td>
<td>MESA and micro-TESE</td>
</tr>
<tr>
<td></td>
<td>Cigdem TANRIKUT (United States)</td>
</tr>
<tr>
<td>15:00</td>
<td>Donor nephrectomy</td>
</tr>
<tr>
<td></td>
<td>Howard LAU (Australia)</td>
</tr>
<tr>
<td>15:20</td>
<td>Image assisted robotic assisted partial nephrectomy</td>
</tr>
<tr>
<td></td>
<td>Isotan SHUJI (Japan)</td>
</tr>
<tr>
<td>15:40</td>
<td>Laparoscopic IVC thrombectomy</td>
</tr>
<tr>
<td></td>
<td>Lu-Lin MA (China)</td>
</tr>
<tr>
<td>16:00</td>
<td>&gt;100g prostate: Green light laser</td>
</tr>
<tr>
<td></td>
<td>Dicken KO (United States)</td>
</tr>
<tr>
<td>16:20</td>
<td>Total exenteration</td>
</tr>
<tr>
<td></td>
<td>Declan MURPHY (Australia), Raj NAIR (Australia)</td>
</tr>
</tbody>
</table>

**14:00 - 17:00 ASE / EASE / HKSE section**

**THEATRE 1**

**14:00 WELCOME ADDRESS**

- Tadashi MATSUDA (Japan), Gyung Tak Mario SUNG (Korea, Republic of), Joseph WONG (Hong Kong)

**14:10 SECTION 1**

- **Moderators:** Joel ALDANA (Philippines), Tadashi MATSUDA (Japan), Joseph WONG (Hong Kong)

  - **14:10** New Korea surgical robot – initial experience  
    - Koon-Ho RHA (Korea, Republic of)

  - **14:25** Retroperitoneal approach in robotic urological surgery  
    - Kuan-hua HUANG (Taiwan)

  - **14:55** The way in searching of early continent control after my minimally invasive radical prostatectomy  
    - Kun-Yuan CHU (Taiwan)

  - **15:10** SentHance Surgical Robotic System: Building on the Principles of Laparoscopy  
    - Gyung Tak Mario SUNG (Korea, Republic of)

**15:25 HKSE ANNUAL GENERAL MEETING / BREAK**

**15:40 SECTION 2**

- **Moderators:** Tae-Gyun KWON (Korea, Republic of), Saint SHIOU-SHENG (Taiwan), Xin GAO (China)

  - **15:40** Past, present and future of RIRS  
    - Ill-Young SEO (Korea, Republic of)

  - **15:55** Transurethral en bloc resection of bladder tumor  
    - Jeremy TEOH (Hong Kong)

  - **16:10** Robotic assisted kidney autotransplantation: initial experience  
    - Motoo ARAKI (Japan)

  - **16:25** Laparoscopic radical prostatectomy for locally advanced prostate cancer – Case selection and surgical techniques  
    - Xin GAO (China)
16:40  How to maximize the use of flexible ureterorenoscope for RIRS and ECIRS  
Sung-Yong CHO (Korea, Republic of)

16:55  Tips and tricks of zero-ischemia HALS partial nephrectomy  
Jae Young PARK (Korea, Republic of)

14:00 - 17:00  Asian society of UTI / STD  
THEATRE 2

14:00  SYMPOSIUM I: DIGEST OF UAA/AAUS-UTI/GTI/STI GUIDELINES

- Moderators: Yong-Hyun CHO (Korea, Republic of), Shingo YAMAMOTO (Japan)
- Uncomplicated UTI  
  Katsumi SHIGEMURA (Japan)
- Complicated UTI in neurogenic bladder  
  Bill WONG (Hong Kong)
- UTI in children  
  Stephen YANG (Taiwan)
- GTI  
  SeungJu LEE (Korea, Republic of)
- STI  
  Ryoichi HAMASUNA (Japan)

15:30  SYMPOSIUM II: PREVENTION OF INFECTIOUS COMPLICATION OF PROSTATE BIOPSY

- Moderators: Tetsuro MATSUMOTO (Japan), Yong-Gil NA (Korea, Republic of)
- Antibiotic procedure  
  Zhen DU (China)
- Non-antibiotic procedure  
  James TSU (Hong Kong)

16:00  SYMPOSIUM III: MULTIDRUG-RESISTANT BACTERIA AND RECURRENT UTI

- Moderators: Ryoichi HAMASUNA (Japan), Wai-Kit MA (Hong Kong)
- Prevalence of multidrug-resistant uropathogens in Asia  
  Masahiro MATSUMOTO (Japan)
- Antibiotic treatment for recurrent UTI caused by multidrug-resistant bacteria  
  Leyland CHUANG (Singapore)
- Prevention of recurrent UTI  
  Hana YOON (Korea, Republic of)

14:00 - 17:00  Masterclass in robotic prostatectomy  
ROOM 228

- Moderators: Wai-Hee CHAN (Hong Kong), James LI (Hong Kong), Samuel YEE (Hong Kong)
- Anatomy of prostate: the current understanding  
  Gang ZHU (China)
- Indication for nerve sparing surgery  
  Edmund CHIONG (Singapore)
- Techniques of a nerve-sparing prostatectomy  
  Sam CHANG (United States)
- Techniques to improve continence: do we need them all?  
  Shigeo HORIE (Japan)
## Detailed Programme

### Friday 4th August

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>15:20</td>
<td>Radical prostatectomy for high risk cancer</td>
<td>Chao Yuan Huang (Taiwan)</td>
</tr>
<tr>
<td>15:40</td>
<td>Lymph node dissection: When and how?</td>
<td>Jens Rassweiler (Germany)</td>
</tr>
<tr>
<td>16:00</td>
<td>Sentinel Node Biopsy in Prostate Cancer: Is It Helpful?</td>
<td>Jun Hyuk Hong (Korea, Republic of)</td>
</tr>
<tr>
<td>16:20</td>
<td>Video session: Intra-operative complication and management</td>
<td>KoanHo Rha (Korea, Republic of)</td>
</tr>
<tr>
<td>16:40</td>
<td>Tips and tricks for challenging prostatectomy</td>
<td>Simon HOU (Hong Kong)</td>
</tr>
</tbody>
</table>

### 14:00 - 17:00 Nursing workshop 1: Practical advice for basic urological care (Part II)

**Room 221**

- **Speakers:** Shun-Fai CHU (Hong Kong), Alan IP (Hong Kong), Yuen-Ching KAM (Hong Kong), Winnie Ka Wai YEUNG (Hong Kong), Sze-Wan KWOK (Hong Kong), Yuen-Bing TSE (Hong Kong)

**Hands on training**

1. How to use a bladder scanner
2. Indwelling catheterization care
3. PCN equipment, dressing & flushing techniques

### 14:00 - 17:00 Abstract Moderated Poster 3 (Nursing session)

**Room 224-225**

**Moderator:** Sau Loi NG (Hong Kong)

- **PM03.18**
  - **How does bladder training and lifestyle modifications make a difference to the management of patients with overactive bladder?**
  - **Y. C. KAM** (Hong Kong)

- **PM03.19**
  - **Percutaneous Tibial Nerve Stimulation (PTNS) therapy for patients with overactive bladder syndrome who failed oral medication therapy.**
  - **Y. Ka Wai Winnie** (Hong Kong)

- **PM03.07**
  - **Provision of “Walk-In” nursing service from nurse-led clinic reduce the unnecessary emergency attendance and admission.**
  - **Y. B. TSE** (Hong Kong)

- **PM03.04**
  - **Enhance safety of cytotoxic drug (Mitomycin C, MMC) instillation procedure for post TURBT patients by introducing use of a catheter valve.**
  - **M. F. NG** (Hong Kong)

- **PM03.05**
  - **Intravesical Bacillus Calmette-Guerin (IV BCG) treatment for bladder cancer – working toward better patient outcome.**
  - **S. LAM** (Hong Kong)

- **PM03.06**
  - **Patients discharged from urologic ward return to emergency department in 72 hours: the clinical features.**
  - **A.-C. CHEN** (Taiwan)

- **PM03.08**
  - **Promoting and maintaining a proper urine bag emptying practice to reduce the risk of catheter-associated urinary tract infection.**
  - **H. L. SO** (China)

- **PM03.09**
  - **Can save napkin for inspection tell the severity of visual haematuria.**
  - **K. K. YAN** (Hong Kong)
DETAILED PROGRAMME
FRIDAY 4TH AUGUST

14:50  PM03.12  INFLUENCING FACTORS OF PELVIC FLOOR MUSCLE TRAINING ADHERENCE FOR POSTPROSTATECTOMY URINARY INCONTINENCE: APPLICATION OF THE HEALTH BELIEF MODEL AMONG KOREAN PATIENTS
J. H. KIM (Korea, Republic of)

14:55  PM03.20  EVALUATION OF THE TREATMENT OUTCOMES OF CLEAN INTERMITTENT CATHETERIZATION ON ACUTE URINARY RETENTION
K. K. LEUNG (Hong Kong)

15:00  PM03.02  REVIEWING CLINICAL OUTCOMES ON SELF-URETHRAL CALIBRATION FOR PATIENTS WITH URETHRAL STRICTURE IN NORTH DISTRICT HOSPITAL
S. W. A. WONG (Hong Kong)

15:05  PM03.01  PREVALENCE OF METABOLIC SYNDROME IN MALE PATIENTS WITH LOWER URINARY TRACT SYMPTOM IN HONG KONG
S. Y. C. LI (Hong Kong)

15:10  PM03.21  COMPARISON OF CONTINENCE STATUS IN PATIENTS UNDERWENT OPEN SURGERY, FIRST OR SECOND GENERATION ROBOTIC RADICAL PROSTATECTOMY
S. Y. C. LI (Hong Kong)

15:15  PM03.17  UROLOGY NURSE-LED CLINIC HELPS IN EARLY DETECTION AND MANAGEMENT OF URINARY TRACT STONES AMONG PATIENTS PRESENTED WITH UNILATERAL OR BILATERAL LOIN(S) PAIN
L. YEUNG (Hong Kong)

15:20  PM03.13  MEETING DEMAND : A NURSE-LED ERECTILE DYSFUNCTION SERVICE
V. Y.K. IP (Australia)

15:25  PM03.15  MANAGEMENT OF ERECTILE DYSFUNCTION WITH LOW INTENSITY EXTRACORPOREAL SHOCK WAVE THERAPY
G. K. L. LUI (Hong Kong)

15:30  PM03.14  OCCURRENCE OF LOWER URINARY TRACT SYMPTOMS AND SEXUAL DYSFUNCTION AND THEIR EFFECTS ON QUALITY OF LIFE AMONG MALE OUTPATIENTS IN A PUBLIC HOSPITAL
K. Lim ABDULLAH (Malaysia)

15:35  PM03.16  NURSE-LED URINARY TRACT STONE TRIAGE SERVICE: IS IT EFFECTIVE, EFFICIENT AND ECONOMICAL?
M. LI (Hong Kong)

14:00 - 17:00  Abstract Moderated Poster 4
(Bladder cancer and transitional cell carcinoma)  ROOM 227

Moderators: Lui-Shiong LEE (Singapore) , Wing-Hang AU (Hong Kong)

14:00  PM04.13  PREOPERATIVE PROGNOSTIC NUTRITIONAL INDEX AND NOMOGRAM PREDICTING RECURRENCE-FREE SURVIVAL IN PATIENTS WITH PRIMARY NON-MUSCLE INVASIVE BLADDER CANCER
Jianfeng CUI (China)

14:05  PM04.30  A PROSPECTIVE COMPARISON OF NARROW-BAND IMAGING CYSTOSCOPY TO STANDARD WHITE LIGHT CYSTOSCOPY IN MALIGNANT BLADDER LESIONS
Kanthi THANDAPANI (Singapore)

14:10  PM04.11  DYNAMIC REAL-TIME MICROSCOPE OF BLADDER UROTHELIAL CARCINOMA USING CONFOCAL LASER ENDOMICROSCOPY
Yiping ZHU (China)
DETAILED PROGRAMME
FRIDAY 4TH AUGUST

14:15 PM04.28 GENE EXPRESSION PROFILE OF THE CLINICALLY SESSILE ARCHITECTURE AND PAPILLARY ARCHITECTURE OF UPPER TRACT URINARY CARCINOMA
Deyong YANG (China)

14:20 PM04.31 EN BLOC TRANURETHRAL RESECTION WITH HYBRID KNIFE FOR TREATMENT PRIMARY NON-MUSCLE-INVASIVE BLADDER CANCER: A SINGLE-CENTER, RANDOMIZED, CONTROLLED TRIAL.
Jia HU (China)

14:25 PM04.15 DETRUSOR MUSCLE SAMPLING RATE AFTER TRANURETHRAL EN BLOC VERSUS STANDARD RESECTION OF BLADDER TUMOUR
Jeremy Yuen Chun TEOH (Hong Kong)

14:30 PM04.27 TRANURETHRAL ENDOSCOPIC SUBMUCOSAL DISSECTION OF BLADDER TUMOR WITH HYBRID KNIFE – 26 CASES REPORT
Jie ZHU (China)

14:35 PM04.10 A COMPARISON STUDY OF ENDOSCOPIC SUBMUCOSAL DISSECTION (ESD) VERSUS CONVENTIONAL TURBT FOR NON-MUSCLE INVASIVE BLADDER CANCER
Yongyi CHENG (China)

14:40 PM04.16 TRANURETHRAL SUBMUCOSAL EN BLOC DISSECTION USING HYBRID-KNIFE COMBINE WITH INTRAVESICAL PIRARUBICIN INSTILLATION FOR NON-MUSCLE INVASIVE BLADDER CANCER
Yongyi CHENG (China)

14:45 PM04.22 SELECTION AND OPTIMIZATION OF LAPAROSCOPIC RADICAL CYSTECTOMY AND URINARY DIVERSION IN FEMALE PATIENTS: A SINGLE CENTER’S EXPERIENCE OF 52 CASES
Fan XINXIANG (China)

14:50 PM04.18 COMPARATIVE EFFICACY OF NEW TECHNOLOGY-ASSISTED TRANURETHRAL RESECTION OF PATIENTS WITH NON-MUSCLE INVASIVE BLADDER CANCER: SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS
Changhao CHEN (China)

14:55 PM04.19 THE NUMBER OF CIRCULATING TUMOR CELLS DOES NOT INCREASE DURING TRANURETHRAL RESECTION OF THE BLADDER TUMOR
Kosuke KITAMURA (Japan)

15:00 PM04.07 OUTCOME OF SECOND-LOOK TRANURETHRAL RESECTION OF BLADDER TUMOR FOR T1 BLADDER CANCER: A FIVE-YEAR EXPERIENCE AT A SINGLE CENTER
Wen-Hsin TSENG (Taiwan)

15:10 PM04.17 PROSPECTIVE IMPLEMENTATION OF ENHANCED RECOVERY AFTER SURGERY (ERAS) PROTOCOLS TO RADICAL CYSTECTOMY
Karl Ho PANG (United Kingdom)

15:20 PM04.02 SHORTER LENGTH OF STAY AFTER RADICAL CYSTECTOMY WITH ENHANCED RECOVERY PROTOCOL
Ikhlas Arief BRAWONO (Indonesia)

15:25 PM04.25 NEOADJUVANT CHEMOTHERAPY IMPROVES THE SURVIVAL OUTCOME IN PATIENTS WITH MUSCLE INVASIVE BLADDER CANCER
Hoi Lung WONG (Hong Kong)

15:50 PM04.08 COMPARISON OF RADICAL CYSTECTOMY AND PARTYIAL CYSTECTOMY IN CT2 BLADDER CANCER:A 10-YEAR EXPERIENCE IN CMUH
Wen-Hsuan HUANG (Taiwan)

16:00 PM04.01 EVALUATION OF EFFECTIVENESS AND ADVERSE EFFECTS OF GEMCITABIN-CISPLATIN CHEMOTHERAPY ADMINISTRATION IN METASTATIC BLADDER CANCER: A SINGLE-CENTER EXPERIENCE
Christof TOREH (Indonesia)
## DETAILED PROGRAMME

### FRIDAY 4TH AUGUST

**16:05 PM04.20**  
URETROSCOPE AND BIOPSY CAN PERFORM RISK STRATIFICATION IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS  
Runzhuo MA (China)

**16:10 PM04.06**  
DETECTING UPPER TRACT UROTHELIAL CANCER BY WHOLE BODY FDG PET/CT  
Han-Yu WENG (Taiwan)

**16:15 PM04.05**  
BOWEL COMPLICATION OF HAND ASSISTED RETROPERINEOSCOPIC NEPHROURETERECTOMY: MECHANISM AND MANAGEMENT  
ZeHong LU (Taiwan)

**16:20 PM04.14**  
INTERMEDIATE-TERM ONCOLOGICAL OUTCOME OF HAND-ASSISTED RETROPERITONEOSCOPIC NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA  
Ta-Yao TAI (Taiwan)

**16:25 PM04.24**  
LAPAROENDOSCOPIC SINGLE-SITE SURGERY FOR RADICAL NEPHROURETERECTOMY WITH BLADDER CUFF EXCISION: A SINGLE-INSTITUTIONAL EXPERIENCE OF 30 CASES IN CHINA  
Qingyi ZHU (China)

**16:30 PM04.21**  
PROGNOSTIC ROLE OF PROGRAMMED CELL DEATH PROTEIN 1 IN UPPER TRACT UROTHELIAL CARCINOMA PATIENTS TREATED WITH RADICAL NEPHROURETOMA  
Nozomi HAYAKAWA (Japan)

### 17:15 - 18:30  
**Astellas Pharma Inc. Evening Symposium**  
**CONVENTION HALL B-C**

- **Modern management of OAB: challenges in adherence**  
  **Chairmen:** Chi Hang YEE (Hong Kong)
  
  **17.15**  
  **Introduction – Prevalence and risk factors of LUTS/OAB**  
  Chi Hang YEE (Hong Kong)

  **17.25**  
  **Management of OAB: Spotlight on treatment adherence**  
  Andrea TUBARO (Italy)

  **17.50**  
  **Managing OAB patients: Experience from clinical practice**  
  Hana YOON (Korea)

  **18.10**  
  **Questions & Answers**  
  Audience and faculty, moderated by the chairman

  **18.25**  
  **Closing remarks**  
  Chi Hang YEE (Hong Kong)

### 17:15 - 18:30  
**Amgen Asia Holding Limited Evening Symposium:**  
**ROOM 221**

- **Advanced Prostate Cancer Bone Metastases in Asia and Optimising SRE Prevention**  
  **Chairman:** Darren POON (Hong Kong)

  **17:15**  
  **Welcome and Introduction**  
  Darren POON (Hong Kong)

  **17:20**  
  **SRE Prevalence of Advanced Prostate Cancer in Asia**  
  Anthony Ng Chi FAI (Hong Kong)

  **17:35**  
  **Optimising SRE Prevention in Advanced Prostate Cancer**  
  Alan SO (Canada)

  **18:15**  
  **Question and Answer Session**  
  Darren POON (Hong Kong)
### 17:15 - 18:30  Karl Storz Evening Symposium

**KARL STORZ IMAGE 1S Showcase Symposium**

**Moderator:** Ming Kwong YIU (Hong Kong)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:15</td>
<td>Welcome Introduction</td>
<td>Ming Kwong YIU (Hong Kong)</td>
</tr>
<tr>
<td>17:20</td>
<td>PCNL+ Flexible Ureteroscope in treatment of Renal Calculi</td>
<td>Jianxing LI (China)</td>
</tr>
<tr>
<td>17:40</td>
<td>Three-port Laparoscopic Radical Prostatectomy</td>
<td>Qian ZHANG (China)</td>
</tr>
<tr>
<td>18:00</td>
<td>ICG application for Urological Surgeries</td>
<td>Joseph Honming WONG (Hong Kong)</td>
</tr>
<tr>
<td>18:20</td>
<td>Questions and Answers</td>
<td></td>
</tr>
</tbody>
</table>

### 17:45 - 18:45  HKUA Open Lecture

**THEATRE 2**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>
07:45 - 08:30  Ferring Morning Symposium  
ROOM 221  
The prostate and beyond – Research updates and best practices with androgen deprivation therapy in prostate cancer

07:30  Registration
07:40  Welcome and introduction  
Per-Anders ABRAHAMSSON (Denmark)
07:45  State of the art lecture:  
The Evolving Role of Androgen Deprivation Therapy in Prostate Cancer Management: Current Advances in Research  
Bertrand TOMBAL (Belgium)
08:15  Interactive panel discussion:  
From Evidence to Practice: Decision Making in Asian Settings  
All faculty, Discussant: Jeremy TEOH (Hong Kong)
08:30  Meeting ends

08:30 - 10:10  Morning plenary  
CONVENTION HALL B-C  
Moderators: Khai Lee TOH (Singapore), David WINKLE (Australia), Farzin SOLEIMANZADEH (Iran, Islamic Republic of)

08:30  EAU Lecture - Active Surveillance of Prostate cancer  
Freddie HAMDY (United Kingdom)
08:50  ACU lecture: Development of prostate cancer management in Hong Kong  
Yau-Tung CHAN (Hong Kong)
09:10  How to improve the scientific impact of Asian urological research to the world  
Masato FUJISAWA (Japan)
09:30  Management of metastatic hormonal sensitive prostate cancer  
Gerhardt ATTARD (United Kingdom)
09:50  Advanced prostate cancer management - Hong Kong consensus statement by HKUA/HKSUO  
Lap-Yin HO (Hong Kong), Darren POON (Hong Kong)

10:10-10:45  COFFEE & TEA BREAK

10:45 - 12:30  Advanced oncology II  
CONVENTION HALL B-C  
Moderators: Francis LEE (Hong Kong), Yao-Chi CHUANG (Taiwan), Marco CHAN (Hong Kong), Mototsugu OYA (Japan)

10:45  Debate: Mass clamping vs. Selective artery clamping in partial nephrectomy  
Ringo CHU (Hong Kong), Tae-Gyun KWON (Korea, Republic of)
11:05  Management of Oligometastasis in prostate cancer  
Shigeo HORIE (Japan)
11:25  Clinical management for upper tract urothelial carcinoma in Japan  
Eiji KIKUCHI (Japan)
11:45  Radium-223 in bony mCRPC: Japanese real-life experience  
Hiroji UEMURA (Japan)
12:00  Penile cancer: Has the local tumor management evolved over the years?  
Krishna SETHIA (United Kingdom)
12:15 Update on lymph node management in penile cancer - is the genie out of the bottle?  
Wayne LAM (Hong Kong)

10:45 - 12:30 Uro-radiology  
Moderators: MA SALAM (Bangladesh), Rajeev KUMAR (India), Phone MYINT (Myanmar)

10:45 MRI as a work up for prostate cancer  
Raghunandan VIKRAM (United States)

11:05 Prostate targeted biopsy - An update  
WaiKit MA (Hong Kong)

11:25 Systemic work up for prostate cancer  
Gladys LO (Hong Kong)

11:45 Focal therapy for prostate cancer: Who? When? How?  
Arjun SWARAMAN (United States)

12:05 Prostate artery embolization  
Simon YU (Hong Kong)

10:45 - 12:30 AUSTEG session  

10:45 The evolution of ureteroscopy - Robotic, disposable, micro-URS: Are we off track?  
Jens RASSWEILER (Germany)

11:15 Does tract size matter in PCNL?  
Bannakij LOJANAPIWAT (Thailand)

11:30 The final statement on ureteral access sheath - does it do more harm than good?  
Michael WONG (Singapore)

11:45 ERAS in stone surgery  
Gang ZHU (China)

12:00 The optimal usage of laser in stone management  
George LEE (Malaysia)

10:45 - 12:30 Abstracts Podium Presentation 3 (Basic and Translation Research)  

10:45 OC3.07  
GERMLINE MUTATIONS IN DNA REPAIR GENES ARE SIGNIFICANTLY ENRICHED IN LETHAL PROSTATE CANCER AND ARE ASSOCIATED WITH DISEASE SURVIVAL  
Jianfeng XU (United States)

10:52 OC3.09  
IDENTIFICATION OF ENDONUCLEASE DOMAIN-CONTAINING 1 AS A NOVEL TUMOR SUPPRESSOR IN PROSTATE CANCER  
Ke LI (China)

11:06 OC3.05  
OVEREXPRESSION OF OLC1 IN BLADDER UROTHELIAL CARCINOMA AND ITS CLINICAL SIGNIFICANCE  
Jianzhong SHOU (China)

11:20 OC3.04  
THE ROLE OF VITAMIN D RECEPTOR POLYMORPHISMS IN PREDICTING RESPONSE TO THERAPY IN NON-MUSCLE INVASIVE BLADDER CARCINOMA  
Yew Koon LIM (Hong Kong)

11:27 OC3.01  
LINCRNA-BLAT1 PROMOTES METASTASIS AND PROLIFERATION OF BLADDER CANCER BY MODULATING TRANSLATION OF P53  
Changhao CHEN (China)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Code</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:34</td>
<td>OC3.10</td>
<td>ANALYSIS OF PANEL GENES MUTATION IN TAIWANESE RENAL CELL CARCINOMA</td>
<td>See-Tong Pang (Taiwan)</td>
</tr>
<tr>
<td>11:41</td>
<td>OC3.06</td>
<td>SPHINGOSINE KINASES 1 IS A NOVEL MOLECULAR THERAPEUTIC TARGET FOR RENAL CELL CARCINOMA</td>
<td>Yunze Xu (China)</td>
</tr>
<tr>
<td>11:48</td>
<td>OC3.02</td>
<td>ASSOCIATIONS BETWEEN PHTHALATE METABOLITES AND OXIDATIVE STRESS IN ADULT MALE WITH BENIGN PROSTATIC HYPERPLASIA</td>
<td>Chia-Yu Wang (Taiwan)</td>
</tr>
<tr>
<td>12:02</td>
<td>OC3.12</td>
<td>A NOVEL TRAINING MODEL FOR LAPAROSCOPIC URETERoureterostomy USING URECHIS UNICINCTUS</td>
<td>Yinian Zhang (China)</td>
</tr>
<tr>
<td>12:09</td>
<td>OC3.11</td>
<td>EXPERIMENTAL STUDY ON ESTABLISHING TISSUE ENGINEERED BIONIC URETHRA BY CELL SHEET TECHNOLOGY AND LABELED BY ULTRASMALL SUPER-PARAMAGNETIC IRON OXIDE (USPIO) FOR FULL-THICKNESS URETHRAL RECONSTRUCTION</td>
<td>Shukui Zhou (China)</td>
</tr>
<tr>
<td>12:16</td>
<td>OC3.14</td>
<td>3D BIOPRINTING OF URETHRA WITH PCL/PLCL BLEND AND DUAL AUTOLOGOUS CELLS IN FIBRIN HYDROGEL: AN IN VITRO EVALUATION OF BIOMIMETIC MECHANICAL PROPERTY AND CELL GROWTH ENVIRONMENT</td>
<td>Kaile Zhang (United States)</td>
</tr>
<tr>
<td>10:45</td>
<td>OC4.06</td>
<td>A PROSPECTIVE RANDOMIZED STUDY TO INVESTIGATE THE EFFECT OF STEPWISE VOLTAGE ESCALATION ON TREATMENT OUTCOME IN EXTRACORPOREAL SHOCKWAVE LITHOTRIPSY OF RENAL CALCULI</td>
<td>Chi Fai Ng (Hong Kong)</td>
</tr>
<tr>
<td>10:53</td>
<td>OC4.05</td>
<td>EFFECT OF PRACTICAL COIN BASED DEMONSTRATION FOR PATIENT EDUCATION AND USE OF HEADPHONES ON PATIENT ANXIETY UNDERGOING EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY</td>
<td>Nadeem Iqbal (Pakistan)</td>
</tr>
<tr>
<td>11:01</td>
<td>OC4.08</td>
<td>RADIATION LESS NAVIGATION PERCUTANEOUS NEPHROLITHOTOMY COMPARED WITH CONVENTIONAL PERCUTANEOUS NEPHROLITHOTOMY IN A SINGLE CENTER IN HONG KONG</td>
<td>Hin Lysander Chau (Hong Kong)</td>
</tr>
<tr>
<td>11:09</td>
<td>OC4.07</td>
<td>COMPARISON OF OUTCOME OF QUALITY OF LIFE IN DAY CASE VERSUS INPATIENT PCNL IN ELDERLY AGE GROUP</td>
<td>Nadeem Iqbal (Pakistan)</td>
</tr>
<tr>
<td>11:25</td>
<td>OC4.01</td>
<td>PROSPECTIVE VALIDATION OF A NOVEL VISUAL ANALOGUE UROFLOWMETRY SCORE (VAUS) IN MEN WITH LOWER URINARY TRACT SYMPTOMS: OUR EARLY EXPERIENCE.</td>
<td>Raj Tiwari (Singapore)</td>
</tr>
<tr>
<td>11:33</td>
<td>OC4.02</td>
<td>COMPARISON OF THE EFFECTS OF NAFTOPIDIL AND TAMSULOSIN ON BLADDER STORAGE SYMPTOMS IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A PROSPECTIVE, MULTI-INSTITUTIONAL STUDY</td>
<td>Se Yun Kv Won (Korea, Republic of)</td>
</tr>
<tr>
<td>11:41</td>
<td>OC4.10</td>
<td>MIRABEGRON IN THE TREATMENT OF NEUROGENIC DETRUSOR OVERACTIVITY DUE TO SPINAL CORD INJURY AND MULTIPLE SCLEROSIS</td>
<td>Jan Krhut (Czech Republic)</td>
</tr>
</tbody>
</table>
12:05  OC4.13  LONG-TERM FOLLOW-UP AND ANALYSIS OF SUBURETHRAL SLINGS FOR FEMALE SUI  
Hueih Ling ONG (Taiwan)

12:13  OC4.12  SINGLE INCISION SLING (MINI-SLING) FOR THE TREATMENT OF STRESS URINARY  
INCONTINENCE PROVIDES EQUAL SUCCESS RATE AND HIGHER PATIENT SATISFACTION AT  
EARLY PERIOD WITH LESS PAIN COMPARED TO TRANSOBUTRATOR TAPE  
Ahmer KELES (Turkey)

12:21  OC4.03  LAPAROSCOPIC URACHAL RESECTION AND NOVEL UMBILICOPLASTY USING DERMAL  
REGENERATIVE GRAFTS FOR URACHAL ABSCESSES  
Mahito ATSUTA (Japan)

10:45 - 12:30 Nursing workshop 2: Advanced urological nursing workshop (part I)  
ROOM 221

10:45  Gender Affirmative Surgery in Hong Kong  
Chi Kwok CHAN (Hong Kong)

11:00  Nursing management of renal transplant patient  
Chua Ru Wei VIVENN (Singapore)

11:30  Experience of percutaneous tibial nerve stimulation in Hong Kong  
Hor Chu TO (Hong Kong)

11:50  MRI-USG fusion prostate biopsy: The nursing perspective  
Jonah RUSERE (United Kingdom)

12:10  Intra-operative nursing management of urology patients  
Angela FONG (Macau)

10:45 - 12:30 Abstract Moderated Poster 5 (Prostate cancer)  
ROOM 223

10:45  PM05.14  PROSTATE MRI IS ACCURATE IN IDENTIFYING DOMINANT LESIONS WHEN COMPARED TO  
RADICAL PROSTATECTOMY SPECIMENS: A REGIONAL CENTRE PERSPECTIVE.  
J. MCKENZIE (Australia)

10:50  PM05.05  THE RELATIONSHIP BETWEEN PI-RADS SCORE AND GLEASON SCORE UPGRADING AFTER  
RADICAL PROSTATECTOMY  
Y. WEI (China)

10:55  PM05.23  MULTI-PARAMETRIC MAGNETIC RESONANCE IMAGING/ULTRASOUND FUSION-GUIDED  
PROSTATE BIOPSY SIGNIFICANTLY IMPROVES CANCER DETECTION IN THE CHINESE  
POPULATION  
W. K. MA (Hong Kong)

11:00  PM05.16  TARGETED PROSTATE BIOPSY USING MRI-ULTRASOUND FUSION APPROACH: OUR INITIAL  
EXPERIENCE  
P. K.-F. CHIU (Hong Kong)

11:05  PM05.17  OPTIMAL BIOPSY TECHNIQUES FOR DETECTION OF SIGNIFICANT PROSTATE CANCER IN MEN  
WITH LESIONS SUSPICIOUS FOR CANCER ON MAGNETIC RESONANCE IMAGING : ANALYSIS  
USING MAGNETIC RESONANCE IMAGING-ULTRASOUND FUSION TARGETED BIOPSY.  
H. UNO (Japan)

11:15  PM05.18  THE ASSOCIATION BETWEEN THE OUTCOMES OF EXTRAPERITONEAL LAPAROSCOPIC RADICAL  
PROSTATECTOMY AND THE ANTHROPOMETRIC MEASUREMENTS OF THE PROSTATE MAGNETIC  
RESONANCE IMAGING  
P. S. PERMPONGKOSOL (Thailand)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:20</td>
<td>PM05.15</td>
<td>Incidence and risk factors of complications for transrectal ultrasound guided prostate biopsies (TRUS Biopsies) in a Chinese cohort</td>
<td>K.-C. CHENG (Hong Kong)</td>
</tr>
<tr>
<td>11:25</td>
<td>PM05.20</td>
<td>Long-term psychological and quality-of-life effects of active surveillance and watchful waiting after diagnosis of low-risk localised prostate cancer</td>
<td>R. CALOPEDOS (Australia)</td>
</tr>
<tr>
<td>11:30</td>
<td>PM05.13</td>
<td>PET PSMA - does it have a role in predicting nerve-sparing in radical prostatectomy?</td>
<td>H. TRAN (Australia)</td>
</tr>
<tr>
<td>11:35</td>
<td>PM05.06</td>
<td>Comparison of outcomes between transvesical single-site laparoscopic vs retrograde nerve sparing endoscopic extraperitoneal radical prostatectomy for low-risk prostate cancer</td>
<td>X. GAO (China)</td>
</tr>
<tr>
<td>11:50</td>
<td>PM05.12</td>
<td>Robot-assisted radical prostatectomy for high risk prostate cancer: an analysis of positive surgical margin rates</td>
<td>S. HUANG (China)</td>
</tr>
<tr>
<td>11:55</td>
<td>PM05.08</td>
<td>Cytoreductive radical prostatectomy for prostate cancer patients with skeletal metastases: feasibility and efficacy study</td>
<td>K. ZHANG (China)</td>
</tr>
<tr>
<td>12:00</td>
<td>PM05.22</td>
<td>Evaluation of early-stage voiding symptoms following image-guided moderate hypofractionated radiation therapy using a CyberKnife M6 for localized prostate cancer</td>
<td>Y. KUBOTA (Japan)</td>
</tr>
<tr>
<td>12:05</td>
<td>PM05.09</td>
<td>The evaluation of antiandrogen withdrawal syndrome after discontinuation of bicalutamide in metastatic castration-resistant prostate cancer</td>
<td>S. YONEYAMA (Japan)</td>
</tr>
<tr>
<td>12:10</td>
<td>PM05.03</td>
<td>The association between androgen deprivation therapy and pulmonary embolism: a population-based study</td>
<td>S.-C. YII (Taiwan)</td>
</tr>
<tr>
<td>12:20</td>
<td>PM05.11</td>
<td>Comparative efficacy and safety of second-line treatment for castration-resistant prostate cancer via a network meta-analysis of randomized controlled trials</td>
<td>C. CHEN (China)</td>
</tr>
<tr>
<td>12:25</td>
<td>PM05.04</td>
<td>The diagnostic value of neutrophil-to-lymphocyte ratio in predicting bone metastasis of prostate cancer</td>
<td>I. M. SUYADNYA (Indonesia)</td>
</tr>
<tr>
<td>10:45</td>
<td>- 12:30</td>
<td>Abstract Moderated Poster 6 (Surgical technology and simulation)</td>
<td>ROOM 227</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Moderators: Gang ZHU (China), Steve CHAN (Hong Kong)</td>
<td></td>
</tr>
<tr>
<td>10:50</td>
<td>PM06.16</td>
<td>The skill assessment of partial nephrectomy by novel anatomical training model at training course of the Asian Urological Training and Education Group (AUSTEG)</td>
<td>S. ISOTANI (Japan)</td>
</tr>
<tr>
<td>10:55</td>
<td>PM06.07</td>
<td>Comparison of polymer and metallic ureteral stent in the management of benign and malignant ureteric obstructions: six years experience</td>
<td>S. X. LUM (China)</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Speaker(s)</td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>PM06.08 CONCURRENT VALIDATION OF A ROBOTIC SIMULATOR CURRICULUM FOCUSED ON ‘CORE’ EXERCISE: DOES IT ENABLE INEXPERIENCED TRAINEES TO PERFORM A COMPLEX TASK REGARDLESS OF BASELINE SKILL?</td>
<td>Y.-H. KO (Korea, Republic of)</td>
<td></td>
</tr>
<tr>
<td>11:05</td>
<td>PM06.17 EVALUATING THE VALIDITY OF LAPAROSCOPIC AND FLEXIBLE URETEROSCOPY TASKS USING INANIMATE SIMULATION TRAINING MODELS IN ASIAN UROLOGY TRAINEES</td>
<td>L. JIRONG (Singapore)</td>
<td></td>
</tr>
<tr>
<td>11:10</td>
<td>PM06.13 DEVELOPMENT OF A NEW 3D NAVIGATION SYSTEM FOR ROBOT-ASSISTED PARTIAL NEPHRECTOMY</td>
<td>A. SAWADA (Japan)</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>PM06.14 PERFORMANCE IN FUNDAMENTALS IN LAPAROSCOPIC SURGERY (FILSTM) REFLECTS GLOBAL RATING SCALES IN OBJECTIVE STRUCTURED ASSESSMENT OF TECHNICAL SKILLS (OSATS) FOR PORCINE LAPAROSCOPIC SURGERY.</td>
<td>H. Y. TIONG (Singapore)</td>
<td></td>
</tr>
<tr>
<td>11:25</td>
<td>PM06.06 TWO-STEP PRECISE TRANSURETHRAL POLY FLEXIBLE URETEROSCOPY FOR TREATMENT OF PARAPELVIC CYST, A LITTLE ADVANCE IN TECHNICAL</td>
<td>G. JINGYANGA (China)</td>
<td></td>
</tr>
<tr>
<td>11:35</td>
<td>PM06.05 URETEROSCOPY AND CYSTOSCOPY TRAINING: COMPARISON BETWEEN TWO GENERATIONS OF TRANSPARENT SIMULATORS</td>
<td>W. HU (China)</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>PM06.04 RETROPERITONEOSCOPIC NEPHROURETERECTOMY USING A HOMEMADE HAND PORT DEVICE</td>
<td>T.-Y. TAI (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>PM06.03 PRELIMINARY STUDY OF NEAR-INFRARED FLUORESCENCE IMAGING FOR ROBOTIC-ASSISTED PARTIAL NEPHRECTOMY--NCKUH EXPERIENCE</td>
<td>T.-Y. TAI (Taiwan)</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>PM06.01 PHOTODYNAMIC DIAGNOSIS OF GIGANTIC PAGET’S DISEASE USING 5-AMINOLEVULINIC ACID AND WOOD LAMP BEFORE MOHS MICROGRAPHIC SURGERY</td>
<td>P. ZHOU (China)</td>
<td></td>
</tr>
<tr>
<td>12:05</td>
<td>PM06.09 3D PRINTING OF KIDNEY MODELS FOR UROLOGICAL SURGERIES: OUR INITIAL EXPERIENCE</td>
<td>T. L. NG (Hong Kong)</td>
<td></td>
</tr>
</tbody>
</table>

**12:30 - 14:00 Ipsen Afternoon Symposium**

**What’s New in the Management of Prostate Cancer?**

Chairmen: Samuel YEE (Hong Kong), Declan MURPHY (Australia)

12:30 Welcome

Samuel YEE (Hong Kong), Declan MURPHY (Australia)

12:35 Locally Advanced Prostate Cancer: How to Choose between Different Therapeutic Options?

Dingwei YE, (China)

12:55 Advanced prostate cancer in 2017 – some key messages for urologists

Declan MURPHY (Australia)

13:15 Recent Progress in Surgical Treatment of Prostate Cancer: Mini Invasive Approach from Laparoscopy to Robotic Surgery

KoanHo RHA (South Korea)

13:35 Q & A
DETAILED PROGRAMME

SATURDAY 5TH AUGUST

12:30 - 14:00 Astellas Afternoon Symposium

Management of advanced PCa: Current novelties and future directions

Chairmen: Richard K. LO (Hong Kong)

12:30 Introduction
Richard K. LO (Hong Kong)

12:35 Treatment approach in Asian mCRPC patients
Tony Tong Lin WU (Taiwan)

12:55 Management of advanced prostate cancer: from empiricism to therapeutic layering
Bertrand TOMBAL (Belgium)

13:25 Panel discussion on clinical dilemmas
Tony Tong Lin WU (Taiwan), Bertrand TOMBAL (Belgium)

13:55 Take home messages
Richard K. LO (Hong Kong)

14:00 - 16:00 Semi-live surgery II

Moderators: Hong Sub KIM (Hong Kong), Masayuki NAKAGAWA (Japan), Vu Le CHUYEN (Vietnam), Franklin HO (Hong Kong)

14:00 Robotic groin lymph node dissection
NingHong CHAN (Hong Kong)

14:20 Retzius-space sparing radical prostatectomy
KoonHo RHA (Korea, Republic of)

14:40 Female continence surgery
ShingHwa LU (Taiwan)

15:00 MIS for small renal mass
Daniel MOON (Australia)

15:20 Robotic / Laparoscopic Partial nephrectomy
GuanChou TEH (Malaysia)

15:40 3-ports laparoscopic prostatectomy
Qian ZHANG (China)

16:00 - 17:00 Menarini Asia-Pacific Evening Symposium

Avanafil: A New Step in ED Management

Chairman: Chan Lung WAI (Hong Kong)

16:00 Opening and Introduction
Chan Lung WAI (Hong Kong)

16:05 Is Avanafil the Optimal On-Demand Oral Treatment for ED?
- PDE5 Selectivity
- Pharmacokinetic Properties
- Molecular Advantage
George LEE (Malaysia)

16:20 Avanafil Clinical Evidence:
- Phase 3 & Phase 4 Data
- Insights from EU Experience
Emmanuele A. JANNINI (Italy)
An investigation on ED Patients’ Insight (Local Survey)  
ESD Life (Hong Kong)

Real Life Clinical Cases Discussion  
Andrew Yip Wai CHUN (Hong Kong)

Q&A and Closing Remarks  
Chan Lung WAI (Hong Kong)

**14:00 - 17:00**  
**APPS / APSU conjoint meeting**

**THEATRE 1**

**14:00 BLADDER CANCER SESSION**  
*Moderators: Hong Gee SIM (Singapore)*

14:00  
Circulation biomarker of bladder cancer  
Masayoshi NAGATA (Japan)

14:20  
New immunotherapy for bladder cancer  
Tsung Wen CHONG (Singapore)

14:40  
Guideline update for bladder cancer  
Sung Kyu HONG (Korea, Republic of)

**15:00 SPECIAL LECTURE: SMART MEDICINE**  
*Moderator: Rainy UMBAS (Indonesia)*

15:00  
Artificial Intelligence (AI) & Clinical Decision Supporting system (CDSS) for Prostate Cancer  
Ji Youl LEE (Korea, Republic of)

**15:20 BREAK**

**15:40 KIDNEY CANCER SESSION**  
*Moderators: Jacob PANG (Taiwan), Choung Soo KIM (Korea, Republic of)*

15:40  
Robotic partial nephrectomy  
Seung Hwan LEE (Korea, Republic of)

16:05  
Biomarker of renal cell cancer  
Lukman HAKIM (Indonesia)

16:25  
Guideline update of target agent for mRCC  
Bannakij LOJANAPIWAT (Thailand)

**THEATRE 2**

**14:00 - 17:00**  
**Asian society of female urology Symposium**

14:00  
Use of perineal USG in the assessment of voiding dysfunction  
Lewis CHAN (Australia)

14:30  
Non-mesh technique for vaginal prolapse / incontinence surgery  
Christophe CHAPPLE (United Kingdom)

15:00  
Future treatment strategies for neurogenic bladder  
Hann-Chorng KUO (Taiwan)

15:30  
Recent advances in surgical management of neurogenic bladder  
SeungJune OH (Korea, Republic of)

16:00  
Modern management of cystoceles: Factors to consider in optimizing surgical outcome  
Vincent TSE (Australia)
**DETAILED PROGRAMME**

**SATURDAY 5TH AUGUST**

### 14:00 - 17:15 Masterclass in advanced prostate cancer

**Moderators:** Angus LEUNG (Hong Kong), Samuel YEE (Hong Kong)

- **14:00** Role of imaging in the staging of prostate cancer
  Seung Hyup KIM (China)

- **14:20** Surgery for advanced or metastatic prostate cancer
  Declan MURPHY (Australia)

- **14:40** Role of radiotherapy in metastatic prostate cancer
  Philip KWONG (Hong Kong)

- **15:00** Mechanism for CRPC & its clinical implications
  Joseph CHIN (Canada)

- **15:20** Sequencing in metastatic prostate cancer management: What do we know?
  Gerhardt ATTARD (United Kingdom)

- **15:40** How to monitor CRPC treatment response
  Teng-Aik ONG (Malaysia)

- **16:00** Bone protective agents in prostate cancer
  Alan SO (Canada)

- **16:20** Emerging therapy for CRPC
  Per Anders ABRAHAMSSON (Sweden)

- **16:40** Case discussion
  Tony WU (Taiwan), Peter JOHNSTONE (Taiwan)

### 14:00 - 17:00 Masterclass in MRI/USG fusion prostate biopsy

- **14:00** Introduction of the programme
  Wai-Kit MA (Hong Kong)

- **14:05** Role of mpMRI prostate, optimal MRI protocol and P1-RADS v2
  Raghunandan VIKRAM (United States)

- **14:25** Which group of men would benefit from mpMRI prostate? Should we biopsy all PIRADS 3 lesions? My fusion biopsy experience.
  Silvan BOXLER (Switzerland)

- **14:45** Is systematic biopsy still needed when we have targeted biopsies? My fusion biopsy experience.
  YungKhan TAN (Singapore)

- **15:05** New standards of quality control in prostate cancer: The right treatment for the right patient. My fusion biopsy experience.
  Kazumi KAMOI (Japan)

- **15:25** Case discussion
  Wai-Kit MA (Hong Kong), Peter CHIU (Hong Kong)

- **15:45** Group demonstration of 3 fusion platforms (Artemis / UroNav / Koelis)

### 14:00 - 17:00 Nursing workshop 2: Advanced urological nursing workshop (part II)

**Speakers:** Chi-Kwok CHAN (Hong Kong), Miu-Ling LI (Hong Kong), Jonah RUSERE (United Kingdom), Hoi-Chu TO (Hong Kong), Joseph LI (Hong Kong), Siu Wan WONG (Hong Kong)

- **14:00** Hands on training
  1. Transrectal prostate sizing
  2. Percutaneous tibial nerve stimulation
  3. Flexible cystoscopy
  4. Bedside ultrasound scanning
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:00</td>
<td>PM07.28</td>
<td>THE ROLE OF BOSNIAK CLASSIFICATION IN MALIGNANT TUMOR DIAGNOSIS: IN KOREA</td>
</tr>
<tr>
<td>14:05</td>
<td>PM07.04</td>
<td>DIAGNOSIS AND THERAPY OF RENAL EPITHELIOID ANGIOMYOLIPOMA: A SINGLE CENTER EXPERIENCE</td>
</tr>
<tr>
<td>14:10</td>
<td>PM07.03</td>
<td>DIAGNOSIS AND TREATMENT OF MULTIPLE PRIMARY CANCER WITH RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>14:15</td>
<td>PM07.13</td>
<td>NEPHRON-SPARING SURGERY FOR THE TREATMENT OF MIT FAMILY TRANSLOCATION RCC IN YOUNG ADULTS</td>
</tr>
<tr>
<td>14:20</td>
<td>PM07.19</td>
<td>LONG-TERM OUTCOMES FOLLOWING LAPAROSCOPIC RADIOFREQUENCY ABLATION FOR T1A RENAL CELL CARCINOMA</td>
</tr>
<tr>
<td>14:25</td>
<td>PM07.08</td>
<td>PREDICTIVE EQUATION TO ESTIMATE RENAL FUNCTIONAL CHANGE IN ROBOTIC ASSISTED PARTIAL NEPHRECTOMY USING RENAL CORTEX VOLUME</td>
</tr>
<tr>
<td>14:30</td>
<td>PM07.11</td>
<td>ROBOT-ASSISTED PARTIAL NEPHRECTOMY WITH SELECTIVE ARTERIAL CLAMPING UNDER NEAR-INFRARED FLUORESCENCE IMAGING GUIDANCE: INITIAL WESTERN AUSTRALIAN EXPERIENCE</td>
</tr>
<tr>
<td>14:35</td>
<td>PM07.10</td>
<td>POSTERIOR HILAR RENAL TUMORS COULD BE TREATED SAFELY THROUGH THE TRANS-PERITONEAL ROBOT-ASSISTED PARTIAL NEPHRECTOMY APPROACH</td>
</tr>
<tr>
<td>15:00</td>
<td>PM07.05</td>
<td>DIRECT LATERAL ACCESS TO RENAL ARtery DURING LAPAROSCOPIC PARTIAL NEPHRECTOMY: SURGICAL TECHNIQUE AND COMPARATIVE OUTCOMES</td>
</tr>
<tr>
<td>15:10</td>
<td>PM07.09</td>
<td>THE RISK OF CORONARY HEART DISEASE IN PATIENTS AFTER PARTIAL NEPHRECTOMY AND RADICAL NEPHRECTOMY: A POPULATION-BASED STUDY</td>
</tr>
<tr>
<td>15:15</td>
<td>PM07.14</td>
<td>FUNCTIONAL AND ONCOLOGIC OUTCOMES OF ROBOTIC, LAPAROSCOPIC AND OPEN PARTIAL NEPHRECTOMY: A MULTICENTER COMPARATIVE MATCHED-PAIR ANALYSES WITH A MEDIAN 5 YEARS FOLLOW UP</td>
</tr>
<tr>
<td>15:20</td>
<td>PM07.12</td>
<td>A COMPARISON OF PERIOPERATIVE, RENAL FUNCTIONAL AND ONCOLOGIC OUTCOMES IN ROBOTIC-ASSISTED VERSUS OPEN PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>15:25</td>
<td>PM07.17</td>
<td>OUTCOMES OF PATHOLOGIC T3A RENAL CELL CARCINOMA UP-STAGED FROM SMALL RENAL TUMOUR: EMPHASIS ON PARTIAL NEPHRECTOMY</td>
</tr>
<tr>
<td>15:30</td>
<td>PM07.15</td>
<td>THE USE OF LEIBOVICH PROGNOSIS SCORE FOR LOCALIZED RENAL CELL CARCINOMA: LONG TERM ONCOLOGICAL OUTCOMES</td>
</tr>
</tbody>
</table>

Moderators: Jian-Ri Li (Taiwan), Shuo Wang (China), Isotani Shuji (Japan)
15:40 PM07.22 EX-VIVO NEPHRON-SPARING SURGERY AND AUTOTRANSPLANTATION FOR COMPLEX RENAL TUMOURS
M. CHEN (China)

15:45 PM07.26 SURGICAL TECHNIQUE AND CLINICAL EXPERIENCE OF MAYO GRADE III TUMOR THROMBUS TREATED WITH RADICAL NEPHRECTOMY AND INFERIOR VENA CAVA THROMBECTOMY
Z. LIU (China)

15:50 PM07.06 IS TUMOR SIZE AN INDICATOR FOR TUMOR UPSTAGING TO PATHOLOGICAL T3A IN RENAL CELL CARCINOMA?
C. F. AU (Taiwan)

16:05 PM07.27 OUTCOMES OF PATIENTS WITH LOCALLY ADVANCED RENAL CELL CARCINOMA AFTER RADICAL NEPHRECTOMY: A 5-YEAR MULTI-CENTRE REVIEW OF RECURRANCE AND SURVIVAL PATTERN
C. CHAN (Hong Kong)

16:10 PM07.23 THE PROGNOSTIC ROLE OF PREOPERATIVE NEUTROPHIL-LYMPHOCYTE DIFFERENCE AND NEUTROPHIL-TO-LYMPHOCYTE RATIO IN NON-METASTATIC RENAL CELL CARCINOMA: RESULTS FROM A LARGE COHORT OF 694 PATIENTS.
R. ZHANG (China)

16:15 PM07.30 CIRCULAR RNA PROFILE IDENTIFIES CIRC-EMT1 AS A PROLIFERATIVE FACTOR AND PROGNOSTIC MARKER IN CLEAR CELL RENAL CELL CARCINOMA
W. LI (China)

16:25 PM07.02 PREDICTIVE FACTORS FOR ADRENAL METASTASIS IN EXTRA-ADRENA L CANCER PATIENTS WITH ADRENAL MASS
J. N. LEE (Korea, Republic of)

16:30 PM07.31 ONCOLOGICAL AND FUNCTIONAL OUTCOMES OF RADICAL NEPHRECTOMY, PARTIAL NEPHRECTOMY AND CRYOABLATION FOR CLINICAL T1 RENAL MASSES
M. MURAKAMI (Japan)

14:00 - 17:00 Abstract Moderated Poster 8 (Stone)
ROOM 227

Moderators: Madhu AGARWAL (India), Lysander CHAU (Hong Kong)

14:00 PM08.11 EFFECT OF BODY MASS INDEX (BMI) ON OUTCOME OF STONE FREE RATE USING A 3RD GENERATION LITHOTRIPTER.
N. IQBAL (Pakistan)

14:05 PM08.04 EXTERNAL VALIDATION OF TRIPLE D SCORE AND ITS MODIFICATION TO TRIPLE D-S SCORE FOR BETTER PREDICTION OF STONE FREE RATES AFTER EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY.
N. IQBAL (Pakistan)

14:10 PM08.24 EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY IN PEDIATRIC UROLITHIASIS: A SINGLE-CENTER 100 CASES EXPERIENCE
Y. TANG (China)

14:15 PM08.17 PREDICTION FOR SUCCESS RATE OF SHOCK WAVE LITHOTRIPSY USING MEAN STONE DENSITY-STONE HETEROGENEITY INDEX RATIO CALCULATING HOUNSFIELD UNIT ON NON-CONTRAST COMPUTED TOMOGRAPHY
J. Y. LEE (Korea, Republic of)

14:20 PM08.05 UPPER URETER PERFORATION FOLLOWING EXTRACORPOREAL SHOCK WAVE LITHOTRIPSY: A RARE COMPLICATION
M. C. CHIANG (Taiwan)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>PM08.25</td>
<td>RIGID URETEROSCOPY FOR PREGNANT WOMEN: SAFE AND EFFECTIVE</td>
<td>N. DENG (China)</td>
</tr>
<tr>
<td>14:35</td>
<td>PM08.06</td>
<td>THE PROSPECTIVE COMPARATIVE EVALUATION OF HO:YAG LASER FRAGMENTATION VERSUS DUSTING TECHNIQUES IN THE TREATMENT OF RENAL CALCULI LARGER THAN 2CM</td>
<td>J. C. X. LEE (United Kingdom)</td>
</tr>
<tr>
<td>14:45</td>
<td>PM08.15</td>
<td>WIRELESS FLEXIBLE RENAL ACCESS BY THE MODIFIED ERGONOMIC LITHOTRIPSY TECHNIQUE (MEL): A SINGLE CENTRE EXPERIENCE</td>
<td>Vineet GAUHAR (Singapore)</td>
</tr>
<tr>
<td>14:50</td>
<td>PM08.23</td>
<td>A CASE OF RIGHT STAGHORN CALCULI TREATED BY FLEXIBLE TRANSURETHRAL URETER LITHOTRIPSY USING PULSE WIDTH VARIABLE TYPE HOLMIUM: YAG LASER (LUMENIS® PULSE™ 120H, LUMENIS).</td>
<td>Y. SUGITA (Japan)</td>
</tr>
<tr>
<td>14:55</td>
<td>PM08.02</td>
<td>URETEROSCOPY AS AN OUTPATIENT DAY CASE PROCEDURE: A SINGLE CENTRE STUDY</td>
<td>C. T. PUN (Hong Kong)</td>
</tr>
<tr>
<td>15:00</td>
<td>PM08.29</td>
<td>IS RETROGRADE INTRARENAL SURGERY A VIABLE TREATMENT OPTION FOR RENAL STONES IN PATIENTS WITH TRANSPLANT KIDNEY?</td>
<td>D. LAI (China)</td>
</tr>
<tr>
<td>15:10</td>
<td>PM08.19</td>
<td>EARLY EXPERIENCE WITH SUPINE PCNL WITH COMBINED SIMULTANEOUS ENDOSCOPIC PROCEDURE</td>
<td>C. NGO (Hong Kong)</td>
</tr>
<tr>
<td>15:20</td>
<td>PM08.18</td>
<td>SYSTEMATIC REVIEW AND META-ANALYSIS TO COMPARE SUCCESS RATES OF RETROGRADE INTRARENAL SURGERY VERSUS PERCUTANEOUS NEPHROLITHOTOMY FOR RENAL STONES &gt; 2 CM: AN UPDATE</td>
<td>J. Y. LEE (Korea, Republic of)</td>
</tr>
<tr>
<td>15:25</td>
<td>PM08.30</td>
<td>“ALL-SEEING-NEEDLE” MICRO PERCUTANEOUS NEPHROLITHOTOMY: INITIAL EXPERIENCE OF USING VISUAL PUNCTURE SYSTEM CONFIRMING ACCESS FOR SOLITARY KIDNEY</td>
<td>D. LAI (China)</td>
</tr>
<tr>
<td>15:30</td>
<td>PM08.09</td>
<td>IS MINIPCNL AN ALTERNATIVE SAFE AND EFFECTIVE TREATMENT MODALITY FOR LARGE PROXIMAL URETERIC STONE?</td>
<td>Y. NAUNG (Myanmar)</td>
</tr>
<tr>
<td>15:45</td>
<td>PM08.22</td>
<td>OUTCOME OF TUBELESS PCNL COMPARED WITH CONVENTIONAL PCNL</td>
<td>L. F. C. LEE (China)</td>
</tr>
<tr>
<td>15:50</td>
<td>PM08.13</td>
<td>EFFICACY AND SAFETY OF PERCUTANEOUS NEPHROLITHOTOMY IN GERIATRIC POPULATION</td>
<td>S.-C. YI (Taiwan)</td>
</tr>
<tr>
<td>15:55</td>
<td>PM08.03</td>
<td>COMPARISON OF GUY’S AND S.T.O.N.E. NEPHROLITHOMETRY SCORING SYSTEMS IN TERMS OF PREDICTING STONE FREE RATES AND COMPLICATIONS POST PERCUTANEOUS NEPHROLITHOTOMY.</td>
<td>N. IQBAL (Pakistan)</td>
</tr>
<tr>
<td>16:00</td>
<td>PM08.08</td>
<td>EVALUATING THE VALUE OF CYTOKINES IN PERCUTANEOUS NEPHROLITHOTOMY – A PROSPECTIVE STUDY</td>
<td>T. A. ONG (Malaysia)</td>
</tr>
<tr>
<td>16:10</td>
<td>PM08.07</td>
<td>STUDY ON URINARY TRACT STONE COMPOSITIONS FOR PATIENTS FROM HONG-KONG UNIVERSITY SHEN-ZHEN HOSPITAL: A REPORT OF 272 CASES</td>
<td>X. LIN (China)</td>
</tr>
</tbody>
</table>
16:15 PM08.16  MINERAL WATER IN THE PREVENTION OF STONES  
P. SUNDARAM (Singapore)

16:20 PM08.01  LEFT RENAL PURE SILICON CALCULUS: A CASE REPORT AND REVIEW OF THE LITERATURE  
X. LIN (China)

16:25 PM08.27  THE CLINICAL EFFECTS FOR ULTRASOUND GUIDED PARAVERTEBRAL NERVE BLOCK ANESTHESIA OF PERCUTANEOUS NEPHROLITHOTOMY  
J. HU (China)

17:15 - 18:30  Olympus Hong Kong and China Limited Evening Symposium  
THEATRE 1

Clinical innovation in Endourology  
Chairman: Eddie CHAN (Hong Kong)

17:15  Welcome and Introduction  
Eddie CHAN (Hong Kong)

17:30  Enhanced Imaging of the Urinary Tract  
Jean DE LA ROSETTE (The Netherlands)

18:00  Transurethral en bloc resection of bladder tumor: A new standard?  
Jeremy TEOH (Hong Kong)

17:15 - 18:30  Pfizer EDU (Educational Development for Urologists) Evening Symposium  
ROOM 221

Holistic Approach of LUTS/BPH Management in Men’s Health  
Chairman: Anthony Ng Chi FAI (Hong Kong)

17:15  Welcome and introduction: Key issues surrounding the topic  
Anthony Ng Chi FAI (Hong Kong)

17:25  Presentation: A deep dive into the relationship between LUTS/BPH, CV events and ED  
Christopher CHAPPLE (United Kingdom)

18:00  Panel discussion: Holistic approach of LUTS/BPH management in men’s health  
Moderator: Anthony Ng Chi FAI (Hong Kong)

Panelists:
Christopher CHAPPLE (United Kingdom)
Teng-Aik ONG (Malaysia)
Joe LEE (Singapore)

18:25  Closing remarks  
Anthony Ng Chi FAI (HK)

17:45 - 18:45  HKUA Open Lecture  
THEATRE 2
### ERBE China Morning Symposium

**Application of ERBE technology in Urology**

*Chairman:* Jian HUANG (China), Yongyi CHENG (China)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:45</td>
<td>Experience of NMIBC by using Hybridknife</td>
</tr>
<tr>
<td></td>
<td>Jie ZHU (China)</td>
</tr>
<tr>
<td>07:55</td>
<td>Advantage of Hybridknife in en-bloc resection of bladder tumor and the experience of 100 cases</td>
</tr>
<tr>
<td></td>
<td>Jia HU (China)</td>
</tr>
<tr>
<td>08:05</td>
<td>Application of ERBE super workstation and instruments</td>
</tr>
<tr>
<td></td>
<td>Yi SUN (China)</td>
</tr>
<tr>
<td>08:15</td>
<td>BT-ESD multicenter study initial results report</td>
</tr>
<tr>
<td></td>
<td>Chun JIANG (China)</td>
</tr>
<tr>
<td>08:25</td>
<td>Questions and Answers</td>
</tr>
<tr>
<td></td>
<td>Jian HUANG (China), Yongyi CHENG (China)</td>
</tr>
</tbody>
</table>

### Morning Plenary

**Moderators:** Henry WOO (Australia), Myung-SoO CHOO (Korea), Brian HO (Hong Kong), Lung-Wai CHAN (Hong Kong)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:30</td>
<td>UAA Honorary Member Lecture: Management of BPH in Asia</td>
</tr>
<tr>
<td></td>
<td>Narmada GUPTA (India)</td>
</tr>
<tr>
<td>08:50</td>
<td>SIU Lecture: MIS for benign prostate hyperplasia</td>
</tr>
<tr>
<td></td>
<td>Jean DE LA ROSETTE (Netherlands)</td>
</tr>
<tr>
<td>09:10</td>
<td>Identifying patients at risk of BPH complications – personalizing treatment for BPH patients</td>
</tr>
<tr>
<td></td>
<td>Peter CHIN (Australia)</td>
</tr>
<tr>
<td>09:30</td>
<td>Ketamine cystitis - An update</td>
</tr>
<tr>
<td></td>
<td>Samuel YEE (Hong Kong)</td>
</tr>
<tr>
<td>09:50</td>
<td>Managing bladder dysfunction</td>
</tr>
<tr>
<td></td>
<td>Lewis CHAN (Australia)</td>
</tr>
</tbody>
</table>

### Reconstructive & Paediatric Urology

**Moderators:** Yi CHIU (Hong Kong), Ada NG (Hong Kong)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:45</td>
<td>Robotic surgery for pelvic organ prolapse</td>
</tr>
<tr>
<td></td>
<td>Kyu-Sung LEE (Korea, Republic of)</td>
</tr>
<tr>
<td>11:05</td>
<td>What is the right option for SUI?</td>
</tr>
<tr>
<td></td>
<td>Vincent TSE (Australia)</td>
</tr>
<tr>
<td>11:25</td>
<td>1-stage vs 2-stage procedure in urethroplasty with interpositioning graft</td>
</tr>
<tr>
<td></td>
<td>Paksi SATYAGRAHA (Indonesia)</td>
</tr>
<tr>
<td>11:45</td>
<td>Gender reassignment surgery: indication and technique</td>
</tr>
<tr>
<td></td>
<td>Chi Kwok CHAN (Hong Kong)</td>
</tr>
<tr>
<td>12:05</td>
<td>Gastrocystoplasty revisited: When and how?</td>
</tr>
<tr>
<td></td>
<td>Peggy CHU (Hong Kong)</td>
</tr>
</tbody>
</table>
## Detailed Programme

### Sunday 6th August

#### 10:45 - 12:30 Urolithiasis

- **Moderators:** Selvalingam SOTHILINGAM (Malaysia), Ka-Lun LO (Hong Kong)

  **10:45**  
  Guidelines for stone management: what we have and what we need?  
  Takahiro YASUI (Japan)

  **11:05**  
  Development and application of tip-flexible semi-rigid ureteroscopy  
  Yong-Han PENG (China)

  **11:35**  
  1.8 cm lower pole stone: The role of miniPCNL vs RIRS  
  Janak DESAI (India), Ill-Young SEO (Korea, Republic of)

  **11:45**  
  New generation of super-mini-PCNL  
  Guohua ZENG (China)

  **12:05**  
  Managing PCNL complications  
  Madhu AGARWAL (India)

#### 12:30 - 13:40 Take home message

- **Moderators:** Wai-Ho SUN (Hong Kong), Martin WONG (Hong Kong)

  **12:30**  
  Uro-Oncology  
  Marco CHAN (Hong Kong)

  **12:45**  
  Andrology  
  Peter CHIU (Hong Kong)

  **12:55**  
  Voiding dysfunction  
  Brian HO (Hong Kong)

  **13:05**  
  Reconstructive Urology  
  Jalil HOSSEINI (Iran, Islamic Republic of)

  **13:15**  
  Urolithiasis  
  Ka-Lun LO (Hong Kong)

  **13:25**  
  Transplantation  
  Tin-Yu CHU (Hong Kong)

  **13:35**  
  Closing remarks  
  Chi-Wai MAN (Hong Kong)
Using ERBEJET® 2 HybridKnife in Micro-Urology

A multi-functional instrument which combines waterjet function with electro-surgery.

New method for NMIBC(Ta,T1): BT-ESD

The advantages of HybridKnife for BT-ESD:
- Improved pathological assessment
- Ability to assess the tumor invasion (lateral and vertical extension of the tumor, R status)
- Improved substaging of T1 tumors
- Initial statements on recurrence and progression rates

Other applications with WaterJet in Urology
- Nerve-Sparing Radical Prostatectomy
- Zero Ischaemia During Partial Nephrectomy
E-POSTERS

VIDEO PRESENTATION

VD01 SELECTIVE RENAL PARENCHYMAL CLAMPING IN NEPHRON-SPARING SURGERY
A. H. G. Wong* · W. K. Ma · T. C. T. Lai · C. F. Tsang · B. S. H. Ho · A. T. L. Ng · H. L. Tsu · M. K. Yiu, Hong Kong

VD03 TRANSPUBIC POSTERIOR URETHROPLASTY VIA PERINEAL APPROACH IN COMPLEX PFUDD
V. Narang* · H. S. Bhatyal · A. Arya, India

VD05 ROBOTIC PARTIAL NEPHRECTOMY FOR A COMPLEX HILAR TUMOR: VIDEO DEMONSTRATION
S. Yadav · P. Singh · R. Kumar*, India

VD06 ROBOT-ASSISTED PARTIAL NEPHRECTOMY USING THE SELECTIVE CLAMPING APPROACH
J. H.-L. Tsu · T. Wong* · W. Ma · A. Ng · B. Ho · C. Tsang · T. Lai · M. Yiu, China

VD07 CLAMPING VESSEL LOOP VIA PORT, NEW METHOD OF LAPAROSCOPIC PARTIAL NEPHRECTOMY
F. Rizaldi* · J. Renaldo · D. Soebadi · W. Djatisoesanto, Indonesia

VD09 EXPERIENCE OF BILATERAL VIDEO ENDOSCOPIC INGUINAL LYMPHADENECTOMY (VEIL) FOR PENILE CARCINOMA
M. Chen* · L. Zhang, China

VD11 EXTRAPERITONEAL PERIPROSTATIC CONSTRUCTION SPARING ROBOT-ASSISTED RADICAL PROSTATECTOMY: THE LATERAL APPROACH TECHNIQUE
T. Jing* · D. Xia · S. Wang, China

VD12 A MILESTONE OF THE DEPARTMENT OF UROLOGY, MANDALAY: HAND-ASSISTED LAPAROSCOPIC DONOR NEPHRECTOMY
M. Thu* · T. M. Lin · W. Khine · Y. Naung · Y. N. Myo Han, Myanmar

VD13 ROBOTIC-ASSISTED PELVIC EXENTERATION - TECHNICAL CONSIDERATIONS AND INITIAL EXPERIENCE
R. Nair · N. Geurts · A. Lamb · B. W. Lamb · A. G. Heriot · C. A. Lynch · D. G. Murphy*, Australia

VD14 CORPORAL SPARING DISMEMBERED CLITOROLABIOPLASTY AS THE SURGICAL MODALITY FOR CLITOROMEGALY IN CONGENITAL ADRENAL HYPERPLASIA
I. Wahyudi* · A. Rodjani · H. Mirza · J. Aritonang, Indonesia

VD15 INSTANT PERCUTANEOUS CYSTOSTOMY FOR POSTERIOR URETHRAL ACCESS
V. Narang* · H. S. Bhatyal · A. Arya, India
POSTER PRESENTATION

PP003  COMPARISON OF POSTOPERATIVE OUTCOMES ACCORDING TO INTRAVESICAL PROSTATIC PROTRUSION IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH) WHO UNDERWENT HOLMIUM LASER ENUCLEATION OF THE PROSTATE (HOLEP)
J. N. Lee - Y.-S. Ha* - H. T. Kim, Korea, Republic of

PP005  COMPARISON OF 1,470 NM DIODE LASER ENUCLEATION OF THE PROSTATE VERSUS TRANSURETHRAL RESECTION OF THE PROSTATE FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA

PP006  THE QUALITY OF LIFE IN PROSTATE ENLARGEMENT SURGERY AT BETHESDA HOSPITAL YOGYAKARTA INDONESIA
D. M. Krisna* - H. Harisatoko - R. Pinzon, Indonesia

PP008  EFFECT OF 12-MM TROCAR CYSTOSTOMY IN MODIFIED TRANSURETHRAL ENUCLEATION AND RESECTION OF THE PROSTATE WITH PROSTATE GLANDS LARGER THAN 80 ML
K. Li* - C. Hu - J. Situ - W. Huang - D. Wang - J. Gu, China

PP010  ELEVATED SERUM PSA IN PATIENTS WITH INDWELLING BLADDER CATHETER: EVALUATING PROSTATE CANCER DETECTION RATE USING TRANS-RECTAL PROSTATE BIOPSY
S. B. Lee* - P. Nagappan - N. I. Ibrahim - R. Malek, Malaysia

PP011  A LONG TERM COMPARISON OF ADHERENCE OF DRUG THERAPY IN 1,471 PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA

PP012  CLINICAL EFFICACY AND SAFETY OF NAFTOPIDIL 50 MG/75 MG TREATMENT FOR PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA: A PROSPECTIVE, OPEN-LABEL STUDY
S. H. Lee* - B. I. Yoon - M. S. Chung, Korea, Republic of

PP014  TREATMENT OUTCOMES OF BENIGN PROSTATE HYPERPLASIA BY LASER VAPOENUCLEATION OF THE PROSTATE (MULTIPULSE TM+1470 LASER SYSTEM)

PP015  INITIAL MONOTHERAPY IN ELDERLY MEN WITH LOWER URINARY TRACT SYMPTOMS BASED ON INTERNATIONAL PROSTATE SYMPTOM SCORE VOIDING-TO-STORAGE SUBSCORE RATIO
J. K. Lee* , Korea, Republic of

PP016  EN BLOC ENUCLEATION TECHNIQUE WITH LATERAL MEDIAN APPROACH FOR SAFE AND QUICKER PERFORMING HOLMIUM LASER ENUCLEATION OF THE PROSTATE

PP017  CORRELATION STUDY OF THE PROSTATIC VOLUMES AND THE URODYNAMIC RESULTS

PP018  DOES 5 ALPHA REDUCTASE INHIBITOR PREVENT SECONDARY BENIGN PROSTATE HYPERPLASIA RELATED ACUTE URINARY RETENTION?
C. F. Lu* - Y. C. Wen - L. M. Lee, Taiwan

PP019  PREVALENCE OF CARDIOVASCULAR RISK FACTORS IN MEN WITH LOWER URINARY TRACT SYMPTOMS: A SEARCHLIGHT TO LOOK BEYOND THE PROSTATE
W. M. Kan* - C. Wong - C. Choi - C. F. Kan - W. H. Au, Hong Kong

PP020  NEOVESICO-CUTANEOUS FISTULA: A CASE REPORT AND A REVIEW OF LITERATURE
H.-Y. Weng* - W.-H. Yang, Taiwan

PP022  MESONEPHRIC CARCINOMA OF THE URINARY BLADDER : CASE REPORT AND LITERATURE REVIEW
M. A. Palmer* - K. Khols - S. Syahhur - G. Arsyadi, Indonesia

PP023  LAPAROSCOPIC PARTIAL CYSTECTOMY FOR THE MANAGEMENT OF BLADDER PHEOCHROMOCYTOMA
T. Y. Hsueh* - A. Chiu - A. Huang, Taiwan
PP024  THE INCIDENCE OF ROBOT-ASSISTED RADICAL CYSTECTOMY COMPLICATIONS ACCORDING TO BODY MASS INDEX: MULTICENTER STUDY FROM KOREA  

PP025  REVIEW OF 5-YEAR DATA ON RADICAL CYSTECTOMY  
H. F. Wong* - C. F. Li - C. M. Ng - R. Kan - C. F. Kan - H. Y. Ngai - W. H. Au, Hong Kong

PP026  DIAGNOSTIC VALUE OF URINE CYTOLOGY FOR DETECTION OF BLADDER CANCER AT DR. SAIFUL ANWAR GENERAL HOSPITAL MALANG: AN ANALYTICAL RETROSPECTIVE STUDY  
A. A. Indra* - B. Daryanto, Indonesia

PP027  DIAGNOSIS AND TREATMENT OF MULTIPLE PRIMARY CANCERS WITH URINARY SYSTEM CARCINOMA  
M. Qiu* - L. L. Ma, China

PP028  EXPERIENCE FROM DESIGNATED INTRAVESICAL BCG THERAPY CLINIC: INSIGHT TO IMPROVE COMPLIANCE  
M. H. Yu* - T. Y. Chan - S. K. Chu - C. W. Man, Hong Kong

PP029  URINARY TRACT ENDOMETRIOSIS: REVIEW OF 6 CASES  
S. Hudaya* - L. Satria - F. Wirawan - C. Wallad, Indonesia

PP030  TRANSURETHRAL ASSISTANT TRANSUMBILICAL LAPORENOENDOSCOPIC SINGLE-SITE RADICAL CYSTECTOMY  
Q. Zhu* - L. Yuan - J. Su - Y. Zhang - Q. Zhang - Y. Wei - L. Shen, China

PP031  TOO LATE CYSCCTECTOMY IN ALGERIA, TIME TO BREAK THE RULES!  
R. H. Kettache*, Algeria

PP032  COMPARISON OF SURVIVAL OUTCOMES BETWEEN LAPAROSCOPIC AND OPEN RADICAL NEPHROURETERECTOMY IN PATIENTS WITH UPPER TRACT UROTHELIAL CARCINOMA.  
T. Sano* - R. Hattori, Japan

PP033  SYSTEMATIC REVIEW AND BAYESIAN NETWORK META-ANALYSIS COMPARING DIAGNOSTIC PERFORMANCE OF PHOTODYNAMIC DIAGNOSIS WITH 5-AMINOLAEVULIC ACID OR HEXYLAMINOLEVULINATE, AND NARROW BAND IMAGING VERSUS WHITE LIGHT CYSTOSCOPY FOR NMIBC  
C. Chen* - Z. Chen - Y. Zhao - F. Su - H. Liu, China

PP034  ENDOSCOPIC LASER ABLATION OF UPPER TRACT UROTHELIAL CARCINOMA: SINGLE CENTER’S EXPERIENCE  
C. Liu*, Taiwan

PP035  REPEATED VERTEBRAL COMPRESSION FRACTURE CAUSED BY ADRENAL FUNCTIONAL TUMOR: A CASE REPORT AND LITERATURE REVIEW  
P. Y. Cheng* - H. K. Li - W. C. Wu - Y. S. Tseng - S. D. Chung, Taiwan

PP036  INTRAVESICAL STENT POSITION AS A PREDICTOR OF QUALITY OF LIFE IN PATIENTS WITH INDWELLING URETERAL STENT  

PP037  THE INDOONESIAN LINGUISTIC VALIDATION OF THE URETERAL SYMPTOMS QUESTIONNAIRE (USSQ)  
C. Fati* - B. S. Noegroho - F. Safriadi - W. Sani, Indonesia

PP038  PSEUDOMYXOMA PERITONEI MIMICKING INGUINAL HERNIA  
H.-Y. Weng*, Taiwan

PP039  ACUTE INTERSTITIAL NEPHRITIS INDUCED BILATERAL SPONTANEOUS URINOMA  
M. C. Chiang* - K. Chi, Taiwan

PP040  TRANSARTERIAL SUPERSELECTIVE EMBOLIZATION FOR INTRACTABLE HAEMATURIA. CASE SERIES FROM A LOCAL HOSPITAL IN HONG KONG  
H. C. Chan* - C. L. Cho - S. M. Yu, Hong Kong
PP046 USEFULNESS OF BUTYLSCOPOLAMINE TO OBTAIN CLEAR MR IMAGE FOR INTENSITY MODULATED RADIOTHERAPY FOR PROSTATE CANCER
O. Tanaka* · H. Komed · T. Iida · M. Tamaki · K. Seike · S. Fujimoto · E. Yama · E. Tokenaka, Japan

PP047 SACRAL NERVE STIMULATION FOR THE TREATMENT OF REFRACTORY OVERACTIVE BLADDER: PRELIMINARY RESULTS
Z. Liu* · X. Tian · L. Ma, China

PP049 INFLUENCE OF REFLUX FLOW VOLUME ON PAIN RESOLUTION AFTER VARICOCELECTOMY FOR PAINFUL VARICOCELE
H. S. Shin* · - J. S. Park · - H. J. Jung · - D. Y. Kim, Korea, Republic Of

PP051 PROSTATE TUBERCULOSIS: CASE REPORT AND LITERATURE REVIEW
M. A. Palmung* · K. Kholis · S. Syahrir · G. Arsyadi, Indonesia

PP052 SCROTAL EXPLORATION FOR EPIDIDYMO-ORCHITIS AND TESTICULAR INFARCTION - AN ANALYSIS
D. Chia* , Australia

PP054 CLINICAL AND ULTRASONOGRAPHIC FEATURES OF MUMPS EPIDIDYMO-ORCHITIS: A SINGLE-CENTER SERIES IN RECENT 10 YEARS
I.-C. Cho* · S. K. Kim · K. Choi · S. K. Min, Korea, Republic of

PP055 PROCALCITONIN LEVELS PREDICT BACTEREMIA IN PATIENTS WITH UROSEPSIS
C. Toreh* · R. Nasution · S. M. Warli, Indonesia

PP057 RISK AND PROTECTIVE FACTORS FOR RECURRENT URINARY TRACT INFECTION FOLLOWING PERCUTANEOUS NEPHROLITHOTOMY
C. F. Au* · C.-Y. Tsai · S. D. Chung, Taiwan

PP059 RISK FACTOR ANALYSIS OF SEPSIS IN PATIENTS WITH ACUTE BACTERIAL PROSTATITIS
T. Choi* · Y. H. Shin · K. H. Yoo · D.-G. Lee · G. E. Min · H.-L. Lee, Korea, Republic of

PP060 CYTOMEGALOVIRUS PNEUMONIA AFTER LIVING-RELATED DONOR KIDNEY TRANSPLANTATION: THE EXPERIENCES OF ONE SINGLE CENTER WITHIN 10 YEARS
Z. Liu* · L. Ma, China

PP062 CHRONIC CONSTIPATION EXACERBATES THE QUALITY OF LIFE IMPAIRMENT SUFFERED BY PRE-MENOPAUSAL WOMEN WITH UNCOMPPLICATED RECURRENT URINARY TRACT INFECTIONS.
M. H. W. Tay* · T. Ho Yee · G. H. Huifang · T. Bee Choo · P. Tambyah · S. Chen, Singapore

PP063 DIABETIC KETOACIDOSIS PRESENTING AS EPIGASTRIC PAIN: A CASE OF EMPHYSEMATOUS PYELOGNPHRITIS IN A 45-YEAR OLD FILIPINO
L. I. Catedral* · J. J. Magbojos · L.-A. Diwa · C. Jimeno, Philippines

PP064 EVALUATION OF DYSMORPHISM OF RED BLOOD CELLS IN PATIENTS WITH ASYMPTOMATIC HAEMATURIA
G. H. Erton* , Turkey

PP065 RISK FACTORS OF SEPSIS IN OBSTRUCTIVE ACUTE PYELOGNPHRITIS ASSOCIATED WITH URINARY TRACT CALCULI
S. H. Chang* , Korea, Republic of

PP066 ANALYSIS OF BETA-HEMOLYTIC STREPTOCOCCI FROM PYELOGNPHRITIS PATIENT IN JAPAN.
M. Minami* · H. Nishiyama · S. Ikegami · M. Kawashima · M. Ohta, Japan

PP067 OUTCOME OF SPERM RETRIEVAL IN ANOOSPERMIC MEn WITH NON-MOSAIC KLINEFELTER’S SYNDROME
T.-Y. Tai* · Y.-M. Lin, Taiwan

PP068 FERTILITY PRESERVATION FOR MALE ADOLESCENT WITH MALIGNANT TUMOR IN CHINA
L. Fu* · Y. Gu · K. Zhang, China

PP070 THE POWER OF MAGNIFICATION: A REVIEW OF MICROSURGICAL SUBINGUINAL VARICOCELECTOMY COHORT
T. C. F. Li* · H. Y. Ngai · W. H. Au, Hong Kong
<table>
<thead>
<tr>
<th>E-POSTERS</th>
</tr>
</thead>
</table>

**PP071** THE ROLE OF COMPUTER TOMOGRAPHY (CT) CALCULATED INTRA-PARENCHYMAL TUMOUR VOLUME (IPV) IN ASSESSMENT OF PATIENTS UNDERGOING PARTIAL NEPHRECTOMY  
R. Tiwari* - A. Sim - C. M. Ho - H. H. Huang, Singapore

**PP072** DIAGNOSIS AND TREATMENT OF MULTIPLE PRIMARY CANCERS WITH URINARY SYSTEM CARCINOMA  
R. Ma* - M. Gu - H. Song, China

**PP074** RENAL ANGIOMYOLIPOMA WITH RENAL VEIN AND INFERIOR VENA CAVA EXTENSION: A CASE REPORT AND LITERATURE REVIEW  
T.-Y. Tai* - Y.-S. Tsai, Taiwan

**PP075** SUCCESSFUL MANAGEMENT OF GIANT ANGIOMYOLIPOMA BY NEPHRON SPARING SURGERY  
V. Narang* - H. Bhatyal - A. Arya, India

**PP077** CLINICAL CHARACTERISTICS, TREATMENTS AND PROGNOSIS OF XP11.2 TRANSLOCATION RENAL CELL CARCINOMA  

**PP078** OUTCOMES OF RETROPERITONEAL LAPAROSCOPIC RENAL CYST UNROOFING IN PATIENTS WITH PARAPERILOCAL CYST  
Z. Liu* - L. Ma - X. Tian, China

**PP079** PRIMARY RETROPERITONEAL CAVERNOUS HEMANGIOMA MIMICKING RENAL CELL CARCINOMA: A RARE CASE AND REVIEW OF LITERATURE  
K. H. Lee* - C.-L. Liu - S. K.-H. Huang, Taiwan

**PP080** CLEAR CELL RENAL CELL CARCINOMA METASTATIC TO BILATERAL PERIRENAL FAT: A CASE REPORT AND LITERATURE REVIEW  
R. Ma* - M. Qiu - J. Lu, China

**PP081** A RAPID AND SYSTEMIC COMPLETE RESPONSE TO STEREOACTIC BODY RADIATION THERAPY AND PEMBROLIZUMAB IN A PATIENT WITH METASTATIC RENAL CELL CARCINOMA  
D. Gu* - G. Xie - S. Chen - S. Zheng, China

**PP083** ESTABLISHMENT AND CLINICAL APPLICATION OF INTRA-ABDOMINAL EXPOSURE SYSTEM (PLADI SYSTEM) IN LAPAROENDOSCOPIC SINGLE-SITE NEPHRECTOMY  
Q. Zhu* - J. Su - L. Yuan - Y. Zhang - Q. Zhang - Y. Wei - L. Shen, China

**PP084** A CASE REPORT: 46 XX CAH (CONGENITAL ADRENAL HYPERPLASIA)  
I. G. L. A. Suharibawa* - B. Daryanto - H. A. Tjahjono, Indonesia

**PP086** PEDIATRIC CYSTINE STONES: A SINGLE TERTIARY CENTER EXPERIENCE IN CHINA  
W. Wang* - J. Li, China

**PP087** COMBINED USE OF FLEXIBLE URETEROSCOPY WITH MICRO-PERCUTANEOUS NEPHROLITHOTOMY IN PEDIATRIC COMPLICATED KIDNEY STONES: A SINGLE TERTIARY CENTER EXPERIENCE IN CHINA  
W. Wang* - J. Li, China

**PP088** TREATMENT OUTCOME AND COST ANALYSIS OF INGUINAL ORCHIDOPEXY AND LAPAROSCOPIC ORCHIDOPEXY FOR UNDESCENDED TESTIS IN MAHARAJ NAKORN CHIANG MAI HOSPITAL  
P. Mahawong* - J. Vuthiwong - B. Lojanapiwat - W. Chongreksut, Thailand

**PP089** OUTSIDE-IN VERSUS GOMCO CLAMP CIRCUMCISION FOR PEDIATRIC PATIENTS  
P. Mahawong* - J. Vuthiwong - B. Lojanapiwat - W. Chongreksut, Thailand

**PP092** ANDROGEN INSensitivity SYNDrome: OUR EXPERIENCES OF SIX CASES AND REVIEW OF LITERATURE  
T. Anno* - M. Tsuyoshi - H. Asakura, Japan

**PP093** DORSAL INLAY GRAFT URETHROPLASTY FOR PRIMARY HYPOSPADIAS REPAIR  

**PP096** MULTIVARIATE ANALYSIS OF FACTORS AFFECTING BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY  
J. D. V. Balingit* - L. Sapino - C. Evangelista - D. Lusaya - D. Serrano - J. Castillo - J. So, Philippines

**PP097** A SINGLE CENTER LONGITUDINAL PROSPECTIVE COHORT STUDY OF TRANSRECTAL ULTRASOUND (TRUS) Guided Prostate Biopsy Morbidity in Malaysia  
M. R. Mohd Mohitar* - A. N. Fadzli - A. H. Abdul Razack, Malaysia
PP098 SHORT TERM OUTCOME OF PROSTATE CANCER IN A SMALL DISTRICT UROLOGY UNIT
K. M. Lam*, China

PP099 RETROSPECTIVE REVIEW OF THE OUTCOMES OF PATIENTS WITH HIGH RISK LOCALIZED PROSTATE CANCER TREATED IN A LOCAL UROLOGICAL CENTRE
C.-F. Ng* - N.-Y. Li - K.-Y. Kong - B.-P. Ng - C.-Y. Li - J.-K. Li - C. Li - S. Leung - J. Y. Teoh, Hong Kong

PP100 METASTATIC NEUROENDOCRINE PROSTATE CANCER TO THE PENIS
D. Chia*, - A. Wang, Australia

PP101 ROLES OF PROSTATE HEALTH INDEX AND MULTIPARAMETRIC MRI AFTER A NEGATIVE TRANSRECTAL ULTRASOUND BIOPSY: PRELIMINARY RESULT FROM A COHORT STUDY

PP104 SYSTEMIC INFLAMMATORY RESPONSE IN PREDICTING PROSTATE CANCER: THE DIAGNOSTIC VALUE OF NEUTROPHIL-TO-LYMPHOCYTE RATIO
K. Prasetya* - G. P. Siregar - F. F. Prapiska - S. M. Warli, Indonesia

PP105 THE TREATMENT PATTERNS OF NON-METASTATIC PROSTATE CANCER IN AN ASIAN COUNTRY

PP107 PUDENDAL NERVE SOMATOSENSORY EVOKED POTENTIALS IN PATIENTS WITH POSTPROSTATECTOMY INCONTINENCE AND ERECTILE DYSFUNCTION
S. Y. Kwon* - K. H. Kim - Y. J. Seo - K. S. Lee, Korea, Republic of

PP108 COMPARISON OF INFECTIVE COMPLICATIONS IN TRANSPERINEAL VERSUS TRANSRECTAL ULTRASOUND GUIDED PROSTATIC BIOPSY IN PATIENTS SUSPECTED TO HAVE PROSTATE CANCER
S. Singh* - L. N. Dorairajan - R. Mankandan - K. Seerag - S. Kumar - U. Dutt, India

PP109 PHARMACOKINETICS OF ENZALUTAMIDE IN CHEMOTHERAPY-NAÏVE PATIENTS WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: AN ASIAN MULTINATIONAL RANDOMIZED PHASE 3 STUDY

PP110 IMPACT OF LARGE PROSTATE VOLUME ON NERVE SPARING ENDOSCOPIC EXTRAPERITONEAL RADICAL PROSTATECTOMY: DESCRIPTION OF TECHNIQUE AND OUTCOMES
D. G. Jiang - X. Gao* - J. Pang - Y. H. Mao - C.-T. Xiao, China

PP111 HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ENZALUTAMIDE (ENZ) VERSUS PLACEBO (PL) IN CHEMOTHERAPY-NAÏVE PATIENTS (PTS) WITH PROGRESSIVE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) FOLLOWING ANDROGEN DEPRIVATION THERAPY (ADT): AN ASIAN MULTINATIONAL STUDY

PP112 COMPARISON OF EXTRAPERITONEAL VERSUS TRANSPERITONEAL ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY: A SINGLE SURGEON RETROSPECTIVE STUDY

PP114 EVALUATION OF PSA RECURRENCE AND POSITIVE SURGICAL MARGINS FOLLOWING THE ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY

PP116 THE UTILITY OF COMBINED ANDROGEN DEPRIVATION THERAPY PLUS EXTERNAL BEAM RADIOTHERAPY IN THE INTERMEDIATE-RISK PROSTATE CANCER
M. Sugimoto* - J. Ishikuchi - M. Shiota - S. Ohtga - M. Ito, Japan

PP118 NEW APPROACH: FROM LAPAROENDOSCOPIC SINGLE-SITE RADICAL PROSTATECTOMY (LESS-RP) TO TRANSPERITREAL-ASSISTED LESS-RP (TU-LESS-RP)
Q. Zhu* - Y. Wei - L. Yuan - J. Su - Y. Zhang - Q. Zhang - Z. Lu - L. Shen, China

PP119 SALVAGE PARTIAL BRACHYTHERAPY FOR PROSTATE CANCER RECURRENCE AFTER PRIMARY BRACHYTHERAPY
M. Iwakura* - H. Sasaki - K. Miki - S. Egawa, Japan

PP120 PATIENTS WITH RAPID DECREASING OF PROSTATE-SPECIFIC ANTIGEN IN THE INITIAL ANDROGEN DEPRIVATION THERAPY ARE MORE LIKELY TO PROGRESS TO CASTRATION-RESISTANT PROSTATE CANCER
G. Ji*, China
PP121 GONADOTROPIN-RELEASING HORMONE ANTAGONIST REDUCES SERUM ADRENAL ANDROGEN LEVELS IN PATIENTS WITH PROSTATE CANCER

PP123 REPEAT TRUS GUIDED PROSTATE BIOPSY: DOES IT PROVIDE ANY CLINICAL BENEFITS IN PATIENTS WITH PSA LEVEL OF 4.0 TO 10.0 NG/ML?

PP124 COMPARISON OF PROSTATE CANCER BIOPSY GUIDED BY MAGNETIC RESONANCE IMAGING, TRANSRECTAL ULTRASOUND AND THEIR COMBINATION SCHEME IN BIOPSY NAÏVE PATIENTS
W. Wu - H. Huang*, China

PP125 INITIAL EXPERIENCE OF FOCAL SALVAGE CRYOTHERAPY FOR LOCAL RECURRENT PROSTATE CANCER, AFTER DEFINITIVE IRRADIATION
K. Iwatani* - K. Mori - S. Kimura - K. Mik - S. Egawa, Japan

PP126 BASAL CELL CARCINOMA OF PROSTATE: REPORT OF THREE CASES AND A REVIEW OF LITERATURE
Z. Liu* - L. Ma - X. Tian, China

PP129 EVALUATION OF PROSTATE HEALTH INDEX (PHI) IN DETECTING CLINICALLY SIGNIFICANT PROSTATE CANCER IN MEN WHO UNDERWENT MRI-ULTRASOUND FUSION PROSTATE BIOPSY

PP130 USING NOMOGRAM TO EVALUATE CLINICAL VALUE OF MAGNETIC RESONANCE IMAGING IN PREDICTING OUTCOMES OF PROSTATE BIOPSY
J. Wang - Y. Ding - X. Wang* - L. Xue, China

PP131 EVALUATION OF BONE TURNOVER / QUALITY MARKERS AND BONE MINERAL DENSITY (BMD) IN PROSTATE CANCER PATIENTS TREATED BY ANDROGEN DEPRIVATION THERAPY WITH OR WITHOUT DENOSUMAB

PP132 DECREASES OF BONE MINERAL DENSITY (BMD) IN NON-METASTATIC PROSTATE CANCER PATIENTS TREATED WITH ANDROGEN DEPRIVATION THERAPY (ADT)
S. Kato*, Japan

PP133 SHORT-TERM OUTCOMES OF ADVERSE PATHOLOGY IN ROBOT-ASSISTED LAPAROSCOPIC RADICAL PROSTATECTOMY
C. Y. Ng* - H. Chow - K. L. Ho - F. K. Cheung, Hong Kong

PP134 PRIMARY PROSTATE LYMPHOMA: A CASE REPORT AND LITERATURE REVIEW
K. Wang* - Y. Fan, China

PP135 MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING TARGETED BIOPSY DECREASES THE UPGRADING OF GLEASON SCORE FROM BIOPSY TO RADICAL PROSTATECTOMY
N. Xu* - Y. Y. Wu - X. D. Li - M. Y. Lin - Q. S. Zheng - S. H. Chen - J. F. Li - X. Y. Xue - Y. Wei, China

PP137 ELEVATED LEVELS OF MALIGNANT BRAIN TUMOR DOMAIN-CONTAINING PROTEIN 1 PREDICTS POOR PROGNOSIS FOR PROSTATE CANCER
W. Wu - H. Huang*, China

PP138 IMPROVEMENT IN THE EARLY CONTINENT OUTCOME OF RETZIUS-SPARING LAPAROSCOPIC RADICAL PROSTATECTOMY WITH THE PREDICTION OF POSTOPERATIVE CYSTOGRAPHY
K. Chiu*, Taiwan

PP139 COMPARING THERAPEUTIC SEQUENCING WITH NOVEL ANDROGEN RECEPTOR AXIS-TARGETED AGENTS(ABIRATERONE AND ENZALUTAMIDE)
K. Mori* - T. Kimura - S. Egawa, Japan

PP140 EFFECT OF STATINS USE ON MORTALITY OF PROSTATE CANCER PATIENTS IN A SINGAPORE TERTIARY HOSPITAL – A RETROSPECTIVE STUDY
M. M. Oo* - B. Sun - T. W. Tan, Singapore

PP142 BASELINE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) PREDICTS PROGNOSIS OF ABIRATERONE ACETATE IN CASTRATION-RESISTANT PROSTATE CANCER
M. Yasui* - T. Kawahara - Y. Kumano - Y. Miyoshi - N. Matsubara - H. Uemura, Japan
PP144 DOES MRI-TRUS FUSION TARGETED PROSTATE BIOPSY HAVE BETTER GLEASON SCORE CONCORDANCE BETWEEN BIOPSY AND PROSTATECTOMY?

PP145 PROSTATE CANCER DETECTION WITH 24-CORE TRANSRECTAL BIOPSY OF THE PROSTATE

PP146 DETECTION OF PROSTATE CANCER AFTER BIPOLAR TRANSURETHRAL ENucleATION AND RESECTION OF THE PROSTATE (BIPOLAR TUERP)

PP147 PREDICTORS OF CANCER DETECTION IN TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY(USI BIOPSYES) IN A CHINESE COHORT

PP148 THE EFFECT OF INTRARECTAL LIDOCAINE GEL INSTILLATION BEFORE TRANSRECTAL ULTRASOUND GUIDED PROSTATE BIOPSY
I.-C. Cho* - S. K. Kim - K. Choi - S. K. Min, Korea, Republic of

PP149 CLINICAL SIGNIFICANCE OF SERUM NEUTROPHIL GELATINASE-ASSOCIATED LIPOCALIN IN THE EARLY DIAGNOSIS OF RENAL FUNCTION DETERIORATION AFTER RADICAL NEPHRECTOMY

PP150 PERFORMANCE OF PROSTATE SPECIFIC ANTIGEN(PSA) AND PSA DENSITY IN A CHINESE COHORT IN DETECTING PROSTATE CANCER IN FIRST BIOPSY WITH NORMAL DIGITAL RECTAL EXAMINATION(DRE)

PP151 LUTETIUM-177 LABELED PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) FOR METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (mCRPC): A SYSTEMATIC REVIEW AND META-ANALYSIS
R. Calopedos* - V. Chalasani - R. Asher - L. Emmett - H. Wuo, Australia

PP152 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF PROGRESSION FREE SURVIVAL AND OVERALL SURVIVAL IN THE FIRST-LINE TREATMENTS OF CASTRATION-RESISTANT PROSTATE CANCER
C. Chen* - T. Lin - L. Thomas - J. Huang, China

PP153 ERECTILE DYSFUNCTION IN ELDERLY PATIENTS

PP154 AROUSAL TO EJACULATION TIME INTERVAL (AETI) AND ERECTION TO EJACULATION TIME INTERVAL (EETI), NEW TOOLS TO MEASURE EJACULATORY LATENCY: A PILOT STUDY
G. S. Bhat* - A. Shastri, India

PP155 CALPAIN INHIBITION AMELIORATES DIABETIC ERECTILE DYSFUNCTION IN MICE BY ACTIVATING ENOS-CGMP PATHWAY
H. Li* - L. Chen - T. Wang - S. Wang - J. Liu, China

PP156 RARE CASE OF SEROUS CARCINOMA, OVARIAN EPITHELIAL TYPE OF THE TESTIS
C. Tao An* - Y. Chia-Cheng, Taiwan

PP157 LIPOSARCOMA IN SCROTAL OR INGUINAL AREA
Z. H. Lu* - Y.-S. Cheng - W.-A. Liao, Taiwan

PP158 PENOSCROTAL EXTRAMAMMARY PAGET’S DISEASE: A REPORT OF A SINGLE CENTER EXPERIENCE

PP159 AGGRESSIVE ANGIOMYXOMA OF SCROTUM IN A MAN WITH DOWN’S SYNDROME: A CASE REPORT AND LITERATURE REVIEW OF 73 CASES OF AGGRESSIVE ANGIOMYXOMA IN MEN
Y. X. T. Law* - K. C. J. Lee, Singapore

PP160 UROLOGICAL COLD SHOWER-DIFFERENT TREATMENTS OF ERECTIONS DURING TRANSURETHRAL SURGERY
Y. Jiang* - R. Lo - Z. Lu - X. Cheng - L. Xiong - X. Xu - B. Luo - Y. Yuan - S. Liao - G. Wei, China

PP161 DIFFERENT WORLDS, DIFFERENT PRACTICES: THE COMPARISON OF PCNL CASES IN MANDALAY GENERAL HOSPITAL AND NORFOLK AND NORWICH UNIVERSITY HOSPITAL
Y. N. Mya Han* - K. Sethia - T. M. Lin - W. Khine - M. Thu, Myanmar
PP172 Efficacy and Safety of Simultaneous Bilateral Percutaneous NephrolithotomY for the Treatment of Bilateral Renal Stone Disease
M. Chhabra* - W. C. Tsang - M. Adhikari, Singapore

PP173 Contrast-Enhanced Ultrasound Used in Percutaneous NephrolithotomY as a Assisted Guiding Method
D. Li* , China

PP174 Urokinase and Its Receptor’s Predictive Values in Percutaneous NephrolithotomY - A Small Prospective Study

PP175 A Prospective, Observational Study on the Feasibility of a Single-Session Endoscopic Combined Intrarenal Surgery for Ipsilateral Large Renal Stones and Retrograde Intrarenal Surgery for Contralateral Renal Stones: Initial Experiences

PP178 Percutaneous Nephrolithotripsy in New Cases versus Those with Previous History of Eswl on Ipsilateral Side.

PP180 Difference of Outcome of Ureteroscopic Treatment of Ureteric Stones between Children of Age Less Than 5 Years and More Than 5 Years: A Single Center Study
N. Iqbal* - H. Hussain - U. B. saif - A. shah - S. Akhter, Pakistan

N. Iqbal* - U. Alam - U. Nadeem - S. Akhter - M. Ali, Pakistan

PP183 Super-Mini Percutaneous NephrolithotomY: A Cross-Sectional Study

PP184 Comparison of Outcome of Retrograde Intrarenal Surgery by Using Semi Rigid Ureteroscope versus Percutaneous Nephrolithotomy for Treatment of Non Lower Pole Renal Stone of Size More Than 20 mm: A Single Center Study
N. Iqbal* - U. bin saif - M. Ali - S. Akhter, Pakistan

PP186 Effect of BMI on Outcome of Ureteroscopic Pneumatic Lithotripsy (Urs).
N. Iqbal - M. H. Hassan* - M. S. Salam - S. Irfan Malik - S. Akhter, Pakistan

PP188 Effect of Body Mass Index on Outcome of Percutaneous NephrolithotomY: Single Center Study
N. Iqbal* - M. ali - Y. malik - S. akhter, Pakistan

PP189 Effectiveness of S.T.O.N.E Score in Predicting the Outcome of Ureteroscopic Pneumatic Lithotripsy (Urs)
N. Iqbal* - M. Haroon Hassan - M. S. Salam - S. I. Malik - S. Akhter, Pakistan

PP190 Metabolic and Haemodynamic Effects of Irrigation Fluids Used in Percutaneous NephrolithotomY (Pcnl)

PP191 When Do We Need Flexible Ureteroscopy During Ureteroscopic Lithotripsy (UrsL) for Ureteric Stones?

PP192 Trends of Stone Composition in Hong Kong Over a Decade

PP193 The Association Between Age and Urolithiasis Prevalence in Tangerang General Hospital, Indonesia in 2016
M. A. Izzan* , Indonesia

PP195 Which Is Better for Renal Stones in Patients with a Solitary Kidney: Shockwave Lithotripsy or Flexible Ureteroscopy?
N. Deng* - P. JiU - Z. Zou - Z. Pan, China
PP196 TWO CASES IN WHICH LITHOTRIPSY WAS SUCCESSFULLY UNDERWENT BY F-TUL AND ESWL FOR RENAL STONES FORMED AFTER TOTAL CYSTECTOMY AND ILEAL CONDUIT
M. Katsu* - T. Arakawa - H. Bessho - T. Ohigashi, Japan

PP198 RESULTS OF COMBINATION OF PERCUTANEOUS NEPHROLITHOTOMY AND EXTRACOPOREAL SHOCK WAVE LITHOTRIPSY IN TREATMENT OF STAGHORN CALCULI
V. D. Kieu* - P. V. Nguyen - C. Tran, Vietnam

PP199 EVALUATION AND COMPARISON OF SHA.LIN, S.T.O.N.E. NEPHROLITHOMETRY SCORING SYSTEM AND CROS NEPHROLITHOMETRY NOMOGRAM FOR PREDICTING STONE FREE RATE AND POSTOPERATIVE OUTCOMES AFTER PERCUTANEOUS NEPHROLITHOTOMY
X. Chen* - P. Peng - Z. Ding - J. Wang - X. Zhou - Y. Tan - N. Liu - G. Zhang, China

PP201 EARLY OUTCOME WITH ULTRA MINI PERCUTANEOUS NEPHROLITHOTOMY

PP202 MINIMALLY ENDOSCOPIC COMBINED INTRARENAL SURGERY FOR STAGHORN CALCULI IN BREASTSTROKE POSITION
D. Lai* - Y. He - X. Li, China

PP203 THE EXPERIENCES OF HANDLING CHANNEL LOSS DURING THE PROCEDURE OF NEPHROSTOMY IN PERCUTANEOUS NEPHROLITHOTRIPSY: REPORT OF 11 CASES
X. Lin* , China

PP204 SUPER MINI-PERCUTANEOUS TRACT (F12) WITH “ALL-SEEING NEEDLE SET” IN PRONE POSITION FOR RENAL STONE: A SINGLE CENTER EXPERIENCE
D. Zhang* - G. Xie - Y. Cheng, China

PP205 PERCUTANEOUS NEPHROLITHOTOMY ASSISTED BY A NOVEL NEGATIVE PRESSURE SHEATH
D. Lai* - M. Sheng - X. Li - Y. He, China

PP207 A MODIFIED TECHNIQUE FOR PERFORMING TRANSURETHRAL NEPHROSCOPY LITHOTRIPSY OF BLADDER STONES WITH/WITHOUT PLASMA KINETIC RESECTION OF THE PROSTATE OF BENIGN PROSTATIC HYPERPLASIA.
S. Mao* - P. Gao, China

PP208 LAPAROSCOPIC INFERIOR VENA CAVA THROMBUS SURGERY BY RETROPERITONEAL APPROACH
S. Zhang* - L. Ma - L. Liu - Y. Tian, China

PP209 OUR 20-YEAR EXPERIENCE IN TREATING URETERIC STRICTURES ENDOSCOPICALLY

PP211 EFFICACY AND COST COMPARISONS OF METALLIC VERSUS POLYMER STENTS IN THE MANAGEMENT KETAMINE INDUCED URETERIC STRICTURES
J. C. X. Lee* - S. X. Lum - G. Lee, United Kingdom

PP212 AN UNSUAL FOREIGN BODY IN THE URETHRA: MULTIPLE HELICAL WIRE
S. N. Yohanes* , Indonesia

PP213 SELECTIVE RENAL PARENCHYMAL CLAMPING IN NEPHRON-SPARING SURGERY: AN ALTERNATIVE TO MINIMIZE RENAL ISCHEMIA

PP215 HAND-ASSISTED LAPAROSCOPIC ADRENALECTOMY FOR LARGE ADRENAL MYELOLIPOMA

PP216 LONG-TERM FOLLOW-UP RESULTS OF LAPAROSCOPIC PYELOPLASTY
T. H. Oh* - I. Y. Seo - J. W. Lee - S. C. Park, Korea, Republic of

PP217 MINIMALLY ENDOSCOPIC COMBINED INTRARENAL SURGERY FOR URETEROPELVIC JUNCTION ATRESIA
D. Lai* - Y. He - X. Li, China

PP218 ONE POSITION TRANSPERITONEAL LAPAROSCOPIC NEPHROURETERECTOMY AND BLADDER CUFF EXCISION
G. Zhu* - K. Zhang, China

PP219 MODIFIED RETROPERITONEOSCOPIC RENAL PEDICLE LYMPHATIC DISCONNECTION FOR CHYLURIA AND THE LITERATURE REVIEW
Y. Yuan* - R. To, China
PP220      UMBILICUS-SPARING LAPAROSCOPIC APPROACH FOR TREATING SYMPTOMATIC URACHAL REMNANTS IN ADULTS
          J. Hu* - Z. Liu, China

PP221      TO TREAT BLADDER STONE IN PATIENTS WITH HIP JOINTS CONTRACTURE
          A. C.-J. Huang* - T. Y. Hsueh - A. W. Chiu, Taiwan

PP222      THE EXPERIENCE AND SKILLS OF RETROPERITONEAL LAPAROSCOPIC NEPHRON-SPARING SURGERY FOR GIANT RENAL ANGIOMYOLIPOMA
          M. Qiu* - L.-L. Ma, China

PP223      LAPAROENDOSCOPIC SINGLE-SITE SURGERIES IN A SERIES OF 465 CONSECUTIVE CASES: EXTENSION OF INDICATION WITH TECHNOLOGICAL INNOVATION MAKES THE TECHNIQUE TOWARDS A NEW LEVEL
          Q. Zhu* - J. Su - L. Yuan - Y. Zhu - Q. Zhang - Y. Wei - L. Shen, China

PP224      IMPLICATION OF PARTIAL NEPHRECTOMY ON RENAL FUNCTION: A 10-YEAR REVIEW

PP225      THE SAFETY AND EFFECTIVITY FOR PERCUTANEOUS URETEROSCOPY LASER UNROOFING IN THE MANAGEMENT OF RENAL CYSTS
          J. Hu* - X. Yu - S. Wang, China

PP226      URETHRAL STRicture EVALUATION PROCEDURES HOLMIUM LASER ENDOURETHROTOMY VS OPTICAL INTERNAL URETHROTOMY (COLD KNIFE): A META-ANALYSIS
          R. Firmanto*, Indonesia

PP227      RETROPERITONEAL LAPAROSCOPIC LIVING DONOR NEPHRECTOMY: EXPERIENCE WITH 383 CASES AT A SINGLE CENTER

PP228      FREQUENCY OF UTI IN RENAL TRANSPLANT RECIPIENT WITH COMMON BACTERIA AND ITS SENSITIVITY
          H. U. Khan* - I. Masood, Pakistan

PP229      SUCCESSFUL REPAIR OF RENAL ARTERIAL RUPTURE AND ARTERIAL PSEUDOANEURYSM IN GRAFT KIDNEYS FROM THE SAME DECEASED DONOR
          C. Iao - C.-W. Ku*, Taiwan

PP230      THE IMPROVEMENT OF PATIENT’S QUALITY OF LIFE AFTER KIDNEY TRANSPLANTATION IN CIPTO MANGUNKUSUMO HOSPITAL, INDONESIA

PP231      EFFECT OF DIFFERENT BMI GROUPS ON OUTCOME OF LIVE RELATED RENAL TRANSPLANT: A SINGLE TRANSPLANT CENTER STUDY.
          N. Iqbal* - A. Masood - A. Khan - S. Akhter, Pakistan

PP232      LEARNING CURVE IN LAPAROSCOPIC LIVING DONOR NEPHRECTOMY
          K. E. Sidabutar* - C. Moctar - I. Wahyudi - A. Hamid, Indonesia

PP233      THE CORRELATION BETWEEN RENAL ARTERIAL LENGTH AND DIAMETER TO ISCHEMIA TIME IN TRANSPLANT PATIENT
          D. Parikesit* - R. Hamid, Indonesia

PP234      EFFICACY OF USING FLOSEAL TO PREVENT POST RENAL TRANSPLANT LYMPHOCELE FORMATION

PP235      HEMODYNAMIC INSTABILITY AND SEVERITY GRADE OF KIDNEY TRAUMA AS THE PREDICTOR FACTORS FOR NEPHRECTOMY
          I. G. L. A. Suharibawa* - B. Daryanto, Indonesia

PP236      SHORT SEGMENT ILEAL INTERPOSITION FOR RECURRENT POST TRAUMATIC URETERIC STRICTURE
          S. K. Steenivasan* - I. N. Dorairajan - R. Manikandan, India

PP237      LONG TERM REVIEW OF UROLOGICAL COMPLICATIONS FOLLOWING PELVIC EXENTERATION
PP241 PLASTIC RECONSTRUCTION SURGERY OF PENILE SKIN BY BILATERAL GROIN FLAPS

PP242 PENILE PARAFFINOMA : WHY THEY DO IT, HOW WE TREAT IT
M. A. Palimunro* - S. Syahrir, Indonesia

PP243 MITROFANOFF AS BLADDER DRAINING TOOL- A SINGLE CENTER EXPERIENCE IN PEDIATRIC PATIENTS.
N. Iqbal * - O. Zia - S. Akhter - I. Hussain, Pakistan

PP245 URETEROSCOPIC DOUBLE J STENTING IN URETERAL INJURY BY GYNECOLOGICAL SURGERY: IS IT EFFECTIVE ?
D. H. LEE* - K. S. KIM - Y. S. CHOI - J. C. Kim, Korea, Republic of

PP247 CASE REPORT: PENILE PENETRATING TRAUMA BY FISH BONE
C. Lungfeng* - Y. Chia-Cheng, Taiwan

PP249 ANTERIOR URETHRAL STRICTURE: PRACTICE SURVEY AMONG UROLOGIST IN HONG KONG
M. Cheung* - K. Lam, Hong Kong

PP251 MANAGEMENT OF RENAL BLUNT TRAUMA IN PRE-EXISTING RENAL PATHOLOGY IN CHO RAY HOSPITAL

PP252 10 YEAR REVIEW OF URETHROPLASTY OUTCOME AND RISK FACTOR FOR RECURRENCE: A SINGLE CENTER EXPERIENCE
T. O. Yu* - H. W. Yueng - S. K. Chu - C. W. Man, Hong Kong

PP253 INTRAVESICAL BOTOX INJECTION FOR VOIDING DYSFUNCTION: AN ENDEAVOR TO SERVE THE FORGOTTEN
K. Lo* - R. Kan - C. Li - C. Ng - C. Kan - H. Ngai - W. Au, Hong Kong

PP254 BLADDER STONE AND URODYNAMICS-A MODEL RESEARCH IN RABBITS
Y. Sun* - J. SUN - H. ZHAO - R. HE, China

PP256 VALIDATION OF THE TOTO FLOWSKY® UROFLOWMETRY DEVICE
W. C. Tsang* - J. Kwong - L. Raman - Z. M. Wai - D. Consigliere - E. Chiong, Singapore

PP258 COMPARING ELECTROMAGNETIC STIMULATION WITH ELECTROSTIMULATION PLUS BIOFEEDBACK IN TREATING MALE REFRACTORY CHRONIC PELVIC PAIN SYNDROME
H. Chien*, Taiwan

PP259 ROBOTIC-ASSISSTED LAPAROSCOPIC SACRAL COLPOPEXY – INITIAL RESULTS OF ONE INSTITUTION IN VIETNAM

PP260 MANAGEMENT REGARDING THE REPROPLICABILITY OF OVERACTIVE BLADDER SYMPTOM SCORE (OABSS)

PP262 SHORT-TERM OUTCOME OF LAPAROSCOPIC SACRAL COLPOPEXY FOR PELVIC ORGAN PROLAPSE
K. Sakamaka* - H. Sasaki - A. Furuta - S. Egawa, Japan

PP263 LONG-TERM SUCCESS RATE OF SUBURETHRAL SLING PROCEDURE IN STRESS URINARY INCONTINENCE FEMALE PATIENTS WITH DIFFERENT BLADDER FUNCTION.
H. L. Ong* - H.-H. Liu - H.-C. Kuo, Taiwan

PP264 FEMALE BLADDER NECK DYSFUNCTION – A VIDEOURODYNAMIC DIFFERENTIAL DIAGNOSIS AMONG WOMEN WITH VOIDING DYSFUNCTION
H. L. Ong* - C. L. Lee - H.-C. Kuo, Taiwan

PP265 CLINICAL EXPERIENCE OF DIFFERENT SURGICAL REPAIR PROCEDURES FOR VESICOVAGINAL FISTULA AFTER GYNECOLOGIC SURGERY
Z. Liu* - X. Tian - L. Ma, China

PP266 VIDEOURODYNAMIC ANALYSIS OF THE URETHRAL SPHINCTER OVERACTIVITY AND THE POOR RELAXING PELVIC FLOOR MUSCLES IN WOMEN WITH VOIDING DYSFUNCTION
H. L. Ong* - C.-H. Peng - H.-C. Kuo, Taiwan

PP267 DOES THE VOLUME EFFECT OF PROSTATIC ADENOMA IN PROSTATE EXIST? : A PROSPECTIVE STUDY
E-POSTERS

PP271 P21-ACTIVATED KINASE 5 IN BLADDER CANCER EMT
A. F. Ismail* - P. Dasgupta - M. S. Khan - C. Wells , United Kingdom

PP274 ABNORMAL EXPRESSION OF SG I IS CLOSELY RELATED TO SEMINAL VESICULITIS
Z. Wang* - B. Liu and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP275 THE PROGRESSION OF PROLACTIN AND ITS RECEPTORS ACTING ON ERECTION AND EJACULATION
Z. Wang* - J. Zhang - A. Xu, China

PP276 EPPIN, A NOVEL MARKER TO DIFFERENTIALLY DIAGNOSE AZOOSPERMIA?
Z. Wang* - B. Liu, China

PP277 ANALYSIS AND DIFFERENCE OF VOLTAGE-DEPENDENT ANION CHANNEL MRNA IN EJACULATED SPERMATOZOA FROM NORMOOSPERMIC FERTILE DONORS AND INFERTILE PATIENTS WITH IDIOPATHIC ASTHENOSPERMIA
Z. Wang* - B. Liu - W. Zhang, China

PP278 ENOLASE1 (ENO1) AND GLUCOSE-6-PHOSPHATE ISOMERASE (GPI) ARE GOOD MARKERS TO PREDICT HUMAN SPERM FREEZABILITY
Z. Wang* - X.-P. Jiang and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP279 A NOVEL SURGICAL MANAGEMENT FOR MALE INFERTILITY SECONDARY TO MIDLINE PROSTATIC CYST
Z. Wang* - G. Cheng - B. Liu and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP281 CLUSTERIN EXPRESSION AND HUMAN TESTICULAR SEMINOMA
Z. Wang* - M. Tang - J. Li, China

PP282 CORRELATION OF EPIDIDYMAL PROTEASE INHIBITOR AND FIBRONECTIN IN HUMAN SEMEN
Z. Wang* - X. Zhang - J. Fang, China

PP283 CHARACTERIZATION OF LACTOFERRIN RECEPTOR ON HUMAN SPERMATOZOA
Z. Wang* - P. Wang - B. Liu, China

PP284 MICROWAVE ABLATION FOR SMALL RENAL MASS. AN EARLY EXPERIENCE FROM A LOCAL HOSPITAL IN HONG KONG

PP287 SEMINAL PLASMA PROTEIN IN RENAL CELL CARCINOMA: EXPRESSION OF SEMENOGELIN I IS A PREDICTOR FOR CANCER PROGRESSION AND PROGNOSIS
Z. Wang* - S. Zhang - X. Zhang, China

PP288 SEMINAL PLASMA PROTEIN IN RENAL CELL CARCINOMA: EXPRESSION OF SEMENOGELIN I IS A PREDICTOR FOR CANCER PROGRESSION AND PROGNOSIS
Z. Wang* - S. Zhang and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP291 EXPRESSION OF LACTATE DEHYDROGENASE C CORRELATES WITH POOR PROGNOSIS IN RENAL CELL CARCINOMA
Z. Wang* - Y. Hua - C. Long - J. Zhu - C. Miao - Y. Yu, China

PP292 MODIFIED RETROPERITONEOSCOPIC RENAL PEDICLE LYMPHATIC DISCONNECTION FOR INTRACTABLE CHYLURIA
Z. Wang* - B. Liu and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP293 GROWTH-INDUCED STRESS ENHANCES EPITHELIAL–MESENCHYMAL TRANSITION INDUCED BY IL-6 IN CLEAR CELL RENAL CELL CARCINOMA VIA THE AKT/GSK-3β/CATENIN SIGNALING PATHWAY

PP294 DOWNREGULATION OF TNASP INHIBITS PROLIFERATION THROUGH REGULATING CELL CYCLE-RELATED PROTEINS AND INACTIVE ERK/MAPK SIGNAL PATHWAY IN RENAL CELL CARCINOMA CELLS
Z. Wang* - J. Fang and State Key Laboratory of Reproductive Medicine and Department of Urology, China

PP295 POLYPYRIMIDINE TRACT–BINDING PROTEIN 1 PROMOTES PROLIFERATION, MIGRATION AND INVASION IN CLEAR-CELL RENAL CELL CARCINOMA BY REGULATING ALTERNATIVE SPlicing OF PKM
X. Chen* - P. Gu - R. Xie - T. Lin, China

PP296 CROSS-CULTURAL ADAPTATION OF FILIPINO VERSION OF FARHAT’S DYSFUNCTIONAL VOIDING SYMPTOM SCORE (DVSS) QUESTIONNAIRE
A. N. Lim* - D. Bolong, Philippines
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PP297</td>
<td>DEMYSTIFYING THE MECHANISTIC AND FUNCTIONAL ASPECTS OF RNA ACTIVATION WITH DOUBLESTRANDED RNAS IN HUMAN PROSTATE CANCER CELLS</td>
<td>J. Hu* · H. Wu, China</td>
</tr>
<tr>
<td>PP298</td>
<td>THREE COMPONENTS OF INHERITED CANCER RISK AND THEIR IMPLICATIONS IN PERSONALIZED CANCER SCREENING</td>
<td>J. Xu*, United States</td>
</tr>
<tr>
<td>PP299</td>
<td>EXPRESSION OF ERG AND SPINK1 IN LATENT, INCIDENTAL, AND METASTATIC PROSTATE CANCER IN JAPAN</td>
<td>T. Kimura* · H. Inaba · H. Koide · J. Miki · S. Sato · H. Takahashi · S. Egawa, Japan</td>
</tr>
<tr>
<td>PP300</td>
<td>EVALUATION OF A SHORT RNA WITHIN PCA3 IN THE PREDICTIVE ROLE FOR FUTURE CANCER USING NON-MALIGNANT PROSTATE BIOPSIES</td>
<td>K. H. Pang* · D. Rosario · S. Morgan · J. Catto, United Kingdom</td>
</tr>
<tr>
<td>PP301</td>
<td>A REVIEW OF DECISION AIDS IN AFFECTING THE PATIENTS’ UNDERSTANDING OF DIFFERENT TREATMENTS FOR LOCALIZED PROSTATE CANCER</td>
<td>W. Zhong* · P. Rathore · L. H. Wong · P. Mancuso · K. Haghighi, Australia</td>
</tr>
<tr>
<td>PP302</td>
<td>AN ORIGINAL PATIENT-DERIVED XENOGRAFT KUCAP2 EXPRESSES AR-V7 WITH ACQUISITION OF CASTRATION RESISTANCE</td>
<td>Y. Makino* · T. Kobayashi · A. Shusuke · T. Naoki · I. Takahira · O. Osamu, Japan</td>
</tr>
<tr>
<td>PP303</td>
<td>ANALYSES AND CLINICAL APPLICATION OF LIQUID BIOPSY FROM PATIENTS WITH ADVANCED PROSTATE CANCER</td>
<td>M. Nagata* · M. Kanayama · N. Nagaya · S. Horie, Japan</td>
</tr>
<tr>
<td>PP304</td>
<td>ASSOCIATION BETWEEN GERMLINE HOMEobox B13 (HOXB13) G84E ALLELE AND PROSTATE CANCER SUSCEPTIBILITY: A META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS</td>
<td>Z. Wang* · J. Zhang · X. Li, China</td>
</tr>
<tr>
<td>PP305</td>
<td>ED TREATMENT USING LOW INTENSITY SHOCKWAVES: NOVEL APPROACHES - FUTURE OUTLOOKS</td>
<td>I. Motl* · T. Sramkova, Czech Republic</td>
</tr>
<tr>
<td>PP306</td>
<td>SCREENING LENTIVIRAL VECTORS CARRYING EFFECTIVE SIRNA OF THE S1P2 GENE</td>
<td>R. Jiang* · X. Yan, China</td>
</tr>
<tr>
<td>PP307</td>
<td>THE FLUOROLESS BREATHING C-ARM TRAINER: AN UPGRADED PERCUTANEOUS RENAL ACCESS TRAINING DEVICE</td>
<td>Z. Zhao* · J. Speich · T. Reihser · L. Poniatskova · R. Sweet, China</td>
</tr>
<tr>
<td>PP308</td>
<td>PRO-INFLAMMATORY AND IMMUNE-ACTIVE RESPONSES LEAD TO RANDALL’S PLAQUE FORMATION ON CALCIUM PHOSPHATE STONE</td>
<td>K. Taguchi* · S. Hamamoto · T. Sugino · R. Urno · Y. Fujii · R. Ando · A. Okada · H. Kamiya · K. Kohri · T. Yasui, Japan</td>
</tr>
<tr>
<td>PP309</td>
<td>TWO NOVEL ASX7 MUTATIONS IDENTIFIED IN CHINESE PATIENTS WITH SEVER BILATERAL MULTIPLE NEPHROLITHIASIS</td>
<td>Y. Du* · J. Li, China</td>
</tr>
<tr>
<td>PP310</td>
<td>NEPHROLITHIASIS OR NEPHROCALCINOSIS?–AN UYGHUR ADOLESCENT WITH FAMILIAL HYPOMAGNESAEAMIA WITH HYPERCALCIURIA AND NEPHROCALCINOSIS DUE TO CLDN16 MUTATION</td>
<td>Y. Du* · J. Li, China</td>
</tr>
<tr>
<td>PP311</td>
<td>LAPAROSCOPIC LIVING DONOR NEPHRECTOMY IN CIPTO MANGUNKUSUMO HOSPITAL : POSTOPERATIVE PAIN AND RECOVERY ANALYSIS</td>
<td>E. Wibisono* · I. Wahyudi, Indonesia</td>
</tr>
<tr>
<td>PP312</td>
<td>DOES THE USE OF TOPICAL ANESTHETIC GEL REDUCE URETHRAL CATHETERIZATION PAIN? A META-ANALYSIS</td>
<td>P. N. B. Firaza* · M. Chua · E. I. Lorenzo · R. Agudera, Philippines</td>
</tr>
<tr>
<td>PP313</td>
<td>EIGHT MEASURES TO IMPROVE EARLY RECOVERY OF CONTINENCE DURING LAPAROSCOPIC RADICAL PROSTATECTOMY</td>
<td>S. Zhang* · L. Ma · L. Liu · Y. Tian, China</td>
</tr>
<tr>
<td>PP314</td>
<td>ROBOT-ASSISTED SURGERY IN UROLOGY: INITIAL APPLICATION AT BINH DAN HOSPITAL</td>
<td>N. P. Cam Hoang* · T. Vinh Hung · V. Le Chuyen · N. Van An · D. V. Phuong · D. Anh Toan · L. T. Khoi · D. L. Hung · P. Huu Doan, Vietnam</td>
</tr>
<tr>
<td>LAST NAME</td>
<td>FIRST NAME</td>
<td>INSTITUTION</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
<td>----------------------------------------------------------</td>
</tr>
<tr>
<td>ABRAHAMSSON</td>
<td>Per Anders</td>
<td>Skåne University Hospital, Lund University</td>
</tr>
<tr>
<td>AGARWAL</td>
<td>Madhu</td>
<td>SN Medical College</td>
</tr>
<tr>
<td>AHLAWAT</td>
<td>Rajesh</td>
<td>Fortis Escorts Heart Institute &amp; Research Center</td>
</tr>
<tr>
<td>AKAZA</td>
<td>Hideyuki</td>
<td>University of Tokyo</td>
</tr>
<tr>
<td>ALDANA</td>
<td>Joel</td>
<td>Department Of Surgery Philippine General Hospital Taft Ave</td>
</tr>
<tr>
<td>ARAKI</td>
<td>Motoo</td>
<td>Okayama University Graduate School of Medicine</td>
</tr>
<tr>
<td>ATTARD</td>
<td>Gerhardt</td>
<td>The Institute of Cancer Research</td>
</tr>
<tr>
<td>BEX</td>
<td>Axel</td>
<td>The Netherlands Cancer Institute</td>
</tr>
<tr>
<td>BINTI ABDULLAH</td>
<td>Khadijah</td>
<td>University of Malaya</td>
</tr>
<tr>
<td>BOXLER</td>
<td>Silvan</td>
<td>Inselspital, Universitätsklinik Bern</td>
</tr>
<tr>
<td>CHAN</td>
<td>Chi-Kwok</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>CHAN</td>
<td>Eddie</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>CHAN</td>
<td>Lewis</td>
<td>Concord Repatriation General Hospital</td>
</tr>
<tr>
<td>CHAN</td>
<td>Ning-Hong</td>
<td>Pamela Youde Nethersole Eastern Hospital</td>
</tr>
<tr>
<td>CHAN</td>
<td>Wai-Ming</td>
<td>The University of Hong Kong</td>
</tr>
<tr>
<td>CHAN</td>
<td>Tze-Yeung</td>
<td>Tuen Mun Hospital</td>
</tr>
<tr>
<td>CHAN</td>
<td>Yau-Tung</td>
<td>Private Practice</td>
</tr>
<tr>
<td>CHANG</td>
<td>Sam</td>
<td>Vanderbilt University</td>
</tr>
<tr>
<td>CHAPPLE</td>
<td>Christophe</td>
<td>Royal Hallamshire Hospital</td>
</tr>
<tr>
<td>CHENG</td>
<td>Christopher</td>
<td>Singapore General Hospital</td>
</tr>
<tr>
<td>CHEN</td>
<td>Shih-Sheng</td>
<td>National Yang-Ming University School of Medicine</td>
</tr>
<tr>
<td>CHIN</td>
<td>Joseph</td>
<td>University of Western Ontario</td>
</tr>
<tr>
<td>CHIN</td>
<td>Peter</td>
<td>The University of Adelaide</td>
</tr>
<tr>
<td>CHIONG</td>
<td>Edmund</td>
<td>National University of Singapore</td>
</tr>
<tr>
<td>CHIU</td>
<td>Allen</td>
<td>Taipei Medical University</td>
</tr>
<tr>
<td>CHIU</td>
<td>Kun-Yuan</td>
<td>Taichung Veterans General Hospital</td>
</tr>
<tr>
<td>CHIU</td>
<td>KF Peter</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>CHO</td>
<td>Carmen</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>CHO</td>
<td>Chak-Lam</td>
<td>Kwong Wah Hospital</td>
</tr>
<tr>
<td>CHO</td>
<td>Sung-Yong</td>
<td>Seoul National University</td>
</tr>
<tr>
<td>CHO</td>
<td>Yong-Hyun</td>
<td>Catholic University of Korea</td>
</tr>
<tr>
<td>CHU</td>
<td>Peggy</td>
<td>Tune Mun Hospital</td>
</tr>
<tr>
<td>CHU</td>
<td>Ringo</td>
<td>Kwong Wah Hospital</td>
</tr>
<tr>
<td>CHU</td>
<td>Shun-Fai</td>
<td>Princess Margaret Hospital, Hong Kong</td>
</tr>
<tr>
<td>CHUA</td>
<td>Rou Wei</td>
<td>Singapore General Hospital</td>
</tr>
<tr>
<td>CHU</td>
<td>Tin Yu</td>
<td>Princess Margaret Hospital</td>
</tr>
<tr>
<td>CHUI</td>
<td>Ka-Lun</td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>CHUNG</td>
<td>Eric</td>
<td>University of Queensland</td>
</tr>
<tr>
<td>DE LA ROSETTE</td>
<td>Jean</td>
<td>AMC University Hospital</td>
</tr>
<tr>
<td>DESAI</td>
<td>Janak</td>
<td>Samved Hospital</td>
</tr>
<tr>
<td>DU</td>
<td>Zhen</td>
<td>Beijing Tong Ren Hospital Capital Medical University</td>
</tr>
<tr>
<td>EGAWA</td>
<td>Shin</td>
<td>Jikei University</td>
</tr>
<tr>
<td>Name</td>
<td>Position</td>
<td>Institution</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------</td>
<td>--------------------------------------------------</td>
</tr>
<tr>
<td>FONG Angela</td>
<td></td>
<td>Centro Hospitalar Conde de S. Januario</td>
</tr>
<tr>
<td>FARAHAT Yasser</td>
<td></td>
<td>Sheikh Khalifa General Hospital</td>
</tr>
<tr>
<td>FOO Keong-Tatt</td>
<td></td>
<td>Singapore General Hospital</td>
</tr>
<tr>
<td>FUJISAWA Masato</td>
<td></td>
<td>Kobe University Graduate School of Medicine</td>
</tr>
<tr>
<td>GAO Xin</td>
<td></td>
<td>Department of Urology, the Third Affiliated Hospital, Sun Yat-sen University</td>
</tr>
<tr>
<td>GUPTA Namada</td>
<td></td>
<td>Medanta Kidney and Urology Institute</td>
</tr>
<tr>
<td>GYUN KWON Tae</td>
<td></td>
<td>Kyungpook National University</td>
</tr>
<tr>
<td>HA CHUNG Byung</td>
<td></td>
<td>Catholic University of Korea</td>
</tr>
<tr>
<td>HAKIM Lukman</td>
<td></td>
<td>Airlangga University, Surabaya</td>
</tr>
<tr>
<td>HAMASUNA Ryoichi</td>
<td></td>
<td>University of Occupational and Environmental Health</td>
</tr>
<tr>
<td>HAMDY Freddie</td>
<td></td>
<td>University of Oxford</td>
</tr>
<tr>
<td>HE Wei</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HO Brian</td>
<td></td>
<td>The University of Hong Kong, Queen Mary Hospital</td>
</tr>
<tr>
<td>HO Henry</td>
<td></td>
<td>Singapore General Hospital</td>
</tr>
<tr>
<td>HO Lap-Yin</td>
<td></td>
<td>Private Practice</td>
</tr>
<tr>
<td>HONG Jun Hyuk</td>
<td></td>
<td>AMC Urologic Cancer Center</td>
</tr>
<tr>
<td>HORIE Shigeo</td>
<td></td>
<td>Teikyo University Hospital</td>
</tr>
<tr>
<td>HOSSENI Jalil</td>
<td></td>
<td>Shahid Beheshti University</td>
</tr>
<tr>
<td>HOU Simon</td>
<td></td>
<td>The Chinese University of Hong Kong</td>
</tr>
<tr>
<td>HSIEH Mike</td>
<td></td>
<td>UC San Diego Health System</td>
</tr>
<tr>
<td>HUANG Chao-Yuan</td>
<td></td>
<td>National Taiwan University</td>
</tr>
<tr>
<td>HUANG Jian</td>
<td></td>
<td>Sun Yat-Sen University</td>
</tr>
<tr>
<td>HUANG Kuan-hua</td>
<td></td>
<td>Chi Mei Medical Center</td>
</tr>
<tr>
<td>IP Alan</td>
<td></td>
<td>Tune Mun Hospital</td>
</tr>
<tr>
<td>JEONG Byong Chang</td>
<td></td>
<td>Samsung Medical Center, Sungkyunkwan University School of Medicine</td>
</tr>
<tr>
<td>JOHNSTONE Peter</td>
<td></td>
<td>Moffitt Cancer Center</td>
</tr>
<tr>
<td>KAM Yuen-Ching</td>
<td></td>
<td>Queen Elizabeth Hospital</td>
</tr>
<tr>
<td>KAMOI Kazumi</td>
<td></td>
<td>Kyoto Prefectural University of Medicine</td>
</tr>
<tr>
<td>KAWAHARA Takeshi</td>
<td></td>
<td>Yokohama City University Medical Center</td>
</tr>
<tr>
<td>YEUNG Winnie Ka-Wai</td>
<td></td>
<td>Pamela Youde Nethersole Eastern Hospital</td>
</tr>
<tr>
<td>KIKUCHI Eiji</td>
<td></td>
<td>Keio University</td>
</tr>
<tr>
<td>KIM Seung Hyup</td>
<td></td>
<td>Seoul National University</td>
</tr>
<tr>
<td>KO Dicken</td>
<td></td>
<td>Harvard Medical School</td>
</tr>
<tr>
<td>KUMAR Rajeev</td>
<td></td>
<td>All India Institute of Medical Sciences</td>
</tr>
<tr>
<td>KUO Hann-Chong</td>
<td></td>
<td>Buddhist Tzu-Chi General Hospital</td>
</tr>
<tr>
<td>KWOK Sze-Wan</td>
<td></td>
<td>Prince of Wales Hospital</td>
</tr>
<tr>
<td>KWONG Philip</td>
<td></td>
<td>The University of Hong Kong</td>
</tr>
<tr>
<td>KYU HONG Sung</td>
<td></td>
<td>Seoul National University Bundang Hospital</td>
</tr>
<tr>
<td>LAM Wayne</td>
<td></td>
<td>Queen Mary Hospital The University of Hong Kong</td>
</tr>
<tr>
<td>LAU Howard</td>
<td></td>
<td>Private Practice</td>
</tr>
<tr>
<td>LEE George</td>
<td></td>
<td>Gleneagles Intan Medical Centre</td>
</tr>
<tr>
<td>LEE Kyu-Sung</td>
<td></td>
<td>Department of Urology Samsung Medical Center</td>
</tr>
<tr>
<td>LEE Lui-Shiong</td>
<td></td>
<td>National University of Singapore</td>
</tr>
<tr>
<td>LEE Seung-Ju</td>
<td></td>
<td>Catholic University of Korea</td>
</tr>
<tr>
<td>Name</td>
<td>Affiliation</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>Leung Yiu Lam Simon</td>
<td>Private Practice</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Li Crystal</td>
<td>Prince of Wales Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Li Jian-Ri</td>
<td>Taichung Veterans General Hospital</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Li Man-Kay</td>
<td>Mount Elizabeth Hospital</td>
<td>Singapore</td>
</tr>
<tr>
<td>Li Miu-Ling</td>
<td>Tuen Mun Hospital</td>
<td>Korea</td>
</tr>
<tr>
<td>Li Zheng</td>
<td>Shanghai Jiao Tong University School of Medicine</td>
<td>China</td>
</tr>
<tr>
<td>Lim Peter</td>
<td>Gleneagles Hospital</td>
<td>Singapore</td>
</tr>
<tr>
<td>Lo Gladys</td>
<td>Hong Kong Sanatorium and Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Lojanapiwat Bannakij</td>
<td>Chiang Mai University</td>
<td>Thailand</td>
</tr>
<tr>
<td>Lo Ka-Lun</td>
<td>North District Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Lo Kwong-Yin Richard</td>
<td>Private Practice</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Lu Shing-Hwa</td>
<td>National Yang Ming University</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Ma Lu-Lin</td>
<td>Peking University 3rd Hospital</td>
<td>China</td>
</tr>
<tr>
<td>Ma Wai-Kit</td>
<td>The University of Hong Kong, Queen Mary Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Matsuda Tadashi</td>
<td>Kansai Medical University</td>
<td>Japan</td>
</tr>
<tr>
<td>Matsumoto Masahiro</td>
<td>University of Occupational and Environmental Health</td>
<td>Japan</td>
</tr>
<tr>
<td>Matsumoto Tetsuro</td>
<td>University of Occupational and Environmental Health</td>
<td>Japan</td>
</tr>
<tr>
<td>Mo Zengnan</td>
<td>Guangxi Medical University</td>
<td>China</td>
</tr>
<tr>
<td>Monga Manoj</td>
<td>Cleveland Clinic</td>
<td>USA</td>
</tr>
<tr>
<td>Moon Daniel</td>
<td>Epworth Healthcare</td>
<td>Australia</td>
</tr>
<tr>
<td>Murphy Declan</td>
<td>Peter MacCallum Cancer Centre</td>
<td>Australia</td>
</tr>
<tr>
<td>Na Yong-Gil</td>
<td>Chungnam National University</td>
<td>Korea</td>
</tr>
<tr>
<td>Nagata Masayoshi</td>
<td>Juntendo University</td>
<td>Japan</td>
</tr>
<tr>
<td>NaIR Raj</td>
<td>Peter MacCallum Cancer Centre</td>
<td>Australia</td>
</tr>
<tr>
<td>Ng Ada Tsui Lin</td>
<td>The University of Hong Kong, Queen Mary Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Ng Sau-Loi</td>
<td>The University of Hong Kong, Queen Mary Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Oh Seung-June</td>
<td>Seoul National University Hospital</td>
<td>South Korea</td>
</tr>
<tr>
<td>Ong Teng-Aik</td>
<td>UM Specialist Centre</td>
<td>Malaysia</td>
</tr>
<tr>
<td>Pangi Jacob</td>
<td>Lin-Kou Chang Gung Memorial Hospital</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Pong Keng-Siang</td>
<td>Tan Tock Seng Hospital</td>
<td>Singapore</td>
</tr>
<tr>
<td>Poona Darren</td>
<td>The Chinese University of Hong Kong</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Rassweiler Jens</td>
<td>SLK Kliniken Heilbronn</td>
<td>Germany</td>
</tr>
<tr>
<td>Rha Koon-Ho</td>
<td>Yonsei University</td>
<td>South-Korea</td>
</tr>
<tr>
<td>Rusero Jonah</td>
<td>Guy’s and St Thomas’ NHS Foundation Trust</td>
<td>UK</td>
</tr>
<tr>
<td>Satyagraha Paksi</td>
<td>Saiful Anwar Hospital</td>
<td>Indonesia</td>
</tr>
<tr>
<td>Schwentner Christian</td>
<td>Eberhard Karls University</td>
<td>Germany</td>
</tr>
<tr>
<td>Seo Ill-Young</td>
<td>Wonkwang University School of Medicine &amp; Hospital</td>
<td>South Korea</td>
</tr>
<tr>
<td>Sethia Krishna</td>
<td>Norfolk and Norwich University Hospital</td>
<td>UK</td>
</tr>
<tr>
<td>Shigemura Katsumi</td>
<td>Katsumi Shigemura</td>
<td>Japan</td>
</tr>
<tr>
<td>Shujii Isotan</td>
<td>Teikyo University</td>
<td>Japan</td>
</tr>
<tr>
<td>Sivaraman Arjun</td>
<td>Memorial Sloan Kettering Cancer Center</td>
<td>USA</td>
</tr>
<tr>
<td>So Alan</td>
<td>Vancouver Prostate Centre</td>
<td>Canada</td>
</tr>
<tr>
<td>So Karina</td>
<td>Concord Repatriation General Hospital</td>
<td>Australia</td>
</tr>
<tr>
<td>So Hing Shing</td>
<td>United Christian Hospital</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Name</td>
<td>Institution</td>
<td>Country</td>
</tr>
<tr>
<td>-------------</td>
<td>--------------------------------------------------</td>
<td>-----------</td>
</tr>
<tr>
<td>KIM</td>
<td>Choung-Soo</td>
<td>Korea</td>
</tr>
<tr>
<td>SUNG</td>
<td>Gyung Tak Mario</td>
<td>Korea</td>
</tr>
<tr>
<td>TAN</td>
<td>Yung-Khan</td>
<td>Singapore</td>
</tr>
<tr>
<td>TANRIKUT</td>
<td>Cigdem</td>
<td>USA</td>
</tr>
<tr>
<td>TEOH</td>
<td>Jeremy</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>THE</td>
<td>Guan-Chou</td>
<td>Malaysia</td>
</tr>
<tr>
<td>TIONG</td>
<td>Ho-Yee</td>
<td>Singapore</td>
</tr>
<tr>
<td>TO</td>
<td>Hoi-Chu</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>TOH</td>
<td>Ka-Fai</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>TSE</td>
<td>Vincent</td>
<td>Australia</td>
</tr>
<tr>
<td>TSE</td>
<td>Yuen-Bing</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>TSU</td>
<td>James</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>UEMURA</td>
<td>Hiroji</td>
<td>Japan</td>
</tr>
<tr>
<td>UMBAS</td>
<td>Rainy</td>
<td>Indonesia</td>
</tr>
<tr>
<td>VENEZIANO</td>
<td>Domenico</td>
<td>Italy</td>
</tr>
<tr>
<td>VIKRAM</td>
<td>Raghunandan</td>
<td>USA</td>
</tr>
<tr>
<td>VOLPE</td>
<td>Alessandro</td>
<td>Italy</td>
</tr>
<tr>
<td>WANG</td>
<td>Shuo</td>
<td>China</td>
</tr>
<tr>
<td>WEH CHONG</td>
<td>Tsung</td>
<td>Singapore</td>
</tr>
<tr>
<td>WONG</td>
<td>Alfred</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>WONG</td>
<td>Bill</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>WONG</td>
<td>Joseph</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>WONG</td>
<td>Michael</td>
<td>Singapore</td>
</tr>
<tr>
<td>WOO</td>
<td>Henry</td>
<td>Australia</td>
</tr>
<tr>
<td>WU</td>
<td>Tony</td>
<td>Taiwan</td>
</tr>
<tr>
<td>YAMAMOTO</td>
<td>Shingo</td>
<td>Japan</td>
</tr>
<tr>
<td>YANG</td>
<td>Cheng-Kuang</td>
<td>Taiwan</td>
</tr>
<tr>
<td>YANG</td>
<td>Stephen</td>
<td>Taiwan</td>
</tr>
<tr>
<td>YASUI</td>
<td>Takahiro</td>
<td>Japan</td>
</tr>
<tr>
<td>YAU</td>
<td>Helen</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>YEE</td>
<td>Samuel</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>YEOW</td>
<td>Eng-Kion</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>YIU</td>
<td>Ming-Kwong</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>YOON</td>
<td>Hana</td>
<td>Korea</td>
</tr>
<tr>
<td>YOUL LEE</td>
<td>Ji</td>
<td>Korea</td>
</tr>
<tr>
<td>YOUNG PARK</td>
<td>Jae</td>
<td>Korea</td>
</tr>
<tr>
<td>YU</td>
<td>Simon</td>
<td>China</td>
</tr>
<tr>
<td>ZENG</td>
<td>Guo-Hua</td>
<td>China</td>
</tr>
<tr>
<td>ZHANG</td>
<td>Qian</td>
<td>China</td>
</tr>
<tr>
<td>ZHANG</td>
<td>Zhu-Dong</td>
<td>China</td>
</tr>
<tr>
<td>ZHU</td>
<td>Gang</td>
<td>China</td>
</tr>
</tbody>
</table>
KOELIS provides a unique 3D Targeted Prostate Biopsy Map for personalized management of prostate cancer.

Such mapping is an invaluable tool for patient selection and treatment choice. Exporting the Biopsy Map is now possible and can assist with planning of Focal Treatment by providing: 3D meshing of the prostate, biopsies, target localization, and reference 3D TRUS image.
UAA 2017 GALA DINNER CUM HKUA 30TH ANNIVERSARY

Date: Saturday, 5 August 2017
Time: 6:30 pm cocktail - 7:30 pm dinner
Venue: Chancellor Room - L4 Hong Kong Convention & Exhibition Centre, 1 Expo Drive, Wan Chai, Hong Kong
Dress code: Suit
Ticket can be purchase during registration process

UAA 2017 PRESIDENT DINNER
(UPON INVITATION ONLY)

Date: Friday, 4 August 2017
Time: 6:00 pm cocktail - 7:30 pm dinner
Venue: TAMARIND PAN-ASIAN - 2/F, Sun Hung Kai Center, 30 Harbour Road, Wan Chai
Dress code: Smart casual
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Booth</th>
</tr>
</thead>
<tbody>
<tr>
<td>A.R. Medicom Inc. (Asia) Limited</td>
<td>E03</td>
</tr>
<tr>
<td>Allergan</td>
<td>Sponsor</td>
</tr>
<tr>
<td>Amgen Asia Holding Limited</td>
<td>B08</td>
</tr>
<tr>
<td>Associated Medical Supplies Company Limited</td>
<td>E04</td>
</tr>
<tr>
<td>Astellas Pharma Inc.</td>
<td>C09</td>
</tr>
<tr>
<td>Baxter Healthcare Ltd.</td>
<td>A05</td>
</tr>
<tr>
<td>Bayer HealthCare Limited</td>
<td>Sponsor</td>
</tr>
<tr>
<td>BK Ultrasound</td>
<td>C15</td>
</tr>
<tr>
<td>Boston Scientific Asia Pacific Pte Ltd</td>
<td>C23</td>
</tr>
<tr>
<td>CHINDEX HONG KONG LIMITED</td>
<td>C26</td>
</tr>
<tr>
<td>Cook Medical</td>
<td>A09</td>
</tr>
<tr>
<td>Dornier Medtech Asia</td>
<td>A02</td>
</tr>
<tr>
<td>EDAP TMS S.A.</td>
<td>B05</td>
</tr>
<tr>
<td>Eli Lilly Asia, Inc.</td>
<td>E08</td>
</tr>
<tr>
<td>Elvation Medical GmbH</td>
<td>B04</td>
</tr>
<tr>
<td>ERBE China Ltd</td>
<td>Sponsor</td>
</tr>
<tr>
<td>Ethicon</td>
<td>C01</td>
</tr>
<tr>
<td>Ferring Pharmaceuticals Ltd</td>
<td>A01</td>
</tr>
<tr>
<td>GSK</td>
<td>C07</td>
</tr>
<tr>
<td>Ipsen Pharma</td>
<td>A10</td>
</tr>
<tr>
<td>Janssen Pharmaceutical Companies of Johnson &amp; Johnson</td>
<td>C01</td>
</tr>
<tr>
<td>Karger Publishers</td>
<td>Sponsor</td>
</tr>
<tr>
<td>KARL STORZ ENDOSCOPY CHINA LTD</td>
<td>C19</td>
</tr>
<tr>
<td>Lilium Otsuka Co., Ltd.</td>
<td>E05</td>
</tr>
<tr>
<td>Lumenis (HK) Limited</td>
<td>E02</td>
</tr>
<tr>
<td>Main Life Corp., LTD and Shenzhen Main Luck Pharmaceuticals Inc.</td>
<td>A08</td>
</tr>
<tr>
<td>MEDA CO., LTD</td>
<td>D05</td>
</tr>
<tr>
<td>MEDA Pharmaceutical Hong Kong Limited</td>
<td>D03</td>
</tr>
<tr>
<td>MEDIFOCUS ASIA LIMITED</td>
<td>B06</td>
</tr>
<tr>
<td>Menarini Asia-Pacific</td>
<td>B01</td>
</tr>
<tr>
<td>Merck Sharp &amp; Dohme (Asia) Ltd</td>
<td>A07</td>
</tr>
<tr>
<td>Olympus Hong Kong and China Limited</td>
<td>C25</td>
</tr>
<tr>
<td>Pfizer Corporation Hong Kong</td>
<td>Sponsor</td>
</tr>
<tr>
<td>QUANTA SYSTEM SPA</td>
<td>D01</td>
</tr>
<tr>
<td>ROCAMED</td>
<td>D02</td>
</tr>
<tr>
<td>sanofi</td>
<td>A03</td>
</tr>
<tr>
<td>ScanMed (China) Ltd</td>
<td>E07</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals (Hong Kong) Limited</td>
<td>D04</td>
</tr>
<tr>
<td>Teleflex Medical Asia Pte. Ltd</td>
<td>B02</td>
</tr>
<tr>
<td>UAA 2018/JUA 2018</td>
<td>D07</td>
</tr>
<tr>
<td>VirtaMed</td>
<td>B03</td>
</tr>
<tr>
<td>Wellspect Healthcare</td>
<td>A04</td>
</tr>
<tr>
<td>Wiley</td>
<td>D06</td>
</tr>
</tbody>
</table>
D08

17TH UROLOGICAL ASSOCIATION OF ASIA CONGRESS (UAA 2019)

info@uaa2019.com
www.uaa2019.com
+60321620566

From 7 - 10 August 2019, the Malaysian Urological Association will host the 17th Urological Association of Asia Congress for the second time since 2002. We aim to welcome all of you as delegates from all across Asia & the world for the most anticipated international urology meeting in Asia. With the theme of Unifying Asia Thru Urology, we are lining up a comprehensive scientific programme of live surgeries, leading opinions from renowned regional & international experts, in-depth master classes, resident training courses & nursing symposiums.

E03

A. R. MEDICOM INC. (ASIA) LIMITED

sales@medicom-asia.com
+85221797105

The Medicom Group is a global healthcare company dedicated to enhancing, manufacturing, and distributing infection control, single-use and preventive products for medical, dental, industrial, veterinary and laboratory markets.

We strive to provide distributors, professionals and their patients, the most trusted branded and private label product at outstanding value.

We bring entrepreneurial passion to everything we do in order to create remarkable customer experiences.

SPONSOR

ALLERGAN

www.allergan.com

Allergan plc (NYSE: AGN), headquartered in Dublin, Ireland, is a bold, global pharmaceutical company and a leader in a new industry model – Growth Pharma. Allergan is focused on developing, manufacturing and commercializing branded pharmaceuticals, devices and biologic products for patients around the world.

Allergan markets a portfolio of leading brands and best-in-class products for the central nervous system, eye care, medical aesthetics and dermatology, gastroenterology, women’s health, urology and anti-infective therapeutic categories.
**AMGEN ASIA HOLDING LIMITED**

medinfo.JAPAC@amgen.com  
+85228083988

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

**ASSOCIATED MEDICAL SUPPLIES COMPANY LIMITED**

general@amscl.com  
www.amscl.com  
85226049389

One of the Hong Kong Government registered medical suppliers of all kinds of medical products to government hospitals, laboratories and medical institutions in Hong Kong.

**ASTELLAS PHARMA INC.**

www.astellas.com/en  

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients.

**BAXTER HEALTHCARE LTD.**

mani_ching@baxter.com  
www.baxter.com.hk  
+85228078500

Baxter Healthcare Limited Hong Kong is a subsidiary of Baxter International Inc., which provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; Advanced surgery products and anesthetics; and pharmacy automation, software and services. Baxter Hong Kong is committed to expanding access to improved care and developing creative approaches to meet tomorrow’s healthcare needs.
BAYER HEALTHCARE LIMITED

www.bayer.com
+85228147337

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.

C15

BK ULTRASOUND
bkchina@bkultrasound.com
www.bkultrasound.com, www.bkultrasound.cn
+4008203345

For more than 40 years, BK Ultrasound solutions have played a central role in procedure-driven markets that include urology, surgery and point-of-care. With award-winning systems and unique transducer designs, BK directly addresses the specialized needs and clinical challenges of physicians worldwide, offering unsurpassed imaging capabilities that enable real-time image guidance with easy-to-use, mobile platforms.

C23

BOSTON SCIENTIFIC ASIA PACIFIC PTE LTD
fatima.khan@bsci.com
www.bostonscientific.com
+6564188888

Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. A global medical technology leader for over 35 years, Boston Scientific advances science for life by addressing the most pressing clinical needs, pursuing excellence and collaborating deeply with healthcare professionals worldwide to solve their toughest challenges. Headquartered in Marlborough, Massachusetts, its market presence extends to over 100 countries globally. For more information visit www.bostonscientific.com

C26

CHINDEX HONG KONG LIMITED
info.hk@chindexmedical.com
www.chindexmedical.com
+85225471536

Chindex Medical Limited (CML) is a leading provider of medical equipment. With over 1,500 employees worldwide and headquarters located in China, the Company’s strategy is to leverage its cross-cultural expertise to provide leading edge healthcare technologies and quality products to healthcare markets globally. CML offers a manufacturing platform for select medical technologies and a unique full-service distribution platform for both Western and Chinese manufacturers of medical devices. CML’s manufactured products are sold in more than 70 countries in Asia, Europe and the Americas.
A09

**COOK MEDICAL**

CustomerSupport@cookmedical.com  
www.cookmedical.com  
+85234721688

A patient-first philosophy and innovative spirit have helped Cook become a leader in urology. With a focus on stone management and urologic oncology, we pride ourselves on providing quality solutions without compromise. By uniting with healthcare professionals around the world, we’re committed to advancing treatment and making a difference, together.

A02

**DORNIER MEDTECH ASIA**

infoasia@dornier.com  
www.dornier.com  
+6565726068

Dornier MedTech, headquartered in Munich, Germany, is a medical device company known for its pioneering technologies and revolutionary therapies in urology. Dornier soars thanks to its deep-rooted spirit of entrepreneurship, excellence and innovation while developing some of the highest quality urology products on the market today. Dornier works closely with physicians, healthcare providers and research groups to ensure their products have the highest level of medical and scientific efficacy.

B05

**EDAP TMS S.A.**

hdsoultrait@edaptms.com.my  
www.edap-tms.com  
+60356349335

Global leader in therapeutic ultrasound and active in the market for more than 35 years, EDAP TMS develops, manufactures, promotes and distributes minimally-invasive medical devices for urology using ultrasound technology for non-invasive treatment of prostate cancer and urinary stones treatment by extracorporeal electroconductive shock waves.

E08

**ELI LILLY**

www.lilly.com

Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at www.lilly.com.
ELVATION MEDICAL GMBH

richard.wong@elvation.de
www.elvation.de
+639778390588

Extracorporeal Shockwave Therapy and Extracorporeal Shockwave Lithotripsy

ERBE CHINA LTD.

mayuan@erbechina.com
https://cn.erbe-med.com/cn-cn/
+862162758440

Erbe Elektromedizin GmbH was founded in 1851 in Tuebingen, Germany. Under the 5th generation of managing directors, Christian O. Erbe and Reiner Thede, this family business develops, produces and sells systems for electrosurgery, vessel sealing, argon plasma coagulation, cryosurgery and hydrosurgery. Erbe is considered a pioneer in electrosurgery, a technology that utilizes high-frequency currents in order to cut through, coagulate or devitalize tissue, or to seal blood vessels.

ETHICON

www.ethicon.com
+85227306080

At Ethicon, we are bringing people together from around the world to create innovative solutions that are advancing surgery and having life-changing impacts in health care. Our purpose is to advance innovation in surgery.

We offer healthcare professionals solutions that address the key challenges of today’s surgical procedures in order to optimize patient outcomes.

We bring people together from around the world to create innovative solutions that advance surgery and improve lives every day.

FERRING PHARMACEUTICALS LTD

enquiry.hk@ferring.com
www.ferring.com/en/home/
+85226228000

Ferring Pharmaceuticals is a research-driven, biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and orthopaedics. The company’s research activities and products are connected by a common focus of providing tailored treatments that work on the body’s own terms, enabling doctors to combat numerous diseases and medical conditions.
GSK
www.gsk.com
+85231898989

GSK is a science-led global healthcare company with a purpose to help people to do more, feel better, live longer. We research, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

We are committed to widening access to our products, so more people can benefit, regardless of their geographic location or affordability. Because of our efforts, we are ranked no. 1 on FORTUNE Magazine’s 2016 Change the World List, which reflects our dedication and commitment to modernise the way we do business.

IPSEN PHARMA
www.ipsen.com

Ipsen is a global specialty-driven pharmaceutical group committed to discovering new solutions for targeted debilitating diseases and improving quality of life for patients.

JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON
www.janssen.com/apac/
+85227375531

At Janssen Asia Pacific, we are more than 7,000 people, including doctors, scientists, engineers, quality and policy experts, business leaders and commercial people, working together across the region to improve people’s health. We research and develop prescription medicines for some of the world’s most serious and prevalent diseases, ranging from cancer and rheumatoid arthritis, to life-threatening bacterial infections and HIV/AIDS.

KARGER PUBLISHERS
karger@karger.com
www.karger.com
+41613061111

Karger Publishers in Basel, Switzerland, is a globally active medical and scientific publishing company. Independent and family-run in the fourth generation, Karger is dedicated to serving the information needs of the scientific community with publications of high-quality content, covering all fields of medical science.
C19

KARL STORZ ENDOSCOPY CHINA LTD.

customer_info@karlstorz.com.hk
www.karlstorz.com
+85228652411

Since its beginnings in 1945, the KARL STORZ family company has grown into a global manufacturer and distributor of endoscopes, medical instruments, and devices. We are no giant on an international scale but a leader in the things that matter: creativity, flexibility, and expertise.

E05

LILium OTSUkA CO., LTD.

support@liotsuka.com
www.lilium.otsuka.com +810427043822

Lilium Otsuka Introducing Lilium (alpha)-200E. Is a handheld ultrasound bladder imaging device. The made-in-Japan device is a bladder scanner to measure post-void residual (PVR) volume. It also can continuously measure urine volume in the bladder up to a maximum of 72 hours and generate an e-bladder diary for the patient.

* Continuous measurement is recommended for advanced practitioners in PVR measurement with α-200E.

E02

LUMENIS (HK) LIMITED

www.lumenis.com
+85221742800

Lumenis, a “Trustworthy, World Class and Innovative” company is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF).

A08

MAIN LIFE CORP., LTD AND SHENZHEN MAIN LUCK PHARMACEUTICALS INC.

info@mainlife.com.hk
+85225242462

Main Life Corp., Ltd is pharmaceutical distributor and Shenzhen Main Luck Pharmaceuticals Inc. is pharmaceutical company.
D05

**MEDA CO., LTD.**

export@meda.com.cn  
+862283713808

MEDA, established in 2004, has been specialized in the R&D, manufacture and sales of medical devices in the fields of urology and ophthalmology. The bladder scanner, our urological product, has been attracting the whole world’s eye with its outstanding performance.

D03

**MEDA PHARMACEUTICAL HONG KONG LIMITED**

www.meda.se

Meda is an international specialty pharma company with its own sales organizations in close to 60 countries and operations expanding in growth markets. Meda’s product portfolio focus on Speciality products, OTC, and branded generics. The Meda share is listed under Large Cap on the Nasdaq Stockholm.

B06

**MEDIFOCUS ASIA LIMITED**

info@medifocusasia.com  
prolieve-asia.com

Medifocus Asia Limited markets and sells Prolieve®, which is an innovative technology from the USA for treating Benign Prostatic Hypertrophy (BPH). Prolieve® has more than 10 years patient experience and over 100,000 cases with successful outcome (no adverse effect reported) in the USA. Coming to Asia for the first time, Prolieve® utilizes a novel combined balloon compression/thermal ablation approach and is a simple 45 minutes office procedure to perform. Coupled with an excellent safety record, Prolieve is a powerful tool to BPH management.

B01

**MENARINI ASIA-PACIFIC**

www.menariniapac.com

Menarini Asia-Pacific is a member of the Menarini Group, the world’s largest Italian biopharmaceutical company, and provides physicians and healthcare professionals with medical and scientific information with competence, correctness and the highest ethical standards in all its work processes”. Menarini has the heritage of over 130 years and over 16,000 employees in more than 100 countries. Menarini Asia-Pacific’s vision is to be a leading provider of important healthcare brands to improve the lives of people in the region.
COMPANY PROFILES

A07

MERCK SHARP & DOHME (ASIA) LTD.
www.msd.hk
+85239712800

C25

OLYMPUS HONG KONG AND CHINA LIMITED
hkm-enquiry.ohc@olympus-ap.com
www.olympusmedical.com.hk/

Olympus delivers total medical solutions to meet customers’ satisfaction. We work with health care professionals, matching our innovative capabilities in medical technology and precision manufacturing with their skills to provide the best outcomes for patients and society. Our products cover endoscopes, MIS equipment and OR design. As a leading medical company, we are promoting the advancement of minimally invasive diagnosis and treatment as well as product development to offer our customers improved safety, security, quality and productivity.

SPONSOR

PFIZER CORPORATION HONG KONG
HKMedinfo.Pfizer@Pfizer.com
www.pfizer.com.hk
+85228119711

D01

QUANTA SYSTEM SPA
quanta@quantasystem.com
www.quantasystem.com
+390331376797

Quanta System is an Italian company which designs and manufacturers sophisticated, high quality lasers for the medical, surgical and scientific sectors. Quanta System provides individual solutions in open, laparoscopic and endoscopic applications in the fields of Laparoscopy, Digestive Endoscopy, Pulmonary and Thoracic Surgery, Bronchoscopy, ENT/ORL, Cancer Vaporization and Resection, Neurosurgery, PLDD and Spine Surgery, Dentistry, Gynaecology, Andrology, Proctology and Procto-Rectology, Urology, Endovenous Laser Treatments and Open Surgery.
D02

**ROCAMED**

customer@rocamed.eu  
www.rocamed-urology.com  
+37797984243

ROCAMED is part of the PROMEPLA group, several decades of existence and experience in medical devices. More than 300 employees and 3 manufacturing sites meet the strictest requirements and the latest European and International standards. The willingness of a group and the strength of our team serving healthcare professionals: ROCAMED.

Quality, Passion, Innovation and Service... Here are the values that define our lives and build the relationships of trust between ROCAMED and healthcare professionals.

A03

**SANOFI**

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. More than 110,000 employees in 100 countries, Sanofi and its partners act to protect health, enhance life and respond to the potential healthcare needs of the 7 billion people around the world.

Sanofi has core strengths in healthcare, with key therapeutic areas in diabetes & cardiovascular, consumer healthcare, specialty Care and vaccines.

E07

**SCANMED (CHINA) LTD**

canasonic@seed.net.tw  
www.scanmed-cn.com  
+88662827177

ScanMed (China) Ltd, the superior enterprise of Chinese medical industrial, was established in June, 2005. ScanMed is focus on researching and manufacturing of high level surgical equipment and accessories. ScanMed products covers Urology, Gynecology and General surgery area. With professional R&D team and the quality control system, ScanMed keeps providing the stable and outstanding products to its customers as well as the best service.
C05

STORZ MEDICAL AG
info@storzmedical.com
www.storzmedical.com
+41716774545

Established in 1987, STORZ MEDICAL AG is a Swiss member company of the KARL STORZ Group. Our products have proved their efficacy all over the world in the medical disciplines of urology, orthopaedics, rehabilitation, cardiology and dermatology.

Today, the focus is on personalized stone management, making it possible to tailor each patient’s treatment to their own particular situation.

The MODULITH® SLK »intelect« represents a new generation of lithotripter which can be adapted to urological workstations or the combination with C-arcs.

D04

TAKEDA PHARMACEUTICALS (HONG KONG) LIMITED
jackel.lee@takeda.com
www.takeda.com
+85292314285

Takeda is a patient-focused, innovation-driven global pharmaceutical company that builds on a distinguished 235-year history, aspiring to bring better health and a brighter future for people worldwide.

The network of Takeda spans over 70 countries and regions worldwide, in Japan, the United States, Europe, Latin America, Africa, the Middle East, and the Asia Pacific Region. Takeda’s pharmaceutical products are marketed in around 100 countries worldwide, including Enantone for Urological focused.

B02

TELEFLEX MEDICAL ASIA PTE. LTD
singaporecustomerservice@teleflex.com
teleflex.com
+6564393000

At Teleflex, we believe in improving the health and quality of people’s lives. We apply purpose-driven innovation in a way that benefits patients, healthcare providers and society.

The Teleflex portfolio comprises many trusted medical technology brands, including Arrow, Deknatel, Hudson RCI, LMA, Pilling, Rüschen and W. E. Weck. Diverse in focus and unique in approach, our brands are united by a common sense of purpose: To leverage best-in-class technologies to enable effective clinical solutions for patients and healthcare providers around the world.
We decided the main theme of this congress to be “Discover Tomorrow of Urology: Message From Asia to the World.” Our association is entering a mature phase over a quarter of a century since its foundation. Fortunately, the 106th Annual Meeting of Japanese Urological Association is scheduled on the same occasion. We are convinced that this will be a unique opportunity to reaffirm the standing of the UAA in the world.

VIRTAMED

info@virtamed.com
www.virtamed.com
+41445009690

The Swiss company develops state-of-the-art surgical training tools of highest possible realism to improve the quality of patient care. VirtaMed offers virtual reality simulators for various endoscopic operations: HystSim™ and PelvicSim™ for OB/GYN training, UroSim™ for urologic surgery, ArthroS™ for arthroscopy. Teaching institutions and medical device companies use VirtaMed’s simulators globally for education and hands-on training. All upcoming events and demo opportunities: www.virtamed.com.

WELLSPECT HEALTHCARE

amy.mui@wellspect.com
www.wellspect.com
+85228715128

Wellspect Healthcare, with headquarters in Mölndal, Sweden, is a leading global provider of innovative medical devices with a focus on helping people suffering from urinary retention. Everyday, more than 1,100 employees are dedicated to make a difference for those who need our products and services. Many of the people we serve have a spinal cord injury, enlarged prostate, spina bifida or multiple sclerosis. We are one of the world’s leading manufacturers of intermittent urinary catheters, with LoFric® as our most known brand.

WILEY

www.wiley.com

Wiley, a global company, helps people and organizations develop the skills and knowledge they need to succeed. Our online scientific, technical, medical, and scholarly journals, combined with our digital learning, assessment and certification solutions help universities, societies, businesses, governments, and individuals increase the academic and professional impact of their work.
It’s time to think of Betmiga®
- The first β3 agonist to treat OAB¹-

Updated to Grade A recommendation by EAU 2017 UI Guidelines¹,*

OAB: overactive bladder; EAU: European Association of Urology; UI: urinary incontinence

Abbreviated prescribing information of Betmiga
Version: 001A
C: Mirabegron is a symptomatic treatment of urgency, increased micturition frequency and/or urgency incontinence as may occur in adults with overactive bladder (OAB) syndrome. D: Adult including elderly 50 mg once daily. A: Swallow whole. Do not chew/divide/crush. CI: Hypersensitivity; severe uncontrolled hypertension. SP: End-stage renal disease, severe renal impairment; severe hepatic impairment (Child-Pugh Class C) & moderate hepatic impairment (Child-Pugh Class B); periodic BP monitoring; history of QT prolongation or taking medicines known to prolong QT interval; bladder outlet obstruction or taking antimuscarinic medications for OAB. Pregnancy & lactation. AR: Urinary tract infection; tachycardia; nausea. INT: In patients w/ mild to moderate renal impairment or mild hepatic impairment concomitantly receiving strong CYP3A inhibitors eg itraconazole, ketoconazole, the recommended dose is 25 mg once daily. CYP3A/P-gp inducers decrease the plasma conc of mirabegron. Medicines w/ narrow therapeutic index & significantly metabolized by CYP2D6 eg thioridazine, type 1C antiarrhythmics (eg flecainide, propafenone) & TCAs (eg imipramine, desipramine); individually dose-titrated CYP2D6 substrates. In combination w/ digoxin, the lowest dose for digoxin should be initially prescribed.

Full prescribing information is available upon request.

* In patients with urgency urinary incontinence and an inadequate response to conservative treatments, offer mirabegron unless they have uncontrolled hypertension.
BEYOND VISION
VISERA ELITE II

All-in-one design
3D Laparoscopy
IR observation